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General introduction and outline
ePideMioLoGy
Colorectal cancer is the third most frequent cancer diagnosed in men (after lung and 
prostate cancer) and the second most frequent cancer diagnosed in women (after 
breast cancer).1 About 10 000 new cases are diagnosed in The Netherlands each 
year, of which approximately 25 percent are located in the rectum.2 The incidence 
rate is increasing. This is mainly due to earlier detection and increasing age of the 
population, as the highest incidence of rectal cancer is found in the sixth and seventh 
decade. Five‑year survival rate of rectal cancer is about 60 percent and depends to a 
large extent on the Tumour Node Metastases (TNM) stage at diagnosis.
PretreatMent staGinG
The TNM staging system is the gold standard for prognostication of rectal cancer 
relying on the morphological and histopathological appearance of the tumour.3 Clas‑
sification into stages with distinct clinical courses enables the clinicians to define 
treatment. Preoperative imaging with computed tomography (CT) is used to identify 
extrapelvic metastases, whereas magnetic resonance imaging (MRI) and endorectal 
ultrasound (EUS) is used for staging and evaluating locoregional disease. The evalu‑
ation of regional lymph node involvement remains relatively inaccurate. In addition, 
MRI is used for visualising the mesorectal fascia and predicting if negative surgical 
margins can be achieved. In that case the tumour is considered surgically resectable 
for cure, which comprises approximately 75 percent.4
surGicaL treatMent
Surgical resection with total mesorectal excision (TME) is the predominant treatment 
option for rectal cancer. Resection of rectal cancer is relatively difficult due to the 
close relation of the rectum to the surrounding structures and the narrow access in 
the deep pelvis. Direct view of the operative field is difficult during deep dissection, 
explaining why rectal resection for cancer remains one of the operations in elective 
abdominal surgery that most frequently requires perioperative blood transfusions.5 
A reduction of blood transfusion has been accomplished especially by sharp dissec‑
tion in the avascular plane between the mesorectum and the surrounding tissues, 
which is implicated in the TME technique.6 Furthermore, the assumed increased risk 
of morbidity and mortality has led to a critical attitude towards blood transfusion. 
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In addition, universal leukocyte depletion has been implemented in order to prevent 
transfusion induced morbidity, which will be further discussed in Chapter 9.7
Anatomically, the rectum extends from the anal verge for about 12‑15 cm, where 
it curves anteriorly and merges into the sigmoid. Circumferentially the rectum is sur‑
rounded by fatty and connective tissue, which is known as the mesorectum. Starting 
at the sacral promontory, the mesorectum being most pronounced at the dorsal site 
of the rectum diminishes below the rectosacral fascia around the levator ani muscles 
at the end of the distal third of the rectum. The mesorectum frequently contains 
microscopic tumour deposits, resulting from radial spread of the tumour. The con‑
cept of lymphatic spread and the importance of the removal of the mesorectal tissue 
had already been established by Miles in 1908.8 Miles’ impact on the development 
of rectal cancer treatment will be discussed in Chapter 2. The aim of TME, which 
was popularised by Heald in 1979, is complete removal of the mesorectum through 
sharp dissection along pre‑existing embryologically determined planes, allowing the 
preservation of the pelvic autonomic nerves.9 This technique has become the gold 
standard, however routine TME in rectal cancer at all levels has been challenged in 
view of increased risk of anastomotic leakage.10 The extent of distal tumour spread in 
the mesorectum after multimodality treatment is currently under discussion. Partial 
mesorectal excision might be more appropriate for upper rectal cancer.
The TME technique results in reproducible specimens for pathological examina‑
tion. The pathologist determines the quality of the resected specimen by assessment 
of resection margins. Studies of Quirke et al. have shown that, rather than the distal 
and proximal margin, the circumferential resection margin (CRM) is of importance 
for prediction of prognosis.11 The CRM is considered positive when tumour tissue 
approaches the resection margin within one millimetre, increasing the risk of lo‑
cal recurrence significantly.12 The development of the TME technique has led to a 
reduced risk of positive CRM and a significant decrease of local recurrence rates 
from (12‑20 to 4 percent).13 For determination of the nodal status also the number 
of involved lymph nodes is determined during pathological examination. Excision 
of a minimum of 10 lymph nodes is recommended for determining a negative nodal 
status.14
Low anterior resection versus abdoMinoPerineaL 
resection
The introduction of TME, the understanding that distal resection margins of 1‑2 cm 
are adequate and the possibility of tumour downsizing allowed abdominoperineal 
resection (APR) to be relegated to use only in a minority of patients.15‑19 Sphincter 
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preservation by low anterior resection (LAR) is currently the gold standard. Tra‑
ditionally, the construction of a colostomy, which is implicated in APR, has been 
regarded as an unfavourable outcome, as quality of life of patients with a colostomy 
is believed to be inferior to patients without a colostomy. However, recent studies 
have shown that quality of life after APR may be not as bad as once believed and 
may be equal or worse after LAR due to faecal incontinence, which occurs frequently 
after restorative surgery.20‑26
Furthermore, the rise in sphincter saving procedures might contribute to an in‑
crease of anastomotic failure. Anastomotic leakage is a frequently reported compli‑
cation after LAR (5‑26 percent) and is associated with high morbidity and mortality 
rates.2,5,6 A defunctioning stoma reduces the risk of clinically relevant anastomotic 
leakage.27 Furthermore, the construction of a tension free anastomosis with good 
blood supply is of major importance and may be influenced by the level of arterial 
ligation during TME, which will be further discussed in Chapter 3.28‑30
(neo-)adjuvant theraPy
Short‑course preoperative radiotherapy (PRT; 5x5 Gy) increased both local con‑
trol and overall survival in the Swedish Rectal Cancer Trial.31,32 However, in this 
trial, surgery consisted of conventional resection, which implies blunt dissection 
of the rectal fascia, resulting in incomplete removal of the mesorectal tissue. To 
evaluate the benefits of PRT followed by TME surgery, the Dutch Colorectal Cancer 
Group conducted the Dutch TME trial. This was a nationwide clinical randomised 
controlled trial comparing PRT and TME surgery with TME surgery alone. From 
January 1996 till December 1999 1 861 patients where randomised. Standardisa‑
tion and quality control of surgery, radiotherapy and pathology were achieved by 
means of a monitoring committee of specially trained instructor surgeons, a panel 
of supervising pathologists and study coordinators for surgery, radiotherapy and 
pathology. Results showed no effect on survival but a reduced local recurrence rate 
after short‑course PRT, which has become the most common type of treatment in 
Europe.33 However, long‑course PRT (45‑55 Gy in 1.8 Gy fractions over 4‑6 weeks) 
combined with chemotherapy is also frequently used.34 In case of locally advanced 
tumours with a threatened or involved CRM, this treatment regimen facilitates 
resection by downsizing the tumour.35 A randomised phase III study (Stockholm 
III) is presently ongoing, comparing long‑course PRT and short‑course PRT with 




Until recently research in rectal cancer treatment has mainly focused on local recur‑
rence and survival rates. However, not only improved tumour control should play a 
role in the debate concerning rectal cancer treatment, but also morbidity. In addition 
to faecal incontinence, urinary and sexual dysfunctions are frequent and distress‑
ing complications of rectal cancer treatment.36‑38 It is suggested that pelvic organ 
function is impaired by radiotherapy, but function can also be affected by surgery 
alone.22,39,40 Damage to the pelvic nerve system might be involved.36,41 Damage to the 
autonomic innervation of the pelvic organs was long thought to be an inevitable part 
of radical surgery for rectal cancer. However, encouraged by improved cure rates of 
oncologic treatment, more research changed its focus of attention from eradication of 
the tumour only, towards combining cure with quality of life of patients after treat‑
ment. The surgical concept of nerve identification and preservation was initiated in 
Japan, where resection techniques were developed which allowed preservation of the 
autonomic innervation of the pelvic organs (hypogastric nerves, inferior hypogastric 
plexus and pelvic splanchnic nerves).42 The American surgeon Enker combined the 
nerve preserving principle with the TME technique, resulting in intact urogenital 
function in almost 90 percent of patients, without compromising oncologic out‑
come.43 Moriya confirmed the feasibility and safety of the nerve sparing technique in 
a prospective study of 47 patients in the Netherlands.44 Surgical training programmes 
spread the technique of TME with nerve preservation world‑wide. However, despite 
this, clinical studies report a high incidence of pelvic organ dysfunction and the good 
functional results achieved by expert rectal surgeons have not yet been reproduced 
in larger studies.22,38,45 The contribution of each treatment component in the develop‑
ment of anorectal and urogenital dysfunction remains unclear. There is a general 
lack of large prospective studies concerning long‑term functional morbidity after 
multimodality treatment for rectal cancer, especially with respect to female sexual 
functioning. The Dutch TME trial was the first trial in which long‑term functional 
outcome was documented extensively, which will be the main focus of the current 
thesis.
outLine
The aim of this thesis was to evaluate long‑term results of rectal cancer treatment, 
specifically focusing on the etiology of long‑term morbidity.
chapter 2 is a historical overview describing the impact of Miles, who introduced 
radical APR, on the development of rectal cancer treatment. With respect to arterial 
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ligation during rectal cancer surgery, Miles recommended division of the superior 
rectal artery just distally to the origin of the left colic artery (low tie).8 Moynihan was 
the first who advocated resection of the inferior mesenteric artery at its origin (high 
tie).46 The level of ligation has been suggested to be associated with oncologic and 
functional outcome.47,48 Currently, consensus does not exist and the level at which 
the arterial supply is ligated during rectal cancer surgery varies greatly, depending 
largely on the surgeon.49 chapter 3 systematically reviews the evidence of benefits 
of both ligation techniques.
chapter 4, chapter 5 and chapter 6 evaluate long‑term sexual dysfunction, uri‑
nary dysfunction and faecal incontinence after rectal cancer treatment, respectively. 
In order to gain insight into the etiology, risk factors associated with poor functional 
outcome were identified in the database of the Dutch TME trial. chapter 7 presents 
a hypothetical patient with incontinence problems after rectal cancer surgery and 
discusses the incidence, etiology and available treatment modalities. Incontinence 
problems may be caused by surgical damage to the innervation of the pelvic floor 
muscles, which are a crucial component of the urinary and faecal continence sys‑
tem.50,51 chapter 8 combines anatomical findings and analysis of clinical data to 
evaluate nerve disruption during TME as a cause of poor functional outcome, with 
special attention to the pelvic floor innervation and incontinence.
Excessive blood loss during rectal cancer surgery is associated with surgical nerve 
disruption, resulting in functional morbidity, but also with blood transfusion, increas‑
ing the risk of short‑term morbidity.45,52‑54 Moreover, blood transfusions are reported 
to be associated with poor cancer prognosis.55 The presence of allogeneic leukocytes 
in transfusion products is presumed to impair response against cancer.56 chapter 9 
reports the long‑term recurrence and survival rates of a randomised controlled trial 
comparing leukocyte depleted and non‑leukocyte depleted red blood cell transfusion 
in gastrointestinal cancer patients.
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In 1908, William Ernest Miles published his article in the Lancet, introducing the 
basis of modern rectal cancer surgery. He established the basis for curative cancer 
treatment by combining the knowledge of anatomy and biological behaviour with 
improved surgical options as a result of better anaesthesiological techniques. Miles’ 
contribution comprised the introduction of the concept of lymphatic spread of cancer 
cells and his consequent radical surgical resection, removing all primary lymph 
nodes en bloc. Miles’ concept has dominated the minds of surgeons throughout the 
20th century and his abdominoperineal resection has been the gold standard for sev‑
eral decades. However, his concept of downward spread of rectal cancer was proven 
wrong, which initiated the historical shift from radical abdominoperineal resection 
to the use of sphincter saving surgery. Since the introduction of total mesorectal exci‑
sion, abdominoperineal excision has been performed in only a minority of patients. 
Further improvement in surgical technique consisted of autonomic nerve preserva‑
tion, improving functional outcome. From a historical overview, it can be concluded 
that the management of rectal cancer has been progressed tremendously over the 
past 100 years, mainly because of an increased understanding of the pathology and 
natural history of the disease, which has been initiated by Miles.
21
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introduction
In 1908, William Ernest Miles published his article in the Lancet, introducing 
the basis of modern rectal cancer surgery (Figure 1).1 He established the basis for 
curative cancer treatment by combining the knowledge of anatomy and biological 
behaviour with improved surgical options as a result of better anaesthesiological 
techniques. Nineteenth‑century anatomists have provided the basis for surgical dis‑
section within anatomically defined planes (Figure 2). Waldeyer’s anatomical atlas 
(Das Becken 1899) is still an important reference book (Figure 3).2 At that time, 
anaesthesiology was greatly improved by the introduction of combined spinal and 
gas anaesthesia, enabling laparotomy under muscle relaxation. Joseph Lister devel‑
oped surgical antisepsis to a level it was safe to perform a laparotomy without the 
increased risk of peritonitis. Miles’ contribution comprised the introduction of the 
concept of lymphatic spread of cancer cells and his consequent surgical resection, 
removing all primary lymph nodes en bloc. The world‑wide establishment of Miles’ 
abdominoperineal amputation of the rectum meant the acknowledgement of the fact 
that cancer surgery should be based on anatomical and biological principles. These 
principles, only slightly adjusted, are still applied nowadays as much as 100 years 
ago. The influence of Miles and the evolving understanding of the natural history of 
the disease on the development of rectal cancer treatment in the past century will be 
discussed in the following historical overview (Figure 4).
(Figuur 1, behorend bij hoofdstuk 2) 
 
 
(Figuur 2, behorend bij hoofdstuk 2) 
 
 
Figure 1. Original publication of W.E. Miles in the Lancet in 1908
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PerineaL and sacraL resection
Rectal resection was not performed until the early 19th century. Up to then de‑
functioning colostomy, as described by Amussat, was the only procedure used for 
the palliation of obstructive rectal cancer.3 In the early eighteen hundreds, French 
(Figuur 1, behorend bij hoofdstuk 2) 
 
 
(Figuur 2, behorend bij hoofdstuk 2) 
 
 
Figure 2. Illustration in Gray’s Anatomy 1860, showing the extensive knowledge concerning 
pelvic fasciae in the 19th century.
Figure 3. Anatomical illustration in Waldeyer’s anatomical atlas (Das Becken 1899).
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surgeons had begun to develop a bolder approach by aiming at direct ablation of the 
lesion through a perineal approach and with construction of a colostomy. The first 
perineal resection was probably performed accidentally by Jean Faget in 1739 and 
was carried out for the sequels of perforated rectal cancer presenting as a bilateral 
ischiorectal abcess.4 Jacques Lisfranc performed the first perineal resection for a 
case of uncomplicated rectal cancer in 1826 by removing only a few centimetres of 
the distal rectum.5 In 1874, the Swiss surgeon Theodor Kocher introduced the trans‑
sacral resection with coccygectomy, which was further extended by Paul Kraske 
to facilitate the operative exposure.6,7 The main problem of the perineal and sacral 
approaches remained the limited exposure of the surgical field making it almost 
impossible to remove the tumour radically. Another problem was the construction 
of a sacral anus, which was difficult to manage for the patient. Rarely, a variant of 
the sacral resection is still performed in case of a small distal rectal tumour, through 
the so‑called parasacral approach of York‑Mason, dividing and subsequently restor‑
ing the sphincter complex.8 However, this technique has been replaced by transanal 
endoscopic procedures.
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Figure 4. Timeline of important developments with respect to rectal cancer treatment also 




abdoMinaL resection (hartMann Procedure)
The mortality rate after perineal resection was mainly caused by peritonitis. 
Therefore, disruption of the peritoneum was considered a major surgical complica‑
tion which should be avoided in rectal surgery. Two important developments at the 
turn of the 19th century enabled performing a laparotomy. First, the development of 
combined spinal and gas anaesthesia, facilitated laparotomy with muscle relaxation, 
making the complicated anatomy of the small pelvis accessible to the surgeon. 
Secondly, Joseph Lister showed how to apply surgical principles of asepsis. Together 
with Goodyear, he invented the sterile surgical glove. In 1879 the first abdominal 
resection of a proximal tumour with intraperitoneal closure of the distal rectum 
was performed by Carl Gussenbauer.9 This method was strongly propagated by the 
French surgeon Henri Hartmann (Hôtel Dieu, Paris) for high‑lying rectal cancer 
because peroperative blood loss was very limited, as the anus and pelvic floor were 
left in situ. The so‑called Hartmann procedure is still performed for emergency or 
palliative procedures and in rare cases for curative resection, but above all it is stan‑
dard practice for acute perforated diverticulitis, never meant as such by Hartmann 
himself.
abdoMinoPerineaL resection (aPr)
Miles received his medical education at St. Bartholomew Hospital in London and 
had been licensed to practice medicine in 1891 (Figure 5). He was a pupil of Har‑
rison Cripps, known for his work on rectal pathology published in 1884.10 Cripps 
was awarded the Jacksonian Prize by the Royal College of Surgeons in 1874 for his 
monograph on rectal cancer. Despite the cautious attitude towards perineal resection 
in England, because of the extremely high morbidity and mortality rates of conti‑
nental surgeons, Cripps introduced rectal cancer surgery through perineal approach 
in England.
By the end of the 19th century, as light microscopy had been available for more 
than 100 years, the cellular basis of disease was commonly accepted. The etiol‑
ogy of cancer was less understood. Constitutionalists believed that metastases were 
multifocal, de novo developments of cancer. Cripps dissociated himself from this 
philosophy and described metastases as disseminations of the primary tumour 
through the blood or lymph vessels. Miles developed this interpretation further.
From 1899 to 1906, Miles performed 57 perineal resections. Of these patients 
54 (95 percent) had early recurrences. Miles carried out post mortem examination 
and found recurrences in the pelvic peritoneum, in the mesocolon and in the lymph 
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nodes situated at the bifurcation of the left common iliac artery. Subsequently, he 
considered that spread occurred, particularly in the lymphatics, in all directions 
(“cylindrical concept”) and that involved lymph nodes were responsible for the 
development of locally recurrent disease. Consequently, he developed en bloc resec‑
tion of rectal cancer with associated lymph nodes through a combined abdominal 
and perineal approach: the APR was born. Removal of the rectum by a combined 
abdominal and perineal operation had been performed before (1884) by Vincent 
Czerny. He was forced to utilise this combined approach due to complications during 
sacral resection of a proximal tumour. However, the patient did not survive the pro‑
cedure. Adding laparotomy to the perineal approach enabled resection of proximal 
lymph nodes and high‑lying tumours. The wider abdominal access allowed Miles 
to bring the anatomical knowledge of the pelvic fasciae and spaces into practice 
and to perform an “anatomically correct” resection (Figure 6). Miles’ revolutionary 
principles included (1) the necessity of an abdominal anus, which was much more 
manageable than a sacral artificial anus, (2) resection of the rectum and the sigmoid, 
as its blood supply is contained in the zone of upward spread, (3) resection of the 
mesorectum, (4) removal of the group of lymph nodes situated over the bifurcation of 
the common iliac artery, and lastly (5) wide perineal part of the operation with resec‑
tion of the levator ani muscle so that the lateral and downward zones of spread could 
be effectively extirpated. In 1908, Miles introduced his technique, converting the R2 
into a curative R0 resection for the first time. In 1923 Miles reported a recurrence 
rate of 29.5 percent.11 The mortality rate of the first series of patients, for the most 
































part caused by blood loss and infectious complications (no blood transfusion and 
antibiotics available) was 31 percent. This reduced to 10 percent just before World 
War Two as a result of overall improvement in anaesthesia, patient care, patient 
selection, operability and other clinical modalities. Due to its mutilating nature, this 
operation was invariably associated with urogenital dysfunction. In the beginning, 
several surgeons other then Miles performed the procedure in two stages in order to 
limit blood loss, first constructing a colostomy and mobilising the rectum through 
a laparotomy. After several weeks the rectum would be resected through a perineal 
approach. Other surgeons, like Quénu and Lloyd‑Davies, preferred to carry out APR 
in one stage, preferably by a simultaneous operating abdominal and perineal team 
in order to speed up the procedure. Until World War Two the technique of Lockhart‑
Mummery was more popular in the United States.9 Lockhart‑Mummery initially 
used the sigmoid to construct a stoma and after several weeks he resected the rectum 
through a perineal approach. The English pathologist Cuthbert Dukes (Dukes clas‑
sification for colorectal tumours) compared this operation with that of Miles and 
concluded that considerably less lymph nodes were resected.12
The apical group of lymph nodes, near the origin of the inferior mesenteric artery, 
was left in situ by Miles, as he advocated ligation of the vascular supply below the 
left colic artery. Moynihan proposed high ligation at the take‑off of the inferior 
mesenteric artery from the aorta in order to resect the apical group of lymph nodes 
too.13 This controversy has not been resolved yet.
sPhincter Preservation
Miles’ APR gained widespread approval and became the gold standard for rectal 
cancer, irrespective of tumour height. The main disadvantage was the necessity of 
a permanent colostomy. In 1910, the American surgeon Donald Balfour described a 
technique of anterior resection through an abdominal approach with the construc‑
tion of a primary end‑to‑end anastomosis.14 This was really in continuation with the 
‘Durchzug’‑procedure (pull‑through technique) after Hochenegg (1888), in which the 
anorectal stump was everted, stripped of its mucosa and returned to its natural posi‑
tion. The distal colon was then drawn through the denuded anorectum and sutured 
to the anal verge.15 Despite the maintenance of bowel continuity, this technique never 
gained wide acceptance due to the high mortality rate caused by anastomotic leakage. 
Moreover, William Mayo stated that this operation would not be radical enough.16 
However, Dukes demonstrated that downward and lateral spread from rectal cancer 
was overestimated by Miles as it was unusual unless the cancer was advanced and 
lymphatics along the superior vessels were blocked by metastases.12 The safety of 
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sphincter saving surgery was established by Claude Dixon in 1948 when he reported 
the results of 400 patients with a mortality rate of 2.6 percent and a five‑year survival 
of 64 percent.17,18 Anterior resection came to be the accepted treatment for cancer in 
the middle or upper third of the rectum, although this approach was not applicable 
for cancers of the lower third (distal 5 cm).
It was generally thought that an adequate resection required a margin of normal 
tissue 5 cm distal to the lower edge of the tumour. However, contrary to Miles’ belief 
concerning all three dimensions of spread, anatomico‑pathological studies showed 
that the majority of lymph nodes were found either parallel to or proximal to the 
level of the primary rectal tumour.19 Subsequent analyses demonstrated that distal 
margins of 2 cm did not compromise survival or local control and that Miles had 
overestimated the incidence of distal spread.20 This observation provided the rationale 
for further developments in surgical technique that facilitated sphincter preservation 
even for tumours of the distal rectum that did not directly invade the anal sphincter. 
The better understanding of what constitutes an adequate distal margin initiated the 
historical shift from radical APR to the use of sphincter saving techniques in the 
late 1970s. At that time, with the recognition of the importance of mechanical bowel 
preparation and antibiotics, the stage was set for the use of circular stapling devices, 
first conceived by the Russians and introduced by Steichen and Ravitch in the United 
States.21 Circular stapling devices facilitated the technical possibility of low rectal 
anastomosis reducing the risk of anastomotic leakage. In addition, several pioneers 
have contributed to the advancement of sphincter saving procedures.
In 1972 Alan Parks described an important modification of the pull‑through tech‑
nique: the construction of a coloanal anastomosis through the dilated anal canal.22 
In 1986 Lazorthes et al. and Parc et al. proposed creation of a colonic reservoir 
combined with coloanal anastomosis to compensate for the loss of reservoir in the 
neorectum.23,24 The benefits of a J‑pouch relative to a straight coloanal anastomosis 
included decreased stool frequency, urgency and nocturnal bowel movements.25 
After the acceptance of preoperative radiotherapy in rectal cancer treatment, the 
risk of leakage of the anastomosis created within the irradiated field remained a 
great concern (10‑25 percent).26 In this respect, at present a temporary defunctioning 
ileostoma is constructed in most cases.
totaL MesorectaL excision (tMe)
Interest in lateral tumour spread from primary rectal cancer was renewed by Phil 
Quirke in 1986.27 Phil Quirke identified that there was a high positive predictive 
value of circumferential margin involvement for the subsequent development of 
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locally recurrent cancer and poor survival. The conventional resection technique 
consisted of blunt dissection, which failed to clear the pelvis of mesorectal disease 
and resulted in an increased risk of positive lateral margins.28 Subsequently, Heald 
developed a resection technique with embryologically defined surgical planes. He 
recognized that the midline hindgut (rectum) and its mesorectum were embryologi‑
cally derived together as a single unit. In 1982 he introduced the “total mesorectal 
excision” (TME) technique, which involved en bloc resection of the tumour and the 
mesorectal tissue to the level of the levator muscles through sharp dissection in the 
avascular plane between the mesorectum and surrounding tissues under direct vision. 
Hida supported the assertion that the principal field of spread is contained within the 
mesorectum. His work confirmed that rectal cancer is a supralevator compartment 
disease and that Miles’ “cylindrical concept” was wrong.29 The TME technique 
resulted in a significant decrease in positive lateral margins.30 Sharp dissection 
reduced the risk of excessive peroperative blood loss and postoperative functional 
disorders (Figure 7).31,32 The TME technique resulted in reproducible specimens for 
pathological examination, decreased local recurrence rates significantly (from 12‑20 
to 4 percent) and allowed ultralow resections with coloanal anastomosis to be ac‑
cepted as appropriate operations.33 These radical reconstructive operations allowed 
APR to be relegated to use in only a minority of patients (15 percent), mainly those 
with direct sphincter invasion and/or pre‑existing faecal incontinence.34 Sphincter 
preservation became possible in even more patients thanks to tumour downstaging 
after neoadjuvant (chemo‑)radiotherapy.35‑37 This approach has become the gold stan‑
dard in the Western World, in contrast with Japan, where an operation also removing 
lateral lymph nodes outside the mesorectum has been developed.
(Figuur 7, behorend bij hoofdstuk 2) 
 
 









Figure 7. Blunt dissection before the introduction of “total mesorectal excision”
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LateraL LyMPh node dissection
Lateral lymph node dissection as part of rectal cancer treatment was structur‑
ally promoted since 1950 by Deddish, despite high rates of urogenital dysfunction.9 
Stearns and Bacon investigated and confirmed lateral spread of rectal cancer and 
practiced rectal cancer resection with lateral lymph node dissection as well.38,39 Later 
on, this technique was revived in Japan, improving local control and survival.40,41 
Outcomes were comparable after TME combined with neoadjuvant radiotherapy.42,43 
Radical resection with lateral lymph node dissection has been generally abandoned 
in the West, because of the low incidence of lateral pelvic node involvement and 
the consideration that lateral node involvement may represent systemic, incurable 
disease.44,45 Additionally, lateral lymph node dissection was associated with more 
blood loss, longer operating time and autonomic nerve damage, causing urogenital 
dysfunction in the majority of patients.45,46 Furthermore, the use of preoperative ir‑
radiation is considered to take care of involved lateral nodes.
nerve PreservinG rectaL resection
Damage to the pelvic autonomic nerve system was long thought to be an inevitable 
part of radical surgery for rectal cancer. However, encouraged by improved cure 
rates of oncologic treatment, more and more research changed its focus of attention 
from eradication of the tumour only, towards combining cure with quality of life of 
patients after treatment. The surgical concept of nerve identification and preserva‑
tion was initiated in Japan. Hojo and Moriya developed new resection techniques, 
allowing preservation of the autonomic innervation of urogenital organs (hypogas‑
tric nerves, inferior hypogastric plexus and pelvic splanchnic nerves; Figure 8).47‑49 
Subsequently, the American surgeon Enker combined the nerve preserving principle 
with the TME technique, resulting in intact urogenital function in almost 90 percent 
of his patients without compromising oncologic outcome.50,51 Moriya demonstrated 
in a prospective study of 47 patients in the Netherlands the feasibility and safety of 
the nerve sparing technique.52 Surgical training programmes spread the technique of 
TME with nerve preservation world‑wide, however urogenital dysfunction, as well 




Although at present the primary treatment of rectal cancer still is surgical resection, 
the role of neoadjuvant (chemo‑)radiotherapy is becoming increasingly important. 
The first time rectal cancer was successfully treated with radiotherapy was in 1914 
by Symons.57 The past decade has shown that preoperative radiotherapy should be 
standard procedure in rectal cancer treatment, especially on the basis of the Dutch 
TME trial.58 The combination of neoadjuvant radiotherapy with TME resulted in sig‑
nificantly improved local control. On the other hand, despite the reduced recurrence 
(Figuur 7, behorend bij hoofdstuk 2) 
 
 









Figure 8. Anatomical illustration of the pelvic nerves (Neurologie. Hirschfeld, Ludovic en 
Leveille 1853)
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rate, radiotherapy does not improve long‑term survival after TME, but significantly 
increases the risk of functional problems.59,60 Adequate patient selection enables 
an individualised treatment strategy, preventing under‑ and overtreatment, which 
reduces (disease‑free) survival and quality of life, respectively. Preoperative imaging 
with CT is used to identify extrapelvic metastases, whereas MRI/EUS is used for 
evaluating locoregional disease. The evaluation of regional lymph node involvement 
remains relatively inaccurate.61 Currently, new imaging modalities are developed 
and molecular biomarkers are identified to predict prognosis, making patient tailored 
treatment possible soon.
Furthermore, minimally invasive techniques are becoming increasingly important 
in rectal cancer surgery. Laparoscopic rectal resection, firstly reported by Jacobs 
in 1991, results in reduced peroperative blood loss and shorter recovery compared 
to open TME.62 However, until now, no differences have been found in long‑term 
oncologic and functional outcome, but findings from large ongoing trials should be 
awaited.63 Current challenge in rectal cancer treatment is rectum saving therapy, 
thus avoiding the morbidity associated with major resectional treatment. A concern 
of rectum saving treatment is the possibility of residual tumour cells in lymph nodes 
or at the tumour site, which might cause local recurrence. However, it has been 
shown that patients with complete response after neoadjuvant chemoradiotherapy 
have little chance of persisting tumour cells.64 Transanal endoscopic microsurgery 
(TEM) was introduced by Buess in 1983 and was in fact a continuation of the local 
electrocoagulation technique, developed by Strauss in 1913 and later only used for 
palliation.15,65 This technique implies local excision and has resulted in promising 
findings in the treatment of early rectal cancer. Habr‑Gama has aimed to omit 
surgery completely from rectal cancer treatment.66 Patients with complete clinical 
response after chemoradiotherapy were closely observed and not operated on. This 
study has shown promising results. However, long‑term follow‑up of prospectively 
conceived multicentre data concerning safety and functional outcome of rectum 
saving approaches is needed.
concLusion
Rectal cancer treatment has progressed tremendously over the past 100 years. Results 
have not really been altered by extremely expensive modern add‑ons, but mainly 
by an increased understanding of the pathology and natural history of the disease. 
Miles initiated this as he established the focus of attention to the importance of local 
tumour spread and lymph node involvement in curative rectal cancer treatment. His 
concept has dominated the minds of surgeons throughout the 20th century. Although 
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Miles was not the first to excise cancer of the rectum, nor even the first to do so by a 
combined abdominoperineal approach, his name has become forever synonymously 
associated with this combined and now synchronous procedure. However, Miles’ 
concept concerning distal spread of rectal cancer has been proven wrong, which 
initiated the historical shift to sphincter saving procedures. The acknowledgement of 
the importance of embryology in defining surgical planes has lead to the introduction 
of TME which is the gold standard nowadays. Although today APR is performed in 
only a minority of patients, wider perineal and pelvic floor resections for low rectal 
cancers have regained interest again, from which it may be concluded that Miles is 
influencing rectal cancer surgery as much as he did 100 years ago.67
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Level of arterial ligation in rectal 
cancer surgery: low tie preferred over 
high tie. a review
Lange MM, Buunen M, van de Velde CJH, Lange JF.




Consensus does not exist on the level of arterial ligation in rectal cancer surgery. 
From oncologic considerations, many surgeons apply high tie arterial ligation (level 
of inferior mesenteric artery). Other strategies include ligation at the level of the 
superior rectal artery, just caudally to the origin of the left colic artery (low tie), and 
ligation at a level without any intraoperative definition of the inferior mesenteric or 
superior rectal arteries.
Publications concerning the level of ligation in rectal cancer surgery were 
systematically reviewed. Twenty‑three articles that evaluated oncologic outcome 
(n=14), anastomotic circulation (n=5), autonomous innervation (n=5), and tension 
on the anastomosis/anastomotic leakage (n=2) matched our selection criteria and 
were systematically reviewed. There is insufficient evidence to support high tie as 
the technique of choice. Furthermore, high tie has been proven to decrease perfu‑
sion and innervation of the proximal limb. It is concluded that neither the high tie 
strategy nor the low tie strategy is evidence based and that low tie is anatomically 
less invasive with respect to circulation and autonomous innervation of the proximal 
limb of anastomosis. As a consequence, in rectal cancer surgery low tie should be 
the preferred method.
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introduction
The most important prognostic factor for survival after rectal cancer surgery is 
represented by both distant metastasis and lymph node involvement. With respect to 
lymph node involvement, in 1908 Miles developed the abdominoperineal resection 
procedure for rectal cancer, incorporating transabdominal removal of lymphatic 
tissue. Believing that the route of lymphatic drainage of the rectum would follow 
its arterial supply, he recommended division of the superior rectal artery (SRA) just 
distally to the origin of the left colic artery (LCA; low tie; Figure 1), with subsequent 
en bloc excision of nodes and bowel below.1 Within the same year Moynihan first 
proposed resection of the inferior mesenteric artery (IMA) at its origin (high tie; 
Figure 1), including the apical group of lymph nodes within the resection.2 During 
subsequent years, the high tie principle was further advocated by several authors.3–7 
However, according to the National Cancer Institute of the United States of America, 
an appropriate proximal lymphatic resection for rectal cancer without clinical evident 
lymph node disease is provided by the removal of the blood supply and lymphatics 
up to the level of the origin of the primary feeding vessel.8 For rectal cancer this is 
at the origin of SRA (low tie), which is immediately distal to the offspring of LCA. 
However, the key report on which this guideline is based is represented by the study 
by Rouffet et al.9 which is a trial on colon, not rectal, carcinoma. Actually, the level 
at which the artery is ligated in operations for rectal cancer varies greatly, depending 
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mean difference=10.56 (SE=2.82) 
* * *
Figure 1. Anatomic graph of vascular ligation techniques A. Inferior mesenteric artery (1), 
superior rectal artery (2), left colic artery (3), ascending limb (4), descending limb of the left 
colic artery (5), sigmoid arteries (6). B. High tie. C. Low tie, cranially or caudally to the origin 
of the sigmoid artery (if present), but always caudally to the origin of the left colic artery.
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largely on the surgeon.4,10–16 In daily practice only a minority of surgeons dissect 
the origin of LCA to estimate the level of arterial ligation with respect to IMA and 
SRA with certainty. Furthermore, in most publications on high tie and low tie, SRA 
is incorrectly denominated as IMA caudally to the origin of LCA. After Lanz and 
Wachsmuth the artery caudally to the origin of LCA is denominated SRA and not 
IMA.17 Most authors use the term “high tie” for every type of ligation of IMA at all 
levels of the 1‑cm to 7‑cm long artery, including “flush” ligation of IMA at its very 
origin at the aorta.
The choice of the level of arterial ligation in rectal cancer surgery can be based on 
three considerations: oncologic, anatomic, and technical. This article systematically 
reviews the evidence of possible benefits of high tie and low tie ligation techniques 
regarding these three different considerations.
Methods
A comprehensive literature search was conducted using PubMed and Cochrane 
database. The following terms were used: high ligation, high tie, low tie, and low 
ligation. In addition the terms IMA, SRA, or LCA were used in combination with 
colorectal cancer, rectal cancer, lymph node, circulation, flow, stump pressure, func‑
tion, autonomous, nerve, and tension. We also hand searched references.
The publication time window was from 1980 to 2007. Studies were included for 
this review if it concerned a randomised, controlled trial or a cohort study (prospec‑
tive/retrospective) that evaluated adult patients who underwent rectal resection with 
high tie or low tie or an anatomic study, describing the location of the autonomous 
nerve supply in relation with ligation technique. Review articles, letters, comments, 
conference proceedings, and case reports were not selected for this review. With 
respect to oncologic considerations outcomes of interest were survival, disease 
recurrence, and incidence of positive lymph nodes at the root of IMA. With respect 
to anatomic considerations outcomes of interest for effect on anastomotic circula‑
tion were tissue blood flow, tissue oxygen tension, and anastomotic leakage, and 
for effect on autonomous innervation were bowel and urogenital dysfunction and 
location of nerve supply in relation with the root of IMA. With respect to technical 
considerations outcomes of interest were length of the proximal limb, tension on the 
anastomosis, and anastomotic leakage. An assessment of the quality of the included 
studies was conducted according to the Oxford Centre for Evidence‑based Medicine 
Levels of Evidence.
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resuLts
No randomised, clinical trials comparing high tie and low tie were found.
In total 23 studies were selected for the three categories as follows:
1. Oncologic considerations: studies that concerned the influence of the level of 
arterial ligation on cancer prognosis and/or the incidence of lymph node metas‑
tasis at the root of IMA. In total 14 studies were selected (Table 1): 7 studies that 
compared high tie and low tie13–16,18–20; and 7 noncomparative studies.21–27
2. Anatomic considerations: studies that concerned the influence of the level of 
arterial ligation on anastomotic circulation (2A) and studies that concerned the 
influence of the level of arterial ligation on autonomous function (2B).
 1.  In total five studies were selected that concerned the influence of the level 
of arterial ligation on anastomotic circulation and/or anastomotic leakage 
rate (Table 2): two studies that compared high tie and low tie18,28; and three 
noncomparative studies.29–31
 2.  In total five studies that concerned the influence of the level of arterial 
ligation on autonomous innervation were selected (Table 3): one study that 
compared high tie and low tie32; and four noncomparative studies.33–36
3. Technical considerations: studies that concerned the influence of the level of 
arterial ligation on the length of the proximal limb of anastomosis. In total two 
studies were found, which are mentioned in Table 1 (Corder et al.18 and Pezim 
and Nicholls14). Both studies compared anastomotic leakage rates between high 
tie and low tie and found no significant difference.
discussion
Oncologic considerations
Lymph node involvement is a major prognostic factor for survival after rectal cancer 
surgery. The high tie technique includes the apical group of lymph nodes at the root 
of IMA within the resection. However, the incidence of metastatic lymph nodes at 
the origin of IMA has been reported to be relatively low in several studies, ranging 
from 0.3 to 8.6 percent.14,20,22,23,25–27 Furthermore, Kanemitsu et al.24 found no nodal 
metastases at the origin of IMA in patients with pT1 rectal tumours. This study sug‑
gested that low tie might be sufficient for pT1 sigmoid or rectal cancers. According 
to these findings, high tie might be beneficial only for patients with nodepositive 
disease. However, even in the case of nodepositive disease, it may be true that once 


















































































































































































































































































































































































































































































































































































































































































































































































































































































































Level of arterial ligation in rectal cancer surgery
this respect a factor could be represented by the generally poor prognosis of patients 
with rectal cancer with more than five involved lymph nodes who, if included in 
studies with high ligation, might obscure its value. Moreover, alternate lymphatic 
routes may frustrate attempts at tumour control by vascular ligation, regardless 
of the level of the tie. Tumours of the upper third of the rectum may drain along 
lymphatic channels that follow the portal vein and may be responsible for isolated 
lymphatic metastases within the hepatoduodenal ligament.37 In the lower third of the 
rectum, drainage may occur laterally to the iliac nodes via lymphatics within the 
lateral ligaments.38
Three retrospective cohort studies on high tie reported advantageous results with 
significant five‑year and ten‑year survival data for the very limited groups of patients 
with positive lymph nodes at IMA.23,24,26 We found the number of studies comparing 
high tie with low tie to be limited. All but one of these studies did not find any survival 
benefit after high tie in rectal cancer surgery.13–16,18–20 Only Slanetz and Grimson15 
reported a stage‑specific survival benefit of high tie in a retrospective study of 1 107 
patients treated with high tie with extensive resection of mesenteric lymph drainage 
table 2. Overview of studies concerning the influence of the level of arterial ligation on 
anastomotic circulation (IMA = inferior mesenteric artery)
study Level of 
evidence
design n Procedure outcome 
measure
results
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and 1 154 treated with low tie. However, this study did not eliminate the stage migra‑
tion phenomenon, which may arise as a result of more accurate staging because 
of more extensive lymphadenectomy. Therefore, a proportion of patients might be 
assigned to a more advanced stage than would otherwise be the case, although their 
prognosis is the same. If this has occurred, the overall results in each stage would 
have improved and the proportion of patients in more advanced stages would have 
increased.39
Previous reports state that the number of harvested lymph nodes correlates signifi‑
cantly with long‑term results in patients with colorectal carcinoma, advocating the 
importance of pathologic examination of 12 or more nodes.40,41 Limited lymph node 
dissection with preservation of IMA may result in a decreased number of harvested 
nodes. However, increasing the number of nodes by dissection of distant free nodes 
is considered to have no clinical impact.42
Most studies concerning high tie vs. low tie took place before the introduction 
of total mesorectal excision (TME) and neoadjuvant treatment for rectal cancer. 
Neoadjuvant treatment also has the potential to sterilise microscopic metastases in 
table 3. Overview of studies concerning the influence of the level of arterial ligation on 
autonomous innervations (IMA = inferior mesenteric artery)
study Level of 
evidence








98 D3‑resection (high tie) Urogenital 
function
75.5% bladder 







132 Rectal resection with 
high or low tie
Bowel 
function







16 Exploration inferior 







plexus was never 







42 Exploration of left 
paraortic trunk in 







Left paraortic trunk 
was never located at 






12 Isolation of inferior 







plexus is invariably 
located at the root of 
IMA
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nodes at the origin of IMA, undermining the rationale of high tie even more.43 On the 
other hand, preoperative radiotherapy did not seem to prevent distant metastasis in 
the Dutch TME trial.44 Possible benefit of high tie in combination with current surgi‑
cal techniques and neoadjuvant treatment procedures needs to be investigated. In 
conclusion, assuming that reports on high tie procedures really reflect anatomically 
correct high tie dissections, there might be a small proportion of patients profiting 
from high tie. However, the amount and level of evidence for high tie is considered 
to be too modest for standardisation of ligation of IMA.
Anatomic considerations
Perfusion of the proximal limb of anastomosis or perfusion of colostomy.
Consensus exists on the necessity of well‑perfused anastomotic limbs. However, 
factors jeopardizing anastomotic circulation are not well known.
The low tie technique allows for adequate blood supply to the colon proximally 
to the anastomosis, whereas after high tie vascularisation of the distal colon and 
sigmoid depends completely on the middle colic and marginal arteries.23,35 The 
marginal artery arising from the middle colic artery is thought to be adequate for 
sustaining the viability of the remaining colon.45,46 However, despite most stud‑
ies support this hypothesis, from preoperative measurements Dworkin et al. and 
Seike et al. concluded that high tie significantly reduces perfusion of the proximal 
limb.14,18,28,29,31 Furthermore, because in many patients a decrease in systemic blood 
pressure occurs during the recovery phase after surgery, it is not excluded that in 
some cases pressure in the marginal artery is insufficient to maintain adequate 
blood flow to the colon limb despite the inherent tendency of “auto‑regulation” in 
its vascular bed.47 In correspondence with colon ischemia as a complication of IMA 
ligation in aorta surgery, especially in older patients with atherosclerotic vessels, 
ligation of IMA might result in hypoperfusion of the proximal limb.31,48 In addition, 
in some patients deficits of the marginal artery might exist at the splenic flexure.48 
Kashiwagi et al.30 reported on the necessity of a larger sigmoid resection in rectal 
carcinoma surgery when IMA was ligated. Consequently, mobilisation of the splenic 
flexure would always be necessary.
Despite evidence for a decreased perfusion of the proximal limb after high tie 
exists, it can be concluded that until now the benefit of low tie concerning perfu‑





Preservation of the autonomous nervous system is important to prevent urogenital 
and anorectal dysfunction.49 The paraortic trunks originate from the mesenteric 
plexus and descend along the aorta to join together and form the superior hypogastric 
plexus. If these are cut, ejaculation disorders and urinary incontinence may occur.50 
Therefore, in high tie it is important to identify the safest point of ligation of IMA 
to avoid autonomous nerve damage during surgery of rectal cancer. In the literature, 
disagreement exists concerning the relationship between the origin and the course of 
IMA and the autonomous nerve supply. Two anatomic studies conclude that the ori‑
gin of IMA is the only safe point of ligation, whereas another found that the inferior 
mesenteric plexus forms a dense network around IMA to a distance of 5 cm from 
the aorta, suggesting that high tie leads to damage of the sympathetic nerves.33,35,51 
Two studies evaluated autonomic function after rectal resection. Liang et al.34 re‑
ported urogenital dysfunction in the majority of patients after high tie. Sato et al.32 
compared patients who underwent rectal cancer resection before the implementation 
of low tie with patients who were treated after this implementation at the specific 
institution. Patients treated with high tie reported worse bowel function. Ligation of 
IMA at its origin disrupts the descending autonomic fibres and consequently leads to 
a long denervated colon segment, causing defecatory dysfunction.52 However, until 
now insufficient evidence exists about whether low tie has a better prognosis with 
regard to autonomic function.
Technical considerations
Length of the proximal limb of anastomosis.
Apart from ischemia, tension on the anastomosis is thought to increase the risk of 
anastomotic leakage.23,35,53 Some authors state that high tie often is indispensable 
to guarantee a tension‑free anastomosis in low anterior resection.35,53,54 With this 
technique the proximal limb is not withheld by an intact LCA‑IMA‑aorta axis.
However, a tension‑free anastomosis also can be achieved in low tie resections 
by cutting the descending branch of LCA.18 To our knowledge, there are no studies 
that evaluate the effect of different ligation techniques on anastomotic tension. The 
aforementioned publications of Pezim and Nicholls14 and Corder et al.18 suggest that 
critical length of the proximal limb is not an issue in low tie strategy. In addition, 
splenic flexure mobilisation is not indicated routinely.55
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Conclusions
Since Miles and Moynihan respectively proposed low tie and high tie techniques 
for rectal carcinoma surgery in the same year (1908), until now the level of arterial 
ligation has been debated. The lack of prospective, randomised, clinical trials with 
sufficient follow‑up in combination with an inconsistent methodology can be held 
responsible for this lack of consensus. In addition it is uncertain whether precise 
peroperative evaluation of anatomy has always been correct in the available stud‑
ies that describe high tie and/or low tie ligation. High tie, because it has regained 
new interest in laparoscopy by its presumed advantage of easily creating mesen‑
teric windows, is still advocated by many.51,54,56–59 However, from our review there 
is insufficient evidence to support high tie as the technique of choice. Although the 
anatomic disadvantage of high tie concerning impaired perfusion and innervation of 
the proximal colon limb has not been proven sufficiently with regard to anastomotic 
leakage and bowel dysfunction until now, low tie is anatomically less invasive and is 
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Sexual dysfunction (SD) is a common and distressing complication of rectal cancer 
treatment. This study aimed to identify risk factors for long‑term male and female 
SD.
Methods
Between 1996 and 1999, patients with resectable rectal cancer were randomised to 
total mesorectal excision (TME) with or without preoperative radiotherapy (PRT). 
Questionnaires concerning SD were completed preoperatively and at 3, 6, 12, 18 and 
24 months postoperatively. Possible risk factors, including patients’ demographics, 
tumour characteristics, PRT and surgical factors were investigated.
Results
Of preoperative sexually active patients 15.2 percent of men (59/388) and 13.7 percent 
of women (19/138) never indicated to be sexually active after treatment, which was 
related to age>65 years and in male patients also to anastomotic leakage.
Increase of general SD, erectile dysfunction and ejaculatory problems was re‑
ported by 76.4, 79.8 and 72.2 percent of male patients, respectively. Risk factors were 
nerve damage, blood loss, anastomotic leakage, PRT and the presence of a stoma. 
In female patients increase of general SD, dyspareunia and vaginal dryness was 
reported by 61.5, 59.1 and 56.6 percent, respectively. This was associated with PRT 
and the presence of a stoma.
Conclusion
Sexual dysfunction is a frequent and serious problem after treatment for rectal 
cancer. Associated risk factors demonstrate that it can be mainly attributed to surgi‑
cal (nerve) damage with an additional effect of PRT. Therefore, patients should be 
informed preoperatively and education of surgeons in pelvic neuroanatomy and cru‑
cial anatomical dissection planes may provide the key to improvement of functional 
outcome.
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introduction
The past two decades have witnessed substantial improvement in survival from rectal 
cancer as a result of earlier diagnosis, improved efficiency and use of radiotherapy 
and advances in surgical techniques such as total mesorectal excision (TME)1,2. Total 
mesorectal excision is defined as “a sharp dissection under clear vision between 
the parietal and visceral planes of the pelvic fascia, removing the mesorectum con‑
tained within an intact endovisceral fascia”1‑3. The practice of TME in rectal cancer 
treatment improved autonomous nerve preservation substantially. Subsequently, the 
rates of sexual dysfunction (SD) were reduced4‑6. However, SD after rectal cancer 
treatment is still a frequent and distressing complication7‑9. There is a suggestion 
that sexual function is impaired by radiotherapy, but function can also be affected 
by surgery alone6,8,10,11. It is difficult to identify the contribution of each treatment 
component in the development of SD. There is a general lack of large, prospective 
studies concerning long‑term SD after rectal cancer treatment, especially in female 
patients. In order to gain insight in the etiology of SD after rectal cancer treatment, 
we prospectively investigated which treatment factors contributed to the development 
of long‑term male and female SD in a large multicentre trial in which all patients 
had been treated by TME surgery and had been randomised for yes/no preoperative 
radiotherapy (PRT).
Methods
study population and treatment
From January 1996 to December 1999, 1 861 patients with histologically proven 
adenocarcinoma of the rectum and without evidence of distant metastases were 
randomised to receive PRT followed by TME or TME alone in a large, international, 
multicentre trial. Details of the TME trial have been described elsewhere12. Patients 
assigned to PRT received a total dose of 25 Gy in five fractions over 5 to 7 days. 
Surgery had to take place within 10 days of the start of PRT. All patients underwent 
surgery according to the TME principles, as advocated by Heald13. Participating 
surgeons attended workshops and symposiums, saw instructional videotapes and 
were monitored by specially trained instructor surgeons. At each hospital, the first 
five total mesorectal excisions were supervised by an instructor surgeon14. Informed 
consent was obtained from all patients before randomisation and was separately 
obtained for the quality‑of‑life study. Health‑related quality of life was evaluated 
in Dutch patients only (n=1 530). Patients with any recurrence during the period of 
Chapter 4
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evaluation were excluded to avoid confounding due to symptoms caused by disease 
recurrence.
Measures
Patients were asked to fill out questionnaires before treatment and at 3, 6, 12, 18 and 
24 months after surgery. Patients who failed to return two consecutive question‑
naires were considered as withdrawn from the study and did not receive further 
questionnaires. For the different time points, the following time windows were 
defined: 1.5 to 4.5 (3 months), 4.5 to 9 months (6 months), 9 to 15 (12 months), 15 to 
21 (18 months) and 21 to 27 (24 months). Patients with a missing preoperative form 
were not analysed, however patients with a missing form at a certain time point after 
treatment were still included in the other time points.
The questionnaire evaluated sexual activity and included several items concerning 
sexual functioning. Responses were given on four‑point scales ranging from “not at 
all” to “very much”. Items within a scale were summed and linearly transformed to 
fit a range from 0 to 100, with lower scores representing better levels of functioning. 
The questionnaire consisted of one general SD scale (three items: interest, pleasure, 
satisfaction; Cronbach’s α for females = 0.88 and for males = 0.85); for females a 
scale on dyspareunia (two items: α = 0.87) and an item on vaginal dryness were also 
included, and for males a scale on erectile dysfunction (three items: α = 0.98) and one 
on ejaculatory problems (two items: α = 0.86) were included.
statistics
Male and female patients were analysed separately. Only patients who were sexu‑
ally active before rectal cancer treatment were evaluated. Sexual activity after rectal 
cancer treatment was assessed and associated factors were identified with univariate 
and multivariable regression analysis. 
Furthermore, postoperative deterioration of sexual functioning was evaluated. To 
do this, relative dysfunction scores were obtained by subtracting the baseline‑score 
(preoperative score) from the score at each subsequent time‑point. For each patient 
the mean postoperative relative scores with respect to general SD and to erectile 
dysfunction and ejaculatory problems or to dyspareunia and vaginal dryness were 
calculated. In this way, even patients who only filled in one postoperative question‑
naire could be evaluated. Scores ranging from 0‑10, 10‑20 and >20 were considered 
as minor, moderate and severe deterioration respectively17. Analysed risk factors 
were gender, age, body mass index (BMI), tumour stage, PRT, resection type (low 
anterior or abdominoperineal resection), level of anastomosis, resection of an ad‑
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ditional organ, excessive peroperative blood loss (>1 500 ml), surgical damage to the 
superior hypogastric plexus, hypogastric nerves and/or pelvic plexus (as mentioned 
in the surgery report), definitive or temporary stoma and anastomotic leakage. The 
influence of these variables was examined in univariate and multivariable regression 
analysis. P≤0.05 was considered statistically significant.
In order to produce figures indicating the development of dysfunction over time, 
linear mixed models with random patient intercepts and time (categoric) and the 
specific risk factor as fixed factors were used to obtain estimates of each of the 
scheduled time points, to account for random drop‑out. In a previous study, it was 
shown that it was not necessary to incorporate non‑ignorable drop‑out16.
resuLts
study population
Of the 1 530 Dutch patients, patients were excluded from analysis for the following 
reasons: ineligible at randomisation (n=50), no operation (n=37), in‑hospital deaths 
(n=52), no informed consent for quality‑of‑life study (n=89) and no quality‑of‑life 
forms returned (n=30). In addition, 282 patients had a local or distant recurrence 
within the first two years, leaving 990 patients. Patient and treatment characteristics 
are listed in Table 1.
sexual activity
Before treatment, 79.2 percent of male (388/490) and 51.7 percent of female patients 
(138/267) were sexually active. Univariate and multivariable regression analysis could 
not identify any clinical or pathological contributing factor correlating with absence 
of sexual activity other than age >65 years, female gender and not having a partner 
(p<0.001, RR=0.16, p<0.001, RR=0.27 and p<0.001, RR=0.12, respectively).
Of the male patients sexually active before treatment, 31.5 percent indicated not to 
be sexually active at three months after surgery. This percentage remained more or 
less stable over time (28.5 percent at two years). However, only 59 male patients (15.2 
percent) never indicated to be sexually active after treatment. Risk factors associ‑
ated with never being sexually active were age >65 years (p=0.002, RR=0.40) and 
anastomotic leakage (p=0.008, RR=0.31). In contrast, of the female patients sexually 
active before treatment, 32.5 percent indicated not to be sexually active at three 
months but this decreased to 18.4 at two years after rectal cancer treatment. Only 19 
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female patients (13.7 percent) never indicated to be sexually active after treatment. 
This was associated with increased age (p=0.041, RR=0.35).
Male sexual functioning
As stated in the methods section, only patients who indicated to be sexually active 
preoperatively were included in the analysis of sexual functioning (388 male and 138 
female patients). 
Both in male and female patients general sexual functioning deteriorated 
postoperatively and remained worse over time for male, but improved for female 
patients (Figure 1). Seventy‑six percent (275/360) of male patients reported either 
newly developed general SD or aggravation of pre‑existent general SD after rectal 
table 1. Patient and treatment characteristics (continuous variables: median (minimum, 
maximum); categorical variables: number of patients (%))






















Preoperative radiotherapy (n=990) 497 (50.3)
Type of resection (n=990)






Resection additional organ (n=990) 185 (18.7)
Peroperative blood loss (ml; n=971) 1000 (20, 15000)
Anastomotic height of LAR (cm; n=607) 5.5 (0, 14.0)
Anastomotic leakage after LAR (n=657) 66 (10.0)
Temporary/definitive stoma (n=950) 725 (73.2)
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cancer treatment, of whom 59.3 percent (163/275) had a mean relative score of more 
than 20 points, indicating severe deterioration. The mean postoperative increase in 
general SD score was 20.2 (standard error [SE]=1.5) and was significantly associated 
with PRT, excessive peroperative blood loss, anastomotic leakage and temporary/
definitive stoma in univariate regression analysis (Table 2). However, in multivari‑
able analysis only PRT and temporary/definitive stoma remained significant risk fac‑
tors (p=0.003, mean difference=8.53, SE=2.9 and p=0.019, mean difference=8.97, 
SE=3.5, respectively; Figure 2a). Postoperative erectile dysfunction developed or 
worsened in 79.8 percent (257/322) of patients compared to the pre‑treatment situ‑
ation. Of these patients 71.2 percent (183/257) had a mean relative score of more 
than 20 points. The mean postoperative increase in erectile dysfunction score was 
31.3 (SE=1.9) and was significantly associated with age>65 years, nerve damage, 
resection type, excessive peroperative blood loss, temporary/definitive stoma and 
anastomotic leakage in univariate regression analysis. However, in multivariable 
analysis only excessive peroperative blood loss and anastomotic leakage remained 
significant risk factors (p=0.033, mean difference=13.6, SE=4.2 and p=0.034, mean 
difference=14.5, SE=7.2, respectively; Table 2; Figure 2b). Ejaculatory problems de‑
  
 
Gender   p<0.001 
Time    p<0.001 
Gender*Time   p<0.001 
* * * *
Gender
Figure 1. Linear mixed models analysis of relative general sexual dysfunction scores in male 
and female patients. Ninety-nine confidence intervals are displayed on the y-axis. An asterisk 
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veloped or worsened postoperatively in 72.2 percent (221/306) of patients, of whom 
67.4 percent (149/221) had a mean relative score of more than 20 points. The mean 
postoperative increase in ejaculatory problem score was 30.4 (SE=2.0) and was sig‑
nificantly associated with PRT (p=0.026, mean difference=8.92, SE=3.9), autonomic 
nerve damage (p=0.011, mean difference=12.07, SE=4.4) and anastomotic leakage 
(p=0.043, mean difference=17.39, SE=7.6; Table 2; Figure 2c).
Female sexual functioning
Sixty‑two percent (72/117) of female patients reported either newly developed 
general SD or aggravation of pre‑existent SD after rectal cancer treatment, of 
whom 45.8 percent (33/72) had a mean relative score of more than 20 points. The 
mean postoperative increase in general SD score was 8.2 (SE=2.5). Preoperative 
radiotherapy was the only significant risk factor (p=0.033, mean difference=10.5, 
SE=4.9; Table 3). Postoperative dyspareunia developed or worsened compared to 
the pre‑treatment situation in 59.1 percent (65/110) of patients, of whom 44.6 percent 
a.    
Stoma    p=0.011 
Time    p=0.047 
Stoma*Time   p=0.505 
Stoma
Figure 2. Linear mixed models analysis of a) relative general sexual dysfunction scores in male 
patients with or without a temporary/definitive colostoma, b) relative erectile dysfunction in 
male patients with or without excessive peroperative blood loss and with or without anastomotic 
leakage and c) relative ejaculatory problems in male patients with or without nerve damage 
and with or without anastomotic leakage. Ninety-nine confidence intervals are displayed on 
the y-axis. An asterisk indicates a significant difference (p<0.001) at a specific time-point. 
(SD=sexual dysfunction; CI=confidence interval) 
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b. 
Anastomotic leakage
Anastomotic leak p=0.051 
Time    p=0.010 
Leak*Time  p=0.507 
* *
Blood    p=0.002 
Time    p=0.001 
Blood*Time   p=0.626 
b. 
Anastomotic leakage
Anastomotic leak p=0.051 
Time    p=0.010 
Leak*Time  p=0.507 
* *
Blood    p=0.002 
Time    p=0.001 








Nerve damage  p=0.011 
Time    p=0.465 
Nerve damage*Time p=0.769 
Anastomotic leakage
Anastomotic leak p=0.035 
Time    p=0.070 
Leak*Time  p=0.212 
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(29/65) had a mean relative score of more than 20 points. The mean postoperative 
increase in dyspareunia score was 12.3 (SE=2.5) and was only associated with the 
presence of a temporary or definitive colostoma (p=0.051, mean difference=11.3, 
SE=5.7; Table 3; Figure 3a). Vaginal dryness developed or worsened postoperatively 
in 56.6 percent (60/106) of patients. Sixty‑two percent (37/60) of these patients had 
a mean relative score of more than 20 points. The mean postoperative increase in 
vaginal dryness score was 13.4 (SE=2.5) and was only associated with the presence 
of a stoma (p=0.063, mean difference=10.8, SE=5.7; Table 3; Figure 3b).
discussion
In light of improved prognosis of rectal cancer quality of life has become an increas‑
ingly important criterion. Policy makers have insisted on including assessment of 
quality of life in clinical trials. However, quality of life is influenced by the ability 
to adapt to unfortunate conditions and it has been shown that it does not reflect 
poor functional outcome.11 The present study evaluated the development of long‑
term sexual morbidity in a large randomised multicentre trial. To our knowledge 
there are no other studies available in which sexual morbidity has been evaluated 
prospectively on such a large scale in both male and female patients.
Prospective questionnaires were used in order to prevent under‑reporting. However, 
SD might still have been underreported for example out of shame. Furthermore, as‑
sessment of female SD remains a difficulty as simple endpoints equivalent to potency 
and ejaculation are not available and sexual intercourse often remains techniqually 
possible, even if SD is present. In addition, the questionnaires were not validated. At 
the time the Dutch TME trial was conducted, validated questionnaires concerning 
specific sexual problems were not available yet, such as the recently developed mod‑
ule CR29 of QLQ‑C30. It should also be noted that the used mean relative scores 
do not account for a possible time‑effect. However, this is justified since the linear 
mixed models showed no time effect of surgical factors.
The clinical importance of SD after rectal cancer treatment is demonstrated by this 
study as the majority of the patients was sexually active (526 of 757 patients). The 
majority of patients reported deterioration of sexual functioning after rectal cancer 
treatment. Sexual dysfunction after rectal cancer treatment is a multidimensional 
problem. Reduced self‑image, fatique, loss of independence, depression, and changes 
in interpersonal relationships might harm sexual function. In this study, the presence 
of a temporary or definitive colostoma was associated with SD in female patients, 
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probably indicating its psychological role in the development of SD. Decreased 
arousal due to the presence of a colostoma may result in reduced lubrication and 
dyspareunia, which were also related to each other (data not shown).17 In addition 
to psychological factors, physical factors can play a role. Pelvic organ dysfunction 
after rectal cancer treatment occurs frequently and surgical damage to the pelvic 
autonomic nerves is believed to be an important cause5,18‑20. Damage to the superior 
hypogastric plexus and hypogastric nerves could lead to disturbed ejaculation21. 
Disruption of the pelvic splanchnic nerves or the pelvic plexus could lead to erectile 
dysfunction. In the present study, the main predictive factor of increased ejaculatory 
problems was peroperative autonomic nerve damage. However, erectile dysfunction 
was only associated with peroperative blood loss and anastomotic leakage and not 
with nerve damage. With respect to autonomic nerve damage, surgeons most com‑
monly indicated “total preservation” or “unclear” in the surgery report. Therefore, 
nerve damage was probably underreported and excessive peroperative blood loss 
may be a surrogate parameter for surgical nerve damage. Use of diathermic co‑
agulation to secure haemostasis may cause nerve damage, especially if it is used 
improperly and in proximity to the pelvic plexus. Moreover, excessive blood loss 
hinders vision deep in the pelvis, making nerve sparing virtually impossible6. 
Anastomotic leakage as an important risk factor may be explained by its association 
with extensive inflammation, which may cause damage to the nerves and seminal 
vesicles. Theoretically, damage to the superior hypogastric plexus in women could 
lead to impaired lubrication and disruption of the pelvic splanchnic nerves or the 
pelvic plexus could cause diminished labia‑swelling response. However, this was not 
supported by the present study. In female patients nerve preservation is less difficult 
than in the narrow conically shaped male pelvis, which could explain why SD was 
more common in male than in female patients. Moreover, in women sexual function 
may be primarily mediated by the sexual centres in the cerebrum and by impulses 
carried by the pudendal nerves.
A well known surgical risk factor for SD is abdominoperineal resection, espe‑
cially with respect to erectile dysfunction in male patients7,18,22,23. Avulsion of the 
pelvic splanchnic nerves from their sacral roots might occur following a tear of 
the presacral parietal fascia during the perineal phase of this procedure22. In the 
present study abdominoperineal resection resulted in increased erectile dysfunction. 
However, this effect did not remain significant after correcting for peroperative 
blood loss, which was increased during abdominoperineal resection compared to 
low anterior resection (data not shown).
In addition to surgical damage, it is known that PRT is associated with long‑term 
functional morbidity7,8,10,11,24. The cause of radiotherapy‑related SD is multifacto‑
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Stoma    p=0.035 
Time    p=0.407 




Stoma    p=0.029 
Time    p=0.330 
Stoma*Time   p=0.132 
Stoma 
Figure 3. Linear mixed models analysis of a) relative dyspareunia scores and b) relative vaginal 
dryness scores in female patients with or without a temporary/definitive colostoma. Ninety-nine 
confidence intervals are displayed on the y-axis. (CI=confidence interval)
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rial, involving fibrosis, vascular toxicity, neurotoxicity and psychological factors25. 
Radiation damage to the cavernous arteries may result in impotence and the seminal 
vesicles may stop functioning after irradiation, resulting in ejaculatory problems.25,26 
However, in the present study PRT was not an independent risk factor for erectile 
dysfunction or ejaculatory problems. Furthermore, the effect of PRT on the dys‑
function scales running to 100 was less than ten points, while postoperative scores 
were approximately 20 points higher than preoperative scores. Therefore, despite the 
additional effect of PRT, SD seems to be mainly caused by surgery. It is difficult to 
influence surgical factors, except for nerve damage. Expert studies have shown that 
autonomic nerve preservation is achievable, but their results have not been repro‑
duced in larger studies6,19. Because exact identification of the autonomic nerves can 
be difficult, the use of a nerve stimulating device could possibly facilitate preserva‑
tion of the pelvic autonomic nerves during TME27. Also high volume hospitals and 
surgeons may have better results.
In conclusion, we believe that education and training of surgeons in pelvic neu‑
roanatomy and crucial anatomical dissection planes is the key to improvement of 
functional outcome.
In addition, any doctor treating rectal cancer patients should be aware that many 
are sexually active and inform their patients about the possible negative sexual con‑
sequences of treatment. At present, there is an ongoing project investigating to what 
extent patients and oncologists believe that patients should also participate in decision 
making regarding therapy. During follow‑up doctors should be aware that patients 
might experience substantial distress from SD and suggest possible therapies28.
71
Sexual dysfunction after rectal cancer treatment
reFerence List
 1. Heald RJ, Husband EM, Ryall RD. The mesorectum in rectal cancer surgery‑‑the clue to 
pelvic recurrence? Br J Surg 1982; 69: 613‑6.
 2. Kapiteijn E, van de Velde CJ. The role of total mesorectal excision in the management of 
rectal cancer. Surg Clin North Am 2002; 82: 995‑1007.
 3. Aeberhard P, Fasolini F. Total mesorectal excision for cancer of the rectum. Recent Results 
Cancer Res 1998; 146: 66‑70.
 4. Havenga K, Enker WE. Autonomic nerve preserving total mesorectal excision. Surg Clin 
North Am 2002; 82: 1009‑18.
 5. Maurer CA, Z’Graggen K, Renzulli P, Schilling MK, Netzer P, Büchler MW. Total me‑
sorectal excision preserves male genital function compared with conventional rectal cancer 
surgery. Br J Surg 2001; 88: 1501‑5.
 6. Moriya Y. Function preservation in rectal cancer surgery. Int J Clin Oncol 2006; 11: 339‑
43.
 7. Hendren SK, Swallow CJ, Smith A et al. Prevalence of male and female sexual dysfunction 
is high following surgery for rectal cancer. Ann Surg 2005; 242: 212‑23.
 8. Heriot AG, Tekkis PP, Fazio VW, Neary P, Lavery IC. Adjuvant radiotherapy is associated 
with increased sexual dysfunction in male patients undergoing resection for rectal cancer: a 
predictive model. Ann Surg 2005; 242: 502‑10.
 9. Kim NK, Aahn TW, Park JK et al. Assessment of sexual and voiding function after total 
mesorectal excision with pelvic autonomic nerve preservation in males with rectal cancer. 
Dis Colon Rectum 2002; 45: 1178‑85.
 10. Bonnel C, Parc YR, Pocard M et al. Effects of preoperative radiotherapy for primary resect‑
able rectal adenocarcinoma on male sexual and urinary function. Dis Colon Rectum 2002; 
45: 934‑9.
 11. Marijnen CA, van de Velde CJ, Putter H et al. Impact of short‑term preoperative radiotherapy 
on health‑related quality of life and sexual functioning in primary rectal cancer: report of a 
multicenter randomized trial. J Clin Oncol 2005; 23: 1847‑58.
 12. Kapiteijn E, Kranenbarg EK, Steup WH et al. Preoperative radiotherapy combined with 
total mesorectal excision for resectable rectal cancer. N Engl J Med 2001; 345: 638‑46.
 13. Heald RJ. Rectal cancer: the surgical options. Eur J Cancer 1995; 31A: 1189‑92.
 14. Kapiteijn E, Kranenbarg EK, Steup WH et al. Total mesorectal excision (TME) with or 
without preoperative radiotherapy in the treatment of primary rectal cancer. Prospective 
randomised trial with standard operative and histopathological techniques. Dutch ColoRec‑
tal Cancer Group. Eur J Surg 1999; 165: 410‑20.
 15. Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in 
health‑related quality‑of‑life scores. J Clin Oncol 1998; 16: 139‑44.
 16. Putter H, Marijnen CA, Kranenbarg EK, van de Velde CJ, Stiggelbout AM. Missing forms 
and dropout in the TME quality of life substudy. Qual Life Res 2005; 14: 857‑65.
 17. Basson R, Brotto LA, Laan E, Redmond G, Utian WH. Assessment and management of 
women’s sexual dysfunctions: problematic desire and arousal. J Sex Med 2005; 2: 291‑300.
 18. Havenga K, Maas CP, DeRuiter MC, Welvaart K, Trimbos JB. Avoiding long‑term dis‑
turbance to bladder and sexual function in pelvic surgery, particularly with rectal cancer. 
Semin Surg Oncol 2000; 18: 235‑43.
Chapter 4
72
 19. Maas CP, Moriya Y, Steup WH, Kiebert GM, Kranenbarg WM, van de Velde CJ. Radical 
and nerve‑preserving surgery for rectal cancer in The Netherlands: a prospective study on 
morbidity and functional outcome. Br J Surg 1998; 85: 92‑7.
 20. Nesbakken A, Nygaard K, Bull‑Njaa T, Carlsen E, Eri LM. Bladder and sexual dysfunction 
after mesorectal excision for rectal cancer. Br J Surg 2000; 87: 206‑10.
 21. Rees PM, Fowler CJ, Maas CP. Sexual function in men and women with neurological disor‑
ders. Lancet 2007; 369: 512‑25.
 22. Santangelo ML, Romano G, Sassaroli C. Sexual function after resection for rectal cancer. 
Am J Surg 1987; 154: 502‑4.
 23. Schmidt C, Bestmann B, Lindemann H, Küchler T, Löhnert M, Kremer B. [Quality of life 
and sexuality after surgery for rectal cancer‑‑a follow‑up study]. Zentralbl Chir 2005; 130: 
393‑9.
 24. Lange MM, den Dulk M, Bossema ER et al. Risk factors for faecal incontinence after rectal 
cancer treatment. Br J Surg 2007; 94: 1278‑84.
 25. Morgentaler A. Male impotence. Lancet 1999; 354: 1713‑8.
 26. Zelefsky MJ, Leibel SA, Gaudin PB et al. Dose escalation with three‑dimensional conformal 
radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 1998; 
41: 491‑500.
 27. da Silva GM, Zmora O, Börjesson L et al. The efficacy of a nerve stimulator (CaverMap) 
to enhance autonomic nerve identification and confirm nerve preservation during total 
mesorectal excision. Dis Colon Rectum 2004; 47: 2032‑8.
 28. Lindsey I, George B, Kettlewell M, Mortensen N. Randomized, double‑blind, placebo‑
controlled trial of sildenafil (Viagra) for erectile dysfunction after rectal excision for cancer 
and inflammatory bowel disease. Dis Colon Rectum 2002; 45: 727‑32.
chaPter 5
urinary dysfunction after rectal 
cancer treatment is mainly caused 
by surgery
Lange MM, Maas CP, Marijnen CAM, Wiggers T, Rutten HJ, Klein 
Kranenbarg E, van de Velde CJH.





Urinary dysfunction (UD) is common after rectal cancer treatment, but the contri‑
bution of each treatment component (surgery and radiotherapy) to its development 
remains unclear. This study aimed to evaluate UD during 5 years after total me‑
sorectal excision (TME) and to investigate the influence of preoperative radiotherapy 
(PRT) and surgical factors.
Methods
Patients with operable rectal cancer were randomised to TME with or without PRT. 
Questionnaires concerning UD were completed by 785 patients before and at sev‑
eral time points after surgery. Possible risk factors, including PRT, demographics, 
tumour location, and type and extent of resection, were investigated by multivariable 
regression analysis.
Results
Long‑term incontinence was reported by 38.1 percent of patients, of whom 72.0 per‑
cent had normal preoperative function. Preoperative incontinence (relative risk (RR) 
2.75, p=0.001) and female sex (RR 2.77, p<0.001) were independent risk factors. 
Long‑term difficulty in bladder emptying was reported by 30.6 percent of patients, 
of whom 65.0 percent had normal preoperative function. Preoperative difficulty in 
bladder emptying (RR 2.94, p<0.001), peroperative blood loss (RR 1.73, p<0.028) 
and autonomic nerve damage (RR 2.82, p=0.024) were independent risk factors. 
PRT was not associated with UD.
Conclusion
UD is a significant clinical problem after rectal cancer treatment and is not related to 
PRT, but rather to surgical nerve damage.
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introduction
The past two decades have witnessed substantial improvement in survival from 
rectal cancer resulting from earlier diagnosis, improved efficiency and delivery of 
radiotherapy, and advances in surgical techniques such as total mesorectal excision 
(TME)1,2. In the light of improved prognosis the quality of functional outcome has 
become increasingly important. As a consequence, an increasing number of studies 
have focused on postoperative urinary, sexual and anorectal dysfunction. Currently, 
the rate of urinary dysfunction (UD) after rectal cancer surgery ranges from 30 to 
70 percent3‑6.
The contribution of each treatment component (surgery and radiotherapy) to the 
development of UD remains unclear. Damage to the pelvic autonomic nerve system, 
either as a result of surgery or radiotherapy, might be involved. Damage to the supe‑
rior hypogastric plexus and the hypogastric nerves causes reduced bladder capacity, 
and may result in urge incontinence. Damage to the sacral splanchnic nerves may 
lead to overflow incontinence and urinary retention, and difficulty in bladder empty‑
ing7. Bilateral surgical disruption of the inferior hypogastric plexus has been shown 
clinically to lead to devastating UD8.
A plane of dissection around the mesorectum is required in TME for rectal cancer, 
in an attempt to avoid nerve disruption. However, despite this, clinical studies show 
that this operation is associated with a high incidence of pelvic organ dysfunction, 
and the good functional results achieved by expert rectal surgeons have not yet been 
reproduced in larger studies3,9. Clinical data from large prospective studies on the 
contribution of surgical nerve damage to UD after TME are, however, lacking.
There is no consensus about the role of preoperative radiotherapy (PRT) in the 
development of UD after rectal cancer treatment either4,9‑12. Other possible risk 
factors have also been investigated in previous studies, with contradictory results 
concerning the influence of age9,12,13, sex5,9,14,15, tumour height14‑16, tumour size12,15 and 
type of resection4,5,9,12,16‑18. Interpretation of results is difficult because of differences 
in definitions of types of UD and their assessment. The number of patients and length 
of follow‑up in these studies were limited. Moreover, the influence of the risk factors 
was often evaluated without distinguishing between incontinence and difficulty in 
bladder emptying, although these problems may have a different etiology.
The aim of the present study was to evaluate UD in both the short and long term, 
and to examine the influence of PRT and surgical factors separately on long‑term 




The database of the Dutch TME trial was used. This international multicentre trial 
investigated the efficacy of short‑term PRT in patients with rectal cancer treated 
with TME. From January 1996 to December 1999, 1 861 patients with histologically 
proven adenocarcinoma of the rectum and without evidence of distant metastases 
were included in the trial, and randomised to receive PRT followed by TME or 
TME alone. Patients were eligible for randomisation when the tumour was clinically 
resectable and located 15 cm or less from the anal verge. Details of the Dutch TME 
trial have been described elsewhere19. Only Dutch patients who underwent low ante‑
rior resection or abdominoperineal resection, and participated in the quality‑of‑life 
study19,20 and in the study of long‑term side‑effects of PRT21, were selected for the 
present analysis. Patients with any recurrence during the period of evaluation were 
excluded to avoid confounding due to symptoms caused by disease recurrence.
Treatment
Patients assigned to PRT received a total dose of 25 Gy in five fractions over 5‑7 
days. The clinical target volume included the primary tumour and the mesentery 
with vascular supply, containing the perirectal, presacral and internal iliac nodes. 
The recommended upper border was at the level of the promontory. The perineum 
was included if abdominoperineal resection was planned, whereas the lower border 
was 3 cm above the anal verge if the planned operation was low anterior resection. 
Surgery had to take place within 10 days of the start of PRT. All patients underwent 
surgery according to the TME principles, as advocated by Heald22. Participating 
surgeons attended workshops and symposiums, watched instructional videotapes, 
and were monitored by specially trained instructor surgeons. At each hospital, the 
first five TMEs were supervised by an instructor surgeon23. Autonomic nerve pres‑
ervation was mentioned in the surgery report as either total preservation, damage to 
the superior hypogastric plexus, one or both hypogastric nerves, one or both sides of 
the inferior hypogastric plexus or the splanchnic nerves, or unclear whether nerves 
were preserved (autonomic nerves not identified).
Outcome measures
For the quality‑of‑life study, questionnaires, including questions on incontinence and 
difficulty in bladder emptying, were sent to patients before surgery and at 3, 6, 12, 18 
and 24 months after TME20. The time frame of these questions was the past week. 
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Responses were given on a four‑point severity scale, with options ‘not at all’, ‘a little’, 
‘quite a bit’ and ‘very much’.
For the study investigating long‑term side‑effects of PRT, only patients without 
recurrent disease who responded to the previous forms were sent a questionnaire 
at a median of 5 years after TME21. In this study the time frame of the questions 
was the past 3 months. The presence of urinary incontinence was indicated on a 
five‑point scale, with options ‘not at all’, ‘less than once a week’, ‘once a week’, ‘a 
few times a week’ and ‘every day’. The frequency of difficulty in bladder emptying 
was indicated on a six‑point scale with options ‘no, not at all’, ‘less than one in five 
times’, ‘less than half of times, ‘in half of times’, ‘in more than half of times’ and 
‘yes, almost always’.
For the evaluation of changes in UD over 5 years, scales for both urinary incon‑
tinence and difficulty in bladder emptying were transformed into three‑point scales: 
‘no dysfunction’ (corresponding to the answer ‘not at all’), ‘moderate dysfunction’ 
(corresponding to: ‘a little’, ‘less than once a week’, ‘once a week’, ‘a few times a 
week’, ‘less than one in five times’, ‘less than half of times’) and ‘severe dysfunction’ 
(corresponding to ‘quite a bit’, ‘very much’, ‘every day’, ‘in more than half of times’ 
and ‘yes, almost always’).
For univariate and multivariable logistic regression analyses, answers were trans‑
formed into a binary outcome measure (absence versus presence of incontinence and 
difficulty in emptying the bladder, irrespective of severity or frequency), to allow for 
differences in questionnaire design.
statistical analysis
Data were analysed with the statistical software SPSS® version 12.0 for Windows® 
(SPSS, Chicago, Illinois, USA). Differences in percentages of patients with UD at 
two time points were analysed with the McNemar test. The influence of the predic‑
tor variables on the risk of UD 5 years after TME was calculated using univariate 
logistic regression analysis. To examine the independent influence of these variables, 
all variables associated with UD with p<0.100 in the univariate regression analysis 
were included in a multiple logistic regression analysis. P≤0.050 was considered 





Of a total of 1 530 Dutch patients, 542 were excluded from analysis for the following 
reasons: ineligible at randomisation (50), did not have surgery (37), died in hospital 
(52), did not provide informed consent for the quality‑of‑life study (89), did not 
return quality‑of‑life forms (30), and developed local or distant recurrence (284). 
table 1. Patient and treatment characteristics (continuous variables: median (minimum, 
maximum); categorical variables: number of patients (%); SHP=superior hypogastric plexus; 
HN=hypogastric nerves)






Body Mass Index (kg/m2; n=629) 25.3 (16.9, 53.1)














Tumour height (cm; n=775) 7.0 (0, 18.0)
Preoperative radiotherapy (n=785) 373 (47.5)
Type of resection (n=785)






Anastomotic height of LAR (cm; n=511) 5.5 (0, 14.0)
Resection additional organ (n=785) 144 (18.3)
Peroperative blood loss (ml; n=771) 1000 (50, 15000)
Autonomic nerve damage
as reported by surgeons (n=777)
 Total preservation
 SHP and/or HN
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Of 988 remaining patients, pretreatment forms were missing for 203 because they 
were completed after the start of PRT (53) or after surgery (67), were not dated (25) 
or were not completed at all (58). The preoperative response rate was 79.5 percent. 
Patient and treatment characteristics of the 785 patients who remained assessable are 
listed in Table 1.
Response rates to the postoperative forms varied between 82.2 and 89.6 percent20,21. 
Questionnaires concerning long‑term side‑effects of PRT were completed between 
3.3 and 7.4 years after TME. Because the percentages of patients with incontinence 
and those with difficulty in bladder emptying did not differ significantly within this 
interval (F=0.17, p=0.680 and F=1.80, p=0.181 respectively), all these patients were 
grouped together and considered as five‑year follow‑up patients.
Incontinence
Some 130 (16.7 percent) of 780 patients reported incontinence before surgery, of whom 
29 (22.6 percent) experienced an aggravation of symptoms after TME. Three months 
after TME the proportion of patients with incontinence was increased to 25.8 percent 
(McNemar χ2=34.16, 1 d.f., p<0.001). A further increase was observed until 5 years after 
TME when 38.1 percent reported incontinence (McNemar χ2=23.94, 1 d.f., p<0.001), 
of whom 72.0 percent had normal preoperative function. At that time the severity of 
dysfunction in patients with incontinence was also increased (McNemar χ2=14.70, 1 
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d.f., p<0.001); 30.7 percent reported severe incontinence at 5 years compared with 
17.8 percent at 3 months after TME. Figure 1 shows the percentages of patients with 
moderate or severe incontinence before and over the first 5 years after TME.
Of 447 patients who reported on the severity of incontinence at 5 years, 385 
had no incontinence before TME; 126 (32.7 percent) of these developed long‑term 
incontinence after treatment, of whom 93 (73.8 percent) reported moderate and 
33 (26.2 percent) reported severe incontinence 5 years after TME. In 63.9 percent 
incontinence that first developed by 3 months after TME persisted for 5 years. In the 
univariate regression analysis, preoperative incontinence, age above 65 years and 
female sex were associated with an increased risk of incontinence. No other risk fac‑
tors for incontinence, including PRT and type of resection, could be identified (Table 
2). In addition, body mass index above 30 kg/m2 (relative risk (RR) 1.69, p=0.141) 
childbirth (analysed in women only; RR 1.19, p=0.698) and posterior versus anterior 
tumour location (RR 0.86, p=0.756) did not increase the risk of urinary incontinence 
significantly. In the multivariable regression analysis, only preoperative incontinence 
(RR 2.75, p=0.001) and female sex (RR 2.77, p<0.001) remained predictive variables 
for urinary incontinence at 5 years after TME. Increased age was not a significant 
independent risk factor (RR 1.39, p=0.118). Except for preoperative dysfunction as a 
risk factor, the results were similar for patients with newly developed incontinence 
after treatment (data not shown).
Difficulty in bladder emptying
Before operation 176 (22.5 percent) of 782 patients reported difficulty in bladder 
emptying, of whom 11 (6.0 percent) experienced an aggravation of symptoms after 
TME. Three months after TME the proportion of patients with difficulty in bladder 
emptying was increased significantly to 36.0 percent (McNemar χ2=46.05, 1 d.f., 
p<0.001). A significant decrease up to 18 months (McNemar χ2=7.31, 1 d.f., p=0.007) 
and a subsequent stabilization occurred, resulting in 30.6 percent of patients with 
difficulty in bladder emptying 5 years after TME, of whom 65.0 percent had normal 
preoperative function. Long‑term improvement in the severity of dysfunction was 
especially apparent in patients with severe difficulty in bladder emptying after TME. 
Figure 2 shows the percentages of patients with difficulty in bladder emptying before 
and over the first 5 years after TME.
Of 445 patients who answered the question concerning bladder emptying at 5 
years, 351 patients had normal preoperative function; 90 (25.6 percent) of these 
developed long‑term difficulty after treatment, of whom 79 (88.0 percent) reported 
moderate and 11 (12.0 percent) reported severe dysfunction 5 years after TME. In 
the univariate regression analysis, increased risk in difficulty in bladder emptying 
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table 2. Regression analysis with urine incontinence at five years after TME as outcome 












33.3 (90 of 270)




29.2 (84 of 288)




33.8 (132 of 391)




38.5 (102 of 365)





40.2 (86 of 214)
35.4 (45 of 127)









35.9 (61 of 170)
38.8 (81 of 209)








37.6 (88 of 234)
38.7 (87 of 225) 1.04 (0.72‑1.53) 0.815
Type of resection (n=459)
 Low anterior resection
 Abdominoperineal resection
 Hartmann
39.7 (123 of 310)
33.1 (44 of 133)









39.8 (41 of 103)
44.4 (52 of 117)





Resection additional organ (n=459)
 No
 Yes
36.6 (138 of 377)
45.1 (37 of 82) 1.42 (0.88‑2.31) 0.151
Peroperative blood loss (n=451)
 <1500 ml
 ≥1500 ml
38.3 (132 of 345)
38.7 (41 of 106) 1.02 (0.65‑1.59) 0.938
Autonomic nerve damage (n=455)
 Total preservation
 SHP and/or HN
 Pelvic plexus/splanchnic nerves
 Unclear
38.1 (133 of 349)
38.5 (15 of 39)
36.4 (8 of 22)









5 years after TME was associated with preoperative difficulty in bladder emptying, 
excessive peroperative blood loss (at least 1 500 ml), and surgical damage to one 
or both sides of the inferior hypogastric plexus and/or the splanchnic nerves. No 
significant effect of PRT was observed (Table 3). In addition, body mass index above 
30 kg/m2 (RR 0.79, p=0.549), childbirth (analysed in women only; RR 2.72, p=0.121) 
and posterior versus anterior tumour location (RR 0.67, p=0.411) did not increase the 
risk of difficulty in bladder emptying significantly. In the multivariable regression 
analysis, preoperative difficulty in bladder emptying (RR 2.94, p<0.001), excessive 
peroperative blood loss (RR 1.73, p=0.028) and autonomic nerve damage (RR 2.82, 
p=0.024) remained significant predictors. Except for preoperative dysfunction as a 
risk factor, the results were similar for patients with newly developed difficulty in 
bladder emptying after TME (data not shown).
discussion
This five‑year follow‑up study has shown that new development and aggravation 
of UD occurs frequently after rectal cancer treatment. Urinary incontinence was 
associated with preoperative incontinence and female sex. Risk factors for difficulty 
in bladder emptying were preoperative difficulty in bladder emptying, peroperative 
blood loss and autonomic nerve damage. PRT did not increase the risk of UD.
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Figure 2. Percentage of patients with difficulty in emptying the bladder with time after total 
mesorectal excision (TME)
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table 3. Regression analysis with difficulties in bladder emptying at five years after TME 












30.9 (83 of 269)




33.1 (92 of 278)
26.5 (45 of 170) 0.73 (0.48‑1.11) 0.141




25.6 (90 of 351)




30.6 (79 of 258)





32.4 (68 of 210)
26.4 (33 of 125)









31.3 (52 of 166)
29.4 (60 of 204)








33.8 (77 of 228)
27.3 (60 of 220) 0.74 (0.49‑1.10) 0.136
Type of resection (n=448)
 Low anterior resection
 Abdominoperineal resection
 Hartmann
29.4 (89 of 303)
31.8 (41 of 129)









30.4 (31 of 102)
31.5 (35 of 111)





Resection additional organ (n=448)
 No
 Yes
30.7 (113 of 368)
30.0 (24 of 80) 0.97 (0.57‑1.64) 0.901
Peroperative blood loss (n=440)
 <1500 ml
 ≥1500 ml
28.4 (95 of 335)
39.0 (41 of 105) 1.62 (1.02‑2.56) 0.040 <0.001
Autonomic nerve damage (n=444)
 Total preservation
 SHP and/or HN
 Pelvic plexus/splanchnic nerves
 Unclear
26.8 (91 of 340)
35.9 (14 of 39)
54.5 (12 of 22)










This is the largest study to investigate potential risk factors for UD, distinguishing 
between urinary incontinence and difficulty in bladder emptying, longitudinally 
over 5 years after TME. The prevalence of UD in the present study is comparable to 
published data3‑6,8‑10,12,16.
Several studies have shown that damage to the autonomic nerves results in 
UD5,14,17,24. The pelvic autonomic nerves are essential for normal urinary function. 
During urine storage, the sympathetic nervous system plays a major role. Pregan‑
glionic neurones in the upper lumbar spinal cord excite sympathetic neurones in 
the inferior mesenteric ganglia through the superior hypogastric plexus, hypogastric 
nerves and pelvic ganglia via the sacral splanchnic nerves. This causes contraction 
of smooth muscle in the trigone and urethra, which is coordinated with contraction 
of the external urethral sphincter. These various neural pathways continue to be 
activated until bladder pressure is sufficient to trigger a micturition reflex.
The parasympathetic nervous system plays a dominant role during voiding. 
Activation of sacral preganglionic neurones excites parasympathetic ganglionic 
neurones in the pelvic splanchnic nerves and inferior hypogastric plexus. This causes 
contraction of the detrusor muscle and relaxation of the urethra, with coordinated 
inhibition of nerve activity to the external urethral sphincter25. Therefore, damage 
to the parasympathetic sacral splanchnic nerves and inferior hypogastric plexus may 
lead to difficulty in bladder emptying, as demonstrated in the present study. The risk 
of difficulty in bladder emptying after TME was significantly increased if there was 
surgical damage to the sacral splanchnic nerves and inferior hypogastric plexus, 
which was recorded by the surgeon in 44 (5.7 percent) of 777 patients.
A correlation between long‑term urinary incontinence and autonomic nerve dam‑
age was not demonstrated. The reason for this might be that surgical disruption of 
the autonomic nerves only leads to significant incontinence when most of the pelvic 
autonomic nerves are seriously damaged. One‑sided preservation of the inferior 
hypogastric plexus only has been shown clinically to result in acceptable urinary 
continence3,8. The incidence of bilateral surgical disruption of the inferior hypogastric 
plexus is not known. Surgeons are often unable to verify whether bilateral damage 
has occurred, but it is not expected to occur frequently during a TME procedure9.
Even with accurate neuroanatomical knowledge, pelvic autonomic nerve sparing 
surgery can be very difficult. Individual differences in the running patterns of the 
nerves and variation in the volumes of nerve fibres in each region of the pelvis ham‑
per appropriate identification of structures. The use of a nerve stimulating device 
might facilitate preservation of the pelvic autonomic nerves during TME. The ef‑
ficacy of a nerve stimulator in assisting intraoperative identification of the autonomic 
nerves during TME and objectively confirming nerve preservation after proctectomy 
was tested by da Silva and colleagues26 in 29 men. Intraoperative visualisation of 
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the hypogastric nerves was possible in 19 of 26 patients. The nerve stimulator suc‑
cessfully identified the nerves in six of the seven remaining patients and confirmed 
preservation of the hypogastric nerves in 27 of 29 patients after proctectomy. The 
ultimate role of this device during TME requires further evaluation.
New anatomical views could also enhance autonomic nerve sparing during 
TME. In a recent publication, a Japanese group meticulously investigated the fascial 
structures posterolateral to the rectum. They identified a prehypogastric nerve fascia 
between the fascia propria of the rectum and the parietal presacral fascia. Sharp dis‑
section in front of the prehypogastric nerve fascia seemed to lead the plane precisely 
between the hypogastric nerves, pelvic plexus and proper rectal fascia which borders 
the mesorectum. In contrast, although the loose areolar space between the presacral 
parietal fascia and the visceral fascia (mesorectal fascia) is easily identified during 
classical TME dissection, some surgeons follow the presacral parietal fascia and 
not the mesorectal fascia. Especially laterally this fascia divides in several compart‑
ments containing the ureter and the autonomic nerves. However, it is not identified 
easily and, once in the wrong plane, the nerves can be severed27.
In the present study excessive peroperative blood loss was significantly associated 
with nerve damage (data not shown). Diathermic coagulation and use of numerous 
sutures to secure haemostasis may cause nerve damage. Moreover, excessive blood 
loss hinders vision deep in the pelvis, making nerve sparing virtually impossible3,5. 
Excessive peroperative blood loss was also an independent risk factor for difficulty 
in bladder emptying, which might be explained by impaired tissue healing or may be 
due to the possibility that nerve damage was underreported.
The decrease in number of patients with difficulty in bladder emptying after 3 
months might be explained by postoperative inflammatory changes in the paravesi‑
cal tissues, which heal with time, and the possible resolution of partial nerve damage 
within the first 3‑6 months after surgery, resulting in functional improvement and 
even complete recovery13.
Difficulty in bladder emptying may result in overflow incontinence28. Indeed, dif‑
ficulty in bladder emptying was significantly associated with urinary incontinence 3 
months after TME (data not shown). Long‑term urinary incontinence after TME was 
not associated with difficulty in bladder emptying in this study (data not shown), be‑
cause the number of patients with urinary incontinence increased during the 5 years 
after TME, probably owing to ageing of the patient group with a concomitant risk 
of urge and stress incontinence29. The present study has shown that newly developed 
incontinence shortly after TME is a predictor of long‑term incontinence. It might 
therefore be worth proposing a pelvic floor and bladder training programme to those 
who develop incontinence after TME30.
Chapter 5
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A surgical factor contributing to the development of long‑term urinary inconti‑
nence after TME might be surgical disruption of the innervation of the levator ani 
muscles. According to renewed anatomical insights, the levator ani muscles, which 
are essential to urinary continence (‘hammock’ hypothesis)31, are not innervated 
by the pudendal nerves, but receive their motor innervation from a separate nerve, 
which runs on the surface of the levator ani muscle. During surgical dissection deep 
within the pelvis, this nerve might be disrupted32. A weak pelvic floor resulting in 
loss of support to urethral and bladder neck can contribute to loss of sphincter tone 
and therefore incontinence31,33. During the TME trial this anatomical insight was 
not acknowledged and was therefore not considered. In this respect an increased 
incidence of urinary incontinence might be expected after abdominoperineal resec‑
tion with implicit (partial) resection of the levator ani muscles. This is not shown by 
the present results, but is in accordance with several earlier studies16,18. The present 
study is possibly biased owing to exclusion of patients with recurrence (relatively 
more patients with advanced tumours and those treated with abdominoperineal 
resection). Such patients, especially those treated with abdominoperineal resection, 
indeed reported more (severe) urinary incontinence 3 months after surgery (data not 
shown).
There was an increased risk of new development of incontinence after TME in 
women in this study. According to Ulmsten31, support to the urethral and bladder neck 
is regulated by surrounding structures, the most important being the pubourethral‑
vesical ligaments, suburethral vaginal wall, levator plate, pubococcygeus muscles 
and connective tissue. These components can compensate for each other in case of 
inappropriate function. In postmenopausal women many of these structures might 
already be impaired because the function of many structures involved in preserving 
continence is influenced by oestrogen receptors31. Additional changed anatomical 
relationships between the bladder, urethra and pelvic floor, and possibly damage to 
the innervation of the levator ani muscles during TME, would further impair the 
continence mechanism and lead to incontinence.
Urinary dysfunction has been reported after radiotherapy for cancer of the pelvic 
organs34,35. Depending on the dose and irradiation field, radiotherapy may cause 
fibrosis in the bladder and the urethral sphincters35. However, there is no consensus 
in the literature about the contribution of radiotherapy to the development of UD 
after rectal cancer treatment. Only one of the published studies randomised for PRT. 
Pollack and colleagues4 recently reported an increased risk of UD after rectal cancer 
treatment in irradiated patients compared with those who had TME alone. However, 
only 139 patients were evaluated. Analysis of data from 785 patients in the Dutch 
trial of TME with or without radiotherapy, which was designed primarily to detect 
the effect and consequences of PRT, has demonstrated that PRT does not contribute 
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to the development of UD after rectal cancer treatment when surgical factors are 
taken into account.
In conclusion, a substantial proportion of patients with rectal cancer suffer from 
long‑term UD. It is a significant clinical problem after treatment for primary rectal 
cancer. Difficulty in bladder emptying is related to surgical damage to the autonomic 
nerves. Because no influence of PRT was found, surgery also seems to play an im‑
portant role in the development of urinary incontinence. Special attention to the 
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after rectal cancer treatment
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Low anterior resection (LAR) may result in faecal incontinence. This study aimed to 
identify risk factors for long‑term faecal incontinence after total mesorectal excision 
(TME) with or without preoperative radiotherapy (PRT).
Methods
Between 1996 and 1999, patients with operable rectal cancer were randomised to 
TME with or without PRT. Eligible patients who underwent LAR were studied 
retrospectively at 2 years (399 patients) and 5 years (339 patients) after TME.
Results
At 5 years after surgery faecal incontinence was reported by 61.5 percent of patients 
who had PRT and 38.8 percent of those who did not (p<0.001). Excessive blood loss 
and height of the tumour were associated with long‑term faecal incontinence, but 
only in patients treated with PRT.
Conclusion
Faecal incontinence is likely to occur after PRT and TME, especially when the 
perineum is irradiated.
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introduction
Local recurrence is a major problem in the treatment of rectal cancer. A significant 
improvement in local control has been achieved by the introduction of preoperative 
radiotherapy (PRT)1,2 and improved surgical techniques, including total mesorectal 
excision (TME)3‑9. TME is defined as ‘a sharp dissection under clear vision between 
the parietal and visceral planes of the pelvic fascia, removing the mesorectum (the 
fatty tissue surrounding the rectal wall) contained within an intact endovisceral 
fascia’3. The understanding that distal resection margins of 1‑2 cm are adequate10 
resulted in an increased number of patients being treated with low anterior resection 
(LAR)7,11,12.
Compared with abdominoperineal resection (APR), LAR has the advantage of 
preserving normal anal continence, provided that adequate function is ensured13. 
However, poor functional outcome is often reported, with several studies demon‑
strating that one‑third of patients experience faecal incontinence after LAR12,14,15. 
Even worse outcomes are reported by patients treated with PRT16‑18. Although re‑
storative surgery is generally thought to result in a better quality of life (QoL), faecal 
incontinence is a major problem. Abdominoperineal resection might, therefore, be a 
more satisfactory option than LAR in selected patients11,19,20. Risk factors should be 
identified that can be used to select patients likely to become incontinent. Previous 
studies generally agree that PRT is such a risk factor16‑18, but differ with respect to the 
influence of other variables7,12,13,19,21‑35.
The aim of the present study was to investigate risk factors for long‑term faecal 
incontinence in the Dutch TME trial2. This trial included over 900 patients treated 
with LAR and provided information on incontinence in both the short and long 
term. Demographic, tumour‑specific and treatment‑related variables were selected 
from the literature, in addition to factors that may have led to nerve damage during 
surgery.
Methods
Data were obtained from the database of the Dutch TME trial2. This international 
multicentre trial investigated the efficacy of short‑term PRT in patients with rectal 
cancer treated with TME. Between January 1996 and December 1999, 1 861 patients 
with histologically proven adenocarcinoma of the rectum and without evidence of 
distant metastases were included in the trial and randomised to undergo TME alone 
or preceded by PRT. Patients were eligible for randomisation if the tumour was clini‑
cally resectable and located 15 cm or less from the anal verge. Only patients who 
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underwent LAR and participated in the QoL study16,17 or in the study on long‑term 
side‑effects of PRT16,17 were selected for this analysis. Patients with recurrence during 
the period of evaluation were excluded to avoid this potential confounding variable.
Treatment
Patients assigned to PRT received a total dose of 25 Gy in five fractions over 5‑7 
days. The target volume included the primary tumour, and perirectal, presacral and 
internal iliac nodes. The perineum was included if APR was planned; otherwise the 
lower border was 3 cm above the anal verge. Surgery took place within 10 days of 
the start of PRT.
Outcome measures
Patients completed a questionnaire for the QoL study16, including a question on fae‑
cal incontinence 3, 6, 12, 18 and 24 months after operation. Responses were given 
on a four‑point severity scale, ranging from ‘not at all’ to ‘very much’. In the study 
investigating long‑term side‑effects of PRT17 (a median of 5 years after surgery), the 
frequency of faecal incontinence was indicated on a four‑point scale ranging from 
‘never’ to ‘always (every day)’. To minimise differences in questionnaires, answers 
were transformed into a binary outcome measure (absence versus presence of incon‑
tinence, irrespective of severity or frequency) for the univariate and multivariable 
logistic regression analyses.
The database did not contain information on anastomotic height, so this was 
estimated by subtracting the distal margin from the distance of the tumour to the 
anal verge (tumour height). The distal margin was evaluated on the macroscopic 
specimen after surgery. If the distal margin was equal to or larger than the estimated 
tumour height, patients were considered to have an ultralow anastomosis (height of 
anastomosis 0 cm). Anastomotic height, ranging from 0 to 12.5 (median 5.5) cm, was 
divided into quartiles for the analysis outlined here.
statistical analysis
Data were analysed with SPSS® version 12.0 for Windows® (SPSS, Chicago, Illinois, 
USA). The influence of the predictor variables on the risk of incontinence 2 and 5 
years after surgery was calculated using univariate logistic regression analysis. To 
examine any independent influence, all variables associated with faecal incontinence 
(p<0.100 in the univariate regression analysis) were entered into a multiple logistic 
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regression analysis. P≤0.050 was considered statistically significant. Patients treated 
with and without PRT were analysed separately.
resuLts
Of the 1 530 Dutch patients, 924 eligible patients underwent LAR. Of these, 371 
patients were excluded owing to in‑hospital death (34), lack of informed consent for 
the QoL study (85), or local or distant recurrence (252). At 2 years after surgery 460 
correctly completed questionnaires were received. This number was 385 at 5 years 
after randomisation owing to intercurrent deaths and non‑compliance. Because of 
the presence of a stoma the question on incontinence was answered by 399 and 339 
patients at 2 and 5 years respectively.
Faecal incontinence
Questionnaires concerning long‑term side‑effects of PRT were completed between 
3.3 and 7.4 years after LAR. The percentage of patients with incontinence did not 
change significantly within this interval (F=0.46, p=0.499), so a median follow‑up 
of 5 years was used in the following analyses. Figure 1 shows the proportions of 
patients with incontinence over time. From 3 to 24 months, the percentage of patients 
















Figure 1. Percentage of patients with faecal incontinence after rectal cancer surgery with 
(PRT+) or without preoperative radiotherapy (PRT‑). Dashed portion of curves is based on only 
one questionnaire for each patient, obtained between 3.3 and 7.4 years after LAR.
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Z=‑2.12, p=0.034) and those who did not receive PRT (Z=‑2.54, p=0.011). At 24 
months 102 (52.0 percent) of the 196 patients treated with PRT and 72 (35.5 percent) 
of 203 without PRT reported incontinence (p=0.001, χ2 test). Between 24 months and 
5 years the percentage of patients with incontinence increased significantly in the 
PRT group (Z=‑2.04, p=0.041), but not in the group without PRT (Z=‑1.33, p=0.182). 
At 5 years 104 (61.5 percent) of 169 patients treated with PRT and 66 (38.8 percent) 
of 170 who did not receive PRT reported faecal incontinence (p<0.001).
Within the group of patients with incontinence, the severity at 2 years was com‑
parable in the groups treated with and without PRT (χ2=0.334, p=0.933) (Figure 2a). 
Most patients reported a little faecal incontinence (68.6 and 72.2 percent among 
patients who did and did not have PRT respectively). At 5 years after surgery, in‑
continent patients with PRT reported a higher frequency of faecal incontinence than 
patients without PRT (χ2= 4.711, p=0.030) (Figure 2b).
risk factors
The influence of potential risk factors on long‑term faecal incontinence was first 
analysed for the total patient group. Because multivariable regression analysis 
showed an interaction effect between PRT and excessive peroperative blood loss 
(more than 1 400 ml) (p=0.001), it was decided to investigate the risk factors for the 
groups with and without PRT separately. The results of the univariate regression 
analysis are shown in Table 1.
(figuur 2, behorend bij hoofdstuk 6) 
 
  





















RT + TME 
TME 
Figure 2. a) Severity of faecal incontinence at 2 years and b) frequency at 5 years after rectal 
cancer surgery with or without preoperative radiotherapy
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Patients treated without preoperative radiotherapy
In patients who did not have PRT no variable significantly influenced incontinence 
risk at 2 or 5 years.
Patients treated preoperative radiotherapy
Excessive blood loss (upper quartile of more than 1 400 ml) was more common in pa‑
tients who received PRT than in those who did not (p=0.014). In patients treated with 
PRT, excessive blood loss was a risk factor for incontinence at both 2 years (relative 
risk 2.26, p=0.012) and 5 years (relative risk 2.89, p=0.006). Level of anastomosis 
was not significantly associated with faecal incontinence at 2 years (p=0.052) or 5 
years (p=0.075). However, patients with an anastomotic level closer than 4.0 cm from 
the anal verge reported significantly more incontinence than patients with an anasto‑
motic level between 5.5 and 7.5 cm from the anal verge at 2 years (p=0.040) and at 5 
years (p=0.033). Low tumour height also increased the risk of incontinence, but only 
at 5 years (p=0.009); 23 of 26 patients with a tumour within 5 cm from the anal verge 
had incontinence compared with 63 of 105 and 18 of 38 patients with a tumour 5‑10 
cm (p=0.011) or more than 10 cm (p=0.002) from the anal verge respectively.
In the multivariable regression analysis, excessive blood loss and anastomotic 
height were included as input variables to predict incontinence at 2 years in patients 
with PRT. Excessive blood loss remained a significant predictor (relative risk 2.32, 
p=0.015), but anastomotic height did not (p=0.081). In the prediction of incontinence 
at 5 years after TME, excessive blood loss, anastomotic height and tumour height 
would be included (p<0.100 in the univariate analysis). However, because anasto‑
motic height was calculated from tumour height, only one of these variables could 
be included in the multivariable regression analysis36. Therefore, the analysis was 
performed twice: first with excessive blood loss and anastomotic height as input 
variables, and then with excessive blood loss and tumour height as input variables 
(Table 2). Excessive blood loss was a significant independent variable (p=0.011) and 
tumour height also remained a significant predictor (p=0.013), but not anastomotic 
height (p=0.070).
When treating low tumours, inclusion of the anal sphincter in the radiation field 
cannot always be avoided. Responses from patients with an anastomosis below the 
median of 5.5 cm were evaluated to determine the influence of sphincter irradiation 
on incontinence. In 21 (22 percent) of 94 patients the perineum, and consequently 
the sphincter, was included in the radiation field. Within this group 16 of 21 patients 
reported incontinence at 2 years after TME compared with 40 of 73 patients whose 
sphincter was not specifically included in the radiation field (relative risk 2.64, 
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p=0.085). Respective figures at 5 years were 14 of 15 versus 47 of 72 (relative risk 
7.45, p=0.059).
discussion
This study identified tumour height and excessive blood loss as independent predic‑
tors of faecal incontinence after LAR with TME in patients who had PRT, whereas 
no risk factors were found in patients who did not receive PRT.
Faecal incontinence may be defined as involuntary rectal evacuation37. This may 
range from inadvertent gas release to minor soiling or complete escape of rectal con‑
tents. The present study analysed the influence of potential risk factors on the risk of 
incontinence, irrespective of its severity. However, slight impairment of continence 
may be more acceptable to patients than a permanent stoma. The clinical relevance 
of the present cut‑off point (absence versus presence of incontinence) is therefore 
limited. It should also be noted that the measurement of tumour height by endoscopy 
or digital rectal examination, and thus the calculation of anastomotic height, are 
not very accurate. However, the present examination of potential risk factors in a 
relatively large study population followed for up to 5 years after surgery provides 
useful information.
table 2. Results of multivariable analyses of risk factors for faecal incontinence. (RR=relative 
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Faecal incontinence after rectal cancer treatment
Faecal incontinence after LAR has already been reported in the Dutch TME 
trial, especially among patients treated with PRT16,17. Some 38.8 percent of patients 
who had TME alone and 61.5 percent of those treated with surgery and PRT were 
incontinent at 5 years. This was in agreement with other studies, generally reporting 
incontinence in about half of patients14‑19. However, only 9 percent of patients treated 
with long‑term PRT (45 Gy over 5 weeks) had incontinence38. This discrepancy may 
be attributed to physician reporting of incontinence in the latter study. Meanwhile 
faecal incontinence may have been overreported in the present study if respond‑
ers had more problems than non‑responders. This should not affect the influence 
of possible risk factors as long as proportional risks are relatively consistent, as 
described.
No consensus was achieved in previous studies on the influence of most potential 
risk factors7,12,13,19,21‑35. However, most agree that the risk of incontinence is not influ‑
enced by the construction of a temporary stoma19,21,22 or increased age7,19,21,22,24,26. It 
is surprising that the influence of age cannot be demonstrated in patients with rectal 
cancer, because incontinence is strongly associated with senescence in the general 
population37. Furthermore, previous investigators32‑35 found that reconstruction with 
a colonic J‑pouch (which compensates for the loss of rectal reservoir) was associated 
with a lower incidence of incontinence than reconstruction with a straight anasto‑
mosis. This was not apparent in the present study, possibly because of the relatively 
small number of patients with a colonic J‑pouch (28.1 percent).
In previous publications a low anastomotic height increased the risk of incon‑
tinence in patients treated with PRT19,21,24,27. These studies evaluated anastomotic 
level (and not tumour height) as a risk factor for incontinence. Both were evaluated 
here because the two variables have a different influence on the underlying mecha‑
nisms of incontinence: tumour height determines the lower border of the radiation 
field, whereas anastomotic height determines the length of residual rectum. At 5 
years tumour height was more predictive than anastomotic height, suggesting that 
the site of irradiation is more important than rectal length. However, incontinence 
is multifactorial37 and it is challenging to separate these metrics based on distance 
alone. The rectum acts as a reservoir and the smaller neorectum has a lower capacity 
and smaller tolerated volumes39. Fibrosis due to PRT diminishes compliance of the 
residual rectum. The anal sphincters keep the anal canal closed in a resting state37. 
Radiotherapy may disrupt the myenteric plexus of the internal anal sphincter39, com‑
promising the rectoinhibitory reflex and resting anal pressures18,37. PRT is known to 
damage the internal sphincter after several years40. However, early problems may 
arise as a result of damage to the innervation of the pelvic floor muscles. The levator 
ani muscles, essential to continence, receive their motor innervation from a nerve 
that runs on the surface41. During dissection deep within the pelvis, this nerve might 
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be disrupted. Furthermore, transection of the inferior mesenteric artery at its origin 
(high tie) might disrupt autonomic nerve fibres42.
The results of this study may contribute to a better understanding of incontinence 
following rectal cancer surgery, and may facilitate the decision to perform a LAR or 
create a permanent stoma. Treating all rectal cancers with PRT would result in some 
degree of overtreatment18, so patient selection for PRT is necessary.
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descriPtion oF the case
A 67‑year‑old woman reported to experience frequent bowel movements during a 
control check‑up after rectal cancer treatment. Five years before, she was treated 
for stage I‑disease (T2N0M0), located 5 cm from the anal verge. The treatment 
consisted of short‑course pelvic radiotherapy (5x5 Gy) followed by low anterior re‑
section (LAR) with straight colorectal anastomosis. No postoperative complications 
had occurred, and a temporary colostomy had been constructed, which was reversed 
after 4 months. The woman had no previous medical history.
On questioning, she reported to have suffered from rectal urgency symptoms ever 
since the colostomy was reversed. These symptoms were quite acceptable, especially 
because she assumed them to be temporary. However, it became worse over time and 
urgency developed into involuntary stool leakage, requiring wearing a protective pad 
constantly. Furthermore, she indicated to experience urine loss, especially during 
coughing, laughing or lifting. She stated that voiding and defaecation were fully 
normal before her treatment for rectal cancer.
are incontinence ProbLeMs aFter rectaL cancer 
treatMent coMMon?
Faecal incontinence after rectal cancer treatment occurs frequently, affecting almost 
half of patients with normal preoperative functioning.1 This may range from inad‑
vertent gas release to minor soiling or complete escape of rectal contents. These 
symptoms are often described as “anterior resection syndrome”.2 Long‑term urinary 
incontinence develops in almost one third of patients and combined urinary and 
faecal incontinence occurs in 14 percent of patients with normal preoperative func‑
tion.3,4 Figure 1 shows the incidence of faecal and urinary incontinence during five 
years after rectal cancer treatment. Incontinence problems lead to avoidance of cer‑
tain activities, such as long‑distance travel by car or plane, during which bathroom 
facilities may not be immediately available. Additionally, sexual dysfunction is a 
frequent and distressing complication of rectal cancer treatment. Male patients may 
experience ejaculatory problems and impotence. Female patients may suffer from 
dyspareunia and vaginal dryness.5 Poor functional outcome of rectal cancer treat‑
ment is a major problem since bowel and urinary dysfunction can have a negative 
impact on a patient’s physical, psychological, social and emotional functioning, as 
well as the patient’s overall well‑being.6
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what couLd have caused her incontinence ProbLeMs?
Faecal incontinence is usually the result of failure of more than one component of the 
continence mechanism. The rectum, the anal sphincters and the pelvic floor muscles 
are essential in the maintenance of faecal continence.7 First of all, the rectum acts 
as a reservoir to store stool. A smaller neorectum after LAR has a lower capacity 
causing a decrease in maximum tolerated volumes. Furthermore, the anal canal 
contains a rich network of nerve endings sensitive to pain, temperature and touch, 
which is used to differentiate solid or liquid stool from flatus, and allows for selective 
passage of flatus. Patients with a small neorectum after resection of a low lying tu‑
mour, as was the case in the present patient, are therefore at increased risk for faecal 
incontinence. Moreover, in this patient’s case, rectal cancer resection was preceded 
by pelvic radiotherapy, which is known to increase the risk of faecal incontinence.8 
Radiotherapy diminishes compliance of the rectum due to fibrosis, resulting in a 
reduced reservoir function. Radiotherapy induced fibrosis of the myenteric plexus of 
the internal anal sphincter can prevent adequate closure of the anal canal in a resting 
state. In addition, faecal incontinence after rectal cancer treatment has been reported 
to be caused by impaired pelvic floor movement, i.e. a disturbed change in anorectal 
angle due to a dysfunctional levator ani muscle.9 According to renewed anatomical 
insight, the levator ani muscle is not innervated by the pudendal nerve, but receives 
its innervation from a separate nerve, which runs on the surface of the pelvic floor 



























Figure 1. Percentage of faecal and urinary incontinence after rectal cancer treatment reported 
by patients without preoperative faecal or urinary incontinence who participated in the Dutch 
TME trial.
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(a three‑dimensional reconstruction of the levator ani nerve can be obtained online 
in a recent publication in Journal of Clinical Oncology4). During surgical dissection 
deep within the pelvis, especially in case of a low lying tumour, this nerve might be 
disrupted.4
Urinary incontinence after rectal cancer treatment may consist of urge, overflow 
and/or stress incontinence. Urge incontinence may result from a reduced bladder 
capacity due to surgical disruption of the sympathetic nerve supply (the hypogastric 
nerves and the pelvic plexus).10 Overflow incontinence may be caused by surgical 
damage to the sacral splanchnic nerves, resulting in bladder emptying problems 
(Figure 2). However, the present patient suffers from involuntary urine loss during 
increased abdominal pressure, which is a sign of urinary stress incontinence. Stress 
urinary incontinence may result from impaired support to the urethra and bladder 
 
Figure 2. Anatomical graph of the pelvic floor and the autonomic nerves (1: hypogastric nerves; 2: pelvic 
splanchnic nerves; 3: pelvic plexus; 4: levator ani nerve. Adapted from: Lange JF (2002) Surgical 





Figure 2. Anatomical graph of the pelvic floor and the autonomic nerves (1: hypogastric nerves; 
2: pelvic splanchnic nerves; 3: pelvic plexus; 4: levator ani nerve. Adapted from: Lange JF 
(2002) Surgical anatomy of the abdomen. Maarssen (Netherlands): Elsevier. p. 178.)
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neck. This support is regulated by surrounding structures, the most important be‑
ing the pubourethral‑vesical ligaments, the suburethral vaginal wall, the levator 
plate, the pubococcygeus muscles and the connective tissue. These components can 
compensate for each other in case of inappropriate function. In postmenopausal 
female patients many of these structures are impaired because the function of many 
structures involved in preserving continence is influenced by oestrogen receptors. 
Additional changed anatomical relations between bladder, urethra and pelvic floor, 
and possibly damage to the innervation of the levator ani muscles during LAR would 
further impair the continence mechanism and lead to urinary incontinence.11
what couLd have caused the worseninG oF syMPtoMs 
over tiMe?
Improvement in anorectal function usually occurs over 6 to 12 months, which cor‑
relates with expansion in the reservoir capacity of the neorectum. Postoperative as‑
sessment of function after one year has shown that many patients achieve continence 
to solid stool but that control of minor staining, flatus, and stool frequency is more 
variable.12 However, worsening of faecal incontinence over time is typically seen in 
patients treated with pelvic radiotherapy (Figure 3). This may be explained by the 
fact that vascular damage is a long‑term effect of radiotherapy, compromising the 














































Figure 3. Incidence of moderate and severe faecal incontinence reported by patients who 
participated in the Dutch TME trial and were treated with preoperative radiotherapy. Only 
patients without preoperative dysfunction were included in this diagram.
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endovascular cushions filling the 7‑8 mm gap within the internal sphincter ring, 
which contribute to continence at rest.13
Worsening of urinary incontinence over time could be due to ageing and laxity of 
the pelvic floor musculature with concomitant risk of increased stress incontinence.
how couLd incontinence ProbLeMs have been Prevented?
First, functional problems after rectal cancer surgery might have been prevented 
by special attention to nerve preservation. Despite the fact that the current rectal 
resection technique, described by total mesorectal excision, permits preservation of 
the innervation of the pelvic organs, nerve sparing surgery can be difficult. Differ‑
ences among individuals in the running patterns of the nerves and variation in the 
volumes of nerve fibres in each region of the pelvis hamper appropriate identification 
of structures. Especially during excessive peroperative blood loss, nerves are at risk 
due to diathermic coagulation and numerous sutures to secure hemostasis. To avoid 
excessive bleeding and accidental nerve disruption during surgery, it is important to 
adhere to the surgical plane and reduce the use of blunt dissection. Also, the use of a 
nerve stimulating device may facilitate preservation of the pelvic autonomic nerves 
during pelvic dissection.14
It is difficult to prevent radiotherapy induced bowel dysfunction, as radiotherapy 
is considered an important part of rectal cancer treatment, decreasing the risk of lo‑
cal recurrence.15,16 However, treating all rectal cancer patients with radiotherapy can 
result in substantial overtreatment. Therefore, it is of great importance to identify 
patients with low risk of local recurrence in which radiotherapy is redundant.16 Cur‑
rently, new imaging modalities are developed and molecular biomarkers are being 
identified to predict prognosis, making patient tailored treatment possible soon.
An alternative to avoid faecal incontinence after rectal cancer treatment is to 
construct a permanent stoma by abdominoperineal resection instead of sphincter 
preservation by LAR. Traditionally, the construction of a stoma has been regarded 
as an unfavourable outcome, as Quality of Life (QoL) of stoma patients is believed 
to be inferior compared to non‑stoma patients. However, recent studies have shown 
that QoL after abdominoperineal resection may not be as bad as once believed and 
may be equal after LAR.17 Moreover, LAR patients with a low anastomosis have 
been reported to have a worse QoL compared to stoma patients, due to poor func‑
tional outcome.18 Obviously, cultural, social, religious and sociodemographic factors 
influence how patients assess their QoL with a permanent stoma. In selected cases, 
abdominoperineal resection might be a more satisfactory option than LAR.
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what treatMent ModaLities are avaiLabLe?
Standards of management of patients with incontinence problems after rectal cancer 
treatment are still lacking. Many treatments are available, however there is not 
enough evidence to support the effectiveness of any of them. First of all, conserva‑
tive measures aimed at symptomatic control (e.g. dietary regiments, absorbent pads 
and pharmacotherapy including hormonal manipulation, constipating agents and 
enemas) may be tried. Colonic irrigation in the morning in order to clean the colon 
from faeces has been shown to reduce symptoms.19 The present patient was offered 
colonic irrigation. During a control check‑up one year later, she reported a beneficial 
effect of colonic irrigation, improving the quality of her life.
Alternatively, there are a number of interventions aimed at correcting the underlying 
cause, including both non‑surgical and surgical techniques. Non‑surgical procedures 
include biofeedback and pelvic floor muscle training. Biofeedback therapy, showing 
patients how to use the pelvic floor muscles properly, is often recommended and may 
consist of rectal sensitivity, strength and coordination training.20 Pelvic floor muscle 
training improves pelvic floor support. It is regarded as the first line treatment for 
urinary incontinence and used to improve faecal incontinence. Pelvic floor muscle 
training may be of limited use in patients in which the innervation of the pelvic floor 
has been damaged during surgery.
If conservative management fails, surgical intervention may be considered. First, 
appropriate assessment should be carried out for characterisation of the underlying 
cause. Anorectal physiology can be evaluated with manometry, and mechanical 
damage to the sphincter muscle can be detected with endoanal ultrasound. If the 
sphincter is intact, sacral nerve stimulation in which electrodes are inserted through 
the sacral foramina under general anaesthetic for stimulation of the sacral nerves 
may be effective for both urinary and faecal incontinence. Several studies have 
shown promising results, however experience with sacral nerve stimulation for fae‑
cal incontinence following rectal resection is still limited.21 In case of a sphincter 
muscle defect, an artificial bowel sphincter can be constructed. This would not be 
an option in the present case as severe complications after artificial bowel sphincter 
construction in a radiation‑injured anorectum have been reported.22 The construction 
of a colostomy is considered an option when all else has failed, but is also associated 
with a significant rate of complications in irradiated patients.23 Uncertainty remains 
whether any surgical intervention does more good than harm.
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discussion
Incontinence problems after rectal cancer treatment are common and can have a 
major impact on QoL. Nevertheless, it often remains undiscussed in clinical practice. 
Patients should be informed preoperatively about the possible development anorec‑
tal and urogenital dysfunction and the increased risk in case of a low tumour and 
radiotherapy. The different surgical options, LAR and abdominoperineal resection, 
and their potential outcomes should be discussed with the patient, as the individual 
preference of the patient is of great importance in this.24 Educating patients on the 
modern stoma care may reduce ill‑informed hesitations towards a permanent stoma 
by patients. At present, there is an ongoing project concerning the perceived costs 
and benefits of preoperative radiotherapy in rectal cancer treatment and investigating 
to what extent patients and oncologists believe that patients should also participate in 
decision making regarding preoperative radiotherapy.
Postoperatively, evaluation of the patients’ functional outcome should be standard 
procedure at every follow‑up appointment. Patients are not likely to bring up incon‑
tinence problems themselves out of shame or because they don’t relate it to rectal 
cancer treatment, especially if incontinence problems occur several years after treat‑
ment. Available therapies, primarily conservative regiments, should be proposed if 
needed.
Although the exact etiology of incontinence problems after multimodality treat‑
ment of rectal cancer is unknown, specific technical aspects of the surgical procedure 
play a major role. Special attention to pelvic autonomic nerves, sharp dissection, 
adhering to the surgical plane and reducing the use of blunt dissection may lower 
the risk of urinary and faecal incontinence.4 Furthermore, to prevent overtreatment 
with radiotherapy, a tailor‑made approach for every rectal cancer patient that is based 
on preoperative prediction of the risk for local recurrence seems to be favourable. 
Currently, new imaging modalities are developed and molecular biomarkers are 
identified to predict prognosis, making patient tailored treatment possible soon.25,26 




major impact on QoL.
•	 Patients	 should	 be	 informed	 about	 the	 surgical	 options,	LAR	and	 abdomino‑




urinary incontinence, with an additional effect of radiotherapy.
•	 Faecal	incontinence	can	worsen	over	time	in	case	of	radiotherapy.
•	 Several	non-surgical	and	surgical	therapies	of	incontinence	problems	are	avail‑
able; conservative therapies should be the first line choice.
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Total mesorectal excision (TME) for rectal cancer may result in anorectal and 
urogenital dysfunction. We aimed to study possible nerve disruption during TME 
and its consequences for functional outcome. Because the levator ani muscle plays 
an important role in both urinary and faecal continence, an explanation could be 
peroperative damage of the nerve supply to the levator ani muscle.
Methods
Total mesorectal excision was performed on cadaver pelves. Subsequently, the 
anatomy of the pelvic floor innervations and its relation to the pelvic autonomic in‑
nervation and the mesorectum were studied. Additionally, data from the Dutch TME 
trial were analysed to relate anorectal and urinary dysfunction to possible nerve 
damage during TME procedure.
Results
Cadaver TME surgery demonstrated that, especially in low tumours, the pelvic floor 
innervation can be damaged. Furthermore, the origin of the levator ani nerve was 
located in close proximity of the origin of the pelvic splanchnic nerves. Analysis of 
the TME trial data showed that newly developed urinary and faecal incontinence 
was present in 33.7 percent and 38.8 percent of patients, respectively. Both types of 
incontinence were significantly associated with each other (p=0.027). Low anasto‑
mosis was significantly associated with urinary incontinence (p=0.049). One third 
of the patients with newly developed urinary and faecal incontinence also reported 
difficulty in bladder emptying, for which excessive peroperative blood loss was a 
significant risk factor.
Conclusion
Peroperative damage to the pelvic floor innervation could contribute to faecal and 
urinary incontinence after TME, especially in case of a low anastomosis or damage 
to the pelvic splanchnic nerves.
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introduction
The past two decades have witnessed substantial improvement in survival from 
rectal cancer, resulting from earlier diagnosis, improved efficiency and delivery of 
radiotherapy, and advances in surgical techniques, such as total mesorectal excision 
(TME).
The TME procedure removes the rectum with its primary lymphovascular field of 
drainage as an intact package. Under direct vision along pre‑existing embryologically 
determined planes, sharp dissection divides the mesorectal fascia (ie, the visceral 
fascia surrounding the mesorectum) from the pelvic parietal fascia overlying the 
pelvic floor, thereby preserving the autonomic nerves required for maintenance of 
urogenital function.1‑3
However, despite this, clinical studies report a high incidence of pelvic organ 
dysfunction, and the good functional results achieved by expert rectal surgeons have 
not yet been reproduced in larger studies.3,4 Surgical damage to the pelvic autonomic 
nerves is believed to be an important cause of urinary dysfunction.5‑7 The pelvic 
parasympathetic supply (pelvic splanchnic nerves or nervi erigentes) arises from 
sacral nerves S2 to S4, whereas the sympathetic supply is by the hypogastric nerves. 
Together, these parasympathetic and sympathetic nerves form the autonomic nerve 
plexus of the small pelvis (pelvic plexus or inferior hypogastric plexus). The pelvic 
plexus is a coarse and flat meshwork that is situated laterally to the pelvic organs and 
supplies the rectum, uterus, vagina, vestibular bulbs, clitoris, bladder, urethra, penis, 
and prostate.8,9 Because of their location, disruption of the pelvic plexus and the pelvic 
splanchnic nerves may occur frequently during dissection of the lateral planes of the 
mesorectum deep in the pelvis.10 Parasympathetic injury (pelvic splanchnic nerves 
or pelvic plexus) produces a hypo‑ or acontractile bladder with decreased sensation, 
causing difficulty in bladder emptying.5,8 The prevalence of faecal incontinence after 
low anterior resection with preoperative radiotherapy (PRT) is reported to be as 
high as 60 percent, and even without PRT, to be as high as 40 percent.11‑13 Damage 
to the pudendal nerve has been suggested as a cause of faecal incontinence after 
rectal cancer treatment.14 Common knowledge among clinicians is that the pudendal 
nerve innervates the levator ani muscle, which is a striated muscular diaphragm that 
closes the pelvic cavity. The levator ani muscle is the main pelvic floor muscle and is 
a crucial component of the urinary and faecal continence system.15‑17 Recent studies 
have re‑emphasised the existence of a separate nerve to the levator ani (the levator 
ani nerve [LAN]), which arises from sacral nerves S3 and/or S4, separately from 
the pudendal nerve. The nerve is mentioned in various anatomy textbooks18,19 but is 
still not clearly illustrated in others.20,21 The LAN approaches the levator ani muscle 
from within the pelvis on the superior surface of the pelvic floor, which makes ac‑
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cidental disruption of the nerve during pelvic surgical interventions conceivable.22‑24 
This is in contrast with the pudendal nerve, which runs inferior to the pelvic floor 
muscles and has only a minor contribution to the levator ani muscle innervation.25 
We hypothesised that surgical disruption of the LAN during TME could play a role 
in the etiology of faecal and urinary incontinence after TME. We aimed to study 
possible nerve disruption during the TME procedure as a cause of postoperative 
anorectal and urinary dysfunction. To do this, we performed TME on cadaver pelves 
and studied the anatomy of the levator ani muscle innervation and its relation to 
the pelvic autonomic innervation and the mesorectum. Subsequently, data from the 
Dutch TME trial were analysed to relate anorectal and urinary dysfunction to pos‑
sible peroperative nerve damage.26
Methods
Anatomy and cadaver surgery
Ten pelves of male cadavers (age range: 67 to 91 years) without signs of pelvic 
surgery were dissected as described elsewhere24 to investigate and quantify the topo‑
graphical anatomy of the LANs and the pelvic splanchnic nerves and the relation 
to the mesorectal fascia. Total mesorectal excision was performed on one midsagit‑
tally transected right male hemipelvis, two complete male pelves, and one complete 
female pelvis by an experienced colorectal surgeon (B.A.B.). The procedure was 
performed as it would be in a patient with a low rectal tumour with an indication for 
a low anterior resection. The rectum was removed according to the TME principles.27 
The pelvic splanchnic nerves and the LAN were subsequently dissected with special 
reference to relations between the nerves and the rectum, the parietal pelvic fascia, 
and the mesorectal fascia.
Dutch TMe trial database
Data were obtained from the database of the Dutch TME trial.26 Between January 
1996 and December 1999, 1 861 patients with histologically proven adenocarcinoma 
of the rectum and without evidence of distant metastases were included in the trial 
and randomly assigned to undergo TME alone or preceded by PRT. All patients 
underwent surgery according to the TME principles, as advocated by Heald.27 Only 
patients who underwent low anterior resection and participated in the quality‑of‑
life study or in the study on long‑term functional outcome were selected for this 
analysis.13,28
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Outcome measures
Faecal and urinary incontinence and difficulty in bladder emptying were evaluated 
preoperatively and at 5 years after TME.13,28 To determine whether preoperative 
dysfunction should be taken into account, the influence of preoperative dysfunction 
on faecal and urinary incontinence and difficulty in bladder emptying was evaluated. 
Newly developed combined faecal and urinary incontinence was assumed to result 
from pelvic floor dysfunction, as this was the most probable causative factor of both 
dysfunctions. Therefore, to evaluate to what extent incontinence could be explained 
by dysfunction of the pelvic floor, faecal and urinary incontinence were related to 
each other. Subsequently, to estimate the risk of simultaneous damage to the LAN 
in case of damage to the pelvic splanchnic nerves, faecal and urinary incontinence 
were related to difficulty in bladder emptying.
statistical Analysis
Data were analysed with SPSS version 14.0 for Windows (SPSS, Chicago, IL). The 
influence of the predictor variables on the risk of the different types of dysfunction 
after TME was calculated using univariate logistic regression analysis. To examine 
any independent influence, all variables associated with the specific type of dysfunc‑
tion (p=0.100 in the univariate regression analysis) were entered into a multivariable 
logistic regression analysis. P=0.05 was considered statistically significant.
resuLts
Anatomy and cadaver surgery
On macroscopical dissection, we found the LAN to originate from sacral nerves S3 
and/or S4. The nerve was macroscopically detectable in all pelves. During its course 
on the surface of the coccygeus and levator ani muscle, the LAN runs 4 cm (95% CI, 
4 to 5.5 cm) lateral to the midsagittal plane at the level of the ischial spine, 4.5 cm 
(95% CI, 4 to 5.5 cm) lateral to the tip of the coccyx, and 9 mm (95% CI, 0 to 14 mm) 
caudal to the ischial spine. In all cases, the nerve was situated underneath the pelvic 
parietal fascia, which covers the levator ani muscle. When the mesorectum was dis‑
sected in the surgical plane between the mesorectal fascia and the pelvic parietal 
fascia and subsequently lifted, the origin of the pelvic splanchnic nerves and the 
LAN presented themselves as joint sacral branches. The pelvic splanchnic nerves, 
whose origin from the sacral nerve plexus lies underneath the pelvic parietal fascia, 
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run in a separate fascial sheath to reach the pelvic plexus that is situated lateral to the 
rectum, tangentially to the lateral surface of the mesorectal fascia. The LAN does 
not run in this fascial sheath, but continues solitary toward the pelvic floor muscles 
underneath the lateral pelvic parietal fascia. Dissection of the LAN in the pelves 
after TME showed a similar anatomic composition. The plane of surgical dissection 
during TME is between the visceral fascia of the mesorectum and the parietal fascia. 
At the most distal part of the rectum, approximately 2 cm cranial from the entrance 
(Figuur 1, behorend bij hoodstuk 8, in kleur) 
 
 
(Figuur 2, behorend bij hoofdstuk 8, in kleur) 
 
Figure 1. Total mesorectal excision (TME) on an adult male pelvis. The pelvis was 
midsagittally transected after TME. Note that the parietal fascia was removed from the surface 
of the levator ani muscle during the TME procedure (black arrows show the cut border). The 
part of the parietal fascia that covered the sacral origin of the levator ani nerve and pelvic 
splanchnic nerves was removed during dissection to visualise the nerves. The most distal part 
of the levator ani nerve was disrupted during TME in this pelvis (not visible). (A) Medial view 
of the right hemi pelvis with part of the parietal fascia still covering the levator ani nerve. (B) 
Medial view of the right hemi pelvis. The parietal fascia, covering the nerves, is now flipped 
sideways to fully reveal the levator ani nerve. A, anus; BL, bladder; P, prostate; Pe, peritoneum; 
PF, parietal fascia; PP, pelvic plexus; PS, pubic symphysis; R, rectum; S, sacrum; S2, S3, S4, 
sacral nerves S1 to S3.
(Figuur 1, behorend bij hoodstuk 8, in kleur) 
 
 
(Figuur 2, behorend bij hoofdstuk 8, in kleur) 
 Figure 2. The levator ani nerve in vivo during total mesorectal excision. (A) Overview. (B) 
Detail of the levator ani nerve (white arrowheads). BL, urinary bladder; PS, pubic symphysis; 
SP, sacral promontory.
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of the rectum through the levator ani muscle, the mesorectal fascia and the parietal 
fascia become inseparable. Therefore, the parietal fascia must be removed from the 
surface of the pelvic floor muscles to preserve the mesorectal package. At this point, 
the LAN is in close proximity of the surgical dissection plane. In one male pelvis, 
the LAN was disrupted unilaterally at this level during the TME procedure. In the 
(Figuur 3, behorend bij hoofdstuk 8, in kleur) 
 Figure 3. Anatomic relation of the mesorectum and the levator ani nerve in the adult male. 
(A) Transverse section through the male pelvis. The level of the section is illustrated in the 
inset. (B) Schematic overview of the structures shown in part A. The green circles represent 
the approximate position of the levator ani nerves. (C, D) Three‑dimensional reconstruction 
of the same adult pelvis as in part A with (D) and without (C) the mesorectum. The levator 
ani muscle (red), coccygeus muscle (pink), obturator internus muscle (mint green), rectum 
(blue), mesorectum (light blue), sacral nerve plexus (light green) are reconstructed from serial 
sections. Because the levator ani nerve (light green, arrowheads in C) was not identifiable in the 
serial sections, it was illustrated with information from our dissection studies. Note the close 
relation of the mesorectum to the levator ani nerves. BL, urinary bladder; BP, bony pelvis; C, 
coccyx; CM, coccygeus muscle; GM, gluteus maximus muscle; LA, levator ani muscle; MR, 
mesorectum; OI, obturator internus muscle; R, rectum; SV, seminal vesicle.
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pelvis where the LAN was disrupted, Figure 1 shows the close relation between the 
surgical dissection plane and the nerve in the lowest part of the dissection. Figure 2 
shows the LAN in vivo during TME. Figure 3 illustrates the close relation between 
the LAN and the mesorectum.
Dutch TMe trial database
Of the 1 530 Dutch patients, patients were excluded from analysis for the following 
reasons: ineligible at randomisation (n=50), no operation (n=37), in‑hospital death 
(n=52), no informed consent for the quality‑of‑life study (n=89), no quality‑of‑life 
forms returned (n=30), no low anterior resection (n=456), and missing pretreatment 
form (n=165). Consequently, 651 patients remained assessable for analysis. However, 
not all questions were answered by every patient in the returned questionnaires, 
resulting in 649, 647, and 649 assessable patients concerning faecal incontinence, 
urinary incontinence, and difficulty in bladder emptying, respectively.
Pre- and postoperative dysfunctions
Faecal incontinence was reported by 269 (41.4 percent) of 649 patients preopera‑
tively and by 134 (48.7 percent) of 275 patients 5 years after rectal cancer treatment 
(p=0.001; relative risk=3.16). Of patients with normal preoperative function, 38.8 
percent (69 of 178 patients) had newly developed faecal incontinence after rectal 
cancer treatment.
Urinary incontinence was reported by 110 (17.0 percent) of 647 patients preopera‑
tively and by 123 (39.5 percent) of 311 patients 5 years after rectal cancer treatment 
(p<0.001; relative risk= 4.19). Of patients with normal preoperative function, 33.7 
percent (88 of 261 patients) had newly developed urinary incontinence after rectal 
cancer treatment. Of patients with newly developed faecal incontinence, 36.5 percent 
(23 of 63 patients) also reported newly developed urinary incontinence (p=0.027; 
relative risk=2.21). Fourteen percent (23 of 160) of patients with normal preop‑
erative function reported both faecal and urinary incontinence after rectal cancer 
treatment.
Difficulty in bladder emptying was reported by 144 (22.2 percent) of 649 patients 
preoperatively and by 89 (29.3 percent) of 304 patients 5 years after rectal cancer 
treatment (p=0.001; relative risk=3.02). Of patients with normal preoperative func‑
tion, 24.3 percent (59 of 243 patients) had newly developed difficulty in bladder 
emptying after rectal cancer treatment. Of patients with newly developed faecal and 
urinary incontinence, 38.8 percent (7 of 18 patients) also reported difficulty in blad‑
der emptying (p=0.044; relative risk=2.34).
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risk factors
Table 1 lists the results of the univariate logistic regression analysis of risk factors for 
faecal and urinary incontinence and difficulty in bladder emptying. In the multivari‑
able analysis of faecal incontinence (Table 2), PRT, low anastomotic height, tumour 
table 1. Logistic regression analyses of risk factors for faecal and urinary incontinence and 
difficulty in bladder emptying after rectal cancer treatment (RR=relative risk)


































































































































































size (p<0.100 in the univariate analysis), and preoperative faecal incontinence were 
included as input variables to predict faecal incontinence after rectal cancer treat‑
ment. In the multivariable analysis, PRT (p=0.004; relative risk=2.25) and preopera‑
tive faecal incontinence (p=0.001; relative risk=3.48) remained significant predic‑
tors. In the multivariable analysis of urinary incontinence (Table 2), female gender 
(p=0.001; relative risk=2.34), age (p=0.014; relative risk=1.96), preoperative urinary 
incontinence (p=0.017; relative risk=2.44), and low anastomotic height (p=0.049; 
relative risk=1.72) remained significant predictors. In the multivariable analysis of 
difficulty in bladder emptying (Table 2), preoperative dysfunction (p<0.001; rela‑
tive risk=3.15) and excessive peroperative blood loss (p=0.038; relative risk=1.95) 
remained significant risk factors.
discussion
The present study aimed to evaluate nerve disruption during TME as a cause of poor 
functional outcome by using anatomic and clinical data, with special attention to 
LAN and incontinence.
Fourteen percent of patients newly developed combined faecal and urinary in‑
continence after TME and, therefore, probably had a dysfunctional pelvic floor. As 
the cadaver surgery study revealed, the nerve supply to the pelvic floor, by means of 
the LAN, lies in the field of operation and can be disrupted during TME. From the 
anatomic findings, it can be predicted that especially during TME for low tumours, 
where the parietal fascia of the levator ani muscle is entered, the LAN is at risk. 
Indeed, our TME database analysis demonstrates that an anastomotic level less than 
6 cm increased the risk of (combined) faecal and urinary incontinence significantly. 
table 2. Multivariable regression analyses of risk factors for faecal and urinary incontinence 
and difficulty in bladder emptying after rectal cancer treatment (RR=relative risk)
Faecal incontinence Urinary incontinence Difficulty in bladder emptying
RR p‑value RR p‑value RR p‑value
Preoperative dysfunction 3.48 <0.001 2.44 0.017 3.15 <0.001
Female gender 2.34 0.001
Age ≥65 1.96 0.014
Tumour size ≥4.0cm 1.57 0.113
Radiotherapy 2.25 0.004
Blood loss ≥1500ml 1.95 0.038
Anastomotic height <6.0cm 1.62 0.089 1.72 0.049
129
The role of levator ani nerve damage in the development of incontinence problems
Additionally, in other studies, low anastomotic level, next to PRT, is considered to 
be the most important risk factor for faecal incontinence.11,29,30 We found that the 
anatomic origin of the LAN was closely related to the origin of the pelvic splanchnic 
nerves. From this, it can be predicted that improper surgical dissection or excessive 
manipulation of the mesorectum hold a risk of combined disruption of the LAN 
and the pelvic splanchnic nerves. In one third of patients, newly developed faecal 
and urinary incontinence was accompanied by newly developed difficulty in bladder 
emptying. This would imply that in one third of patients, in whom the LAN was 
disrupted, simultaneous disruption of the LAN and pelvic splanchnic nerves oc‑
curred at the sacral origin.
The TME dissection plane along the parietal presacral fascia is likely to mis‑
lead the surgeon and result in injury to the pelvic splanchnic nerves and/or pelvic 
plexus because the parietal presacral fascia divides into several laminae lining or 
enclosing these nerves. In addition, when an incorrect plane is followed, the sacral 
venous plexus, which lies in close proximity of the pelvic splanchnic nerves, may be 
damaged, resulting in excessive blood loss.31 Indeed, excessive peroperative blood 
loss was significantly associated with difficulty in bladder emptying in our study. 
Diathermic coagulation and numerous sutures to secure hemostasis may cause nerve 
damage. Moreover, excessive blood loss hinders sight deep in the pelvis, making 
nerve sparing virtually impossible.3,32 An increased risk of nerve damage and poor 
functional outcome in case of a posteriorly located tumour would be expected. How‑
ever, this is not supported in the present study. Apparently, surgical damage during 
TME does not depend on characteristics of the tumour but only on specific aspects 
of the surgical technique used.
Faecal incontinence is multifactorial.33 The rectum acts as a reservoir, and the 
smaller neorectum after TME has a lower capacity and smaller tolerated volume.34 
Furthermore, PRT is known to increase the risk of faecal incontinence, which is 
also supported by the present study.11,35 Radiotherapy diminishes compliance of 
the residual rectum because of fibrosis and may disrupt the myenteric plexus of the 
internal anal sphincter, compromising the rectoinhibitory reflex and resting anal 
pressures.33,34 In addition, faecal incontinence after rectal cancer treatment has been 
reported to be caused mainly by impaired pelvic floor movement (ie, a disturbed 
change in anorectal angle resulting from a dysfunctional puborectalis muscle).36
Urinary incontinence after TME is multifactorial as well. Unfortunately, the 
questionnaires did not differentiate between urge, overflow, and stress incontinence. 
Damage to the sympathetic nerve supply (the hypogastric nerves and the pelvic 
plexus) causes a reduced bladder capacity and may result in urge incontinence.5 
However, one‑sided preservation of the pelvic plexus has been clinically shown to re‑
sult in acceptable urinary continence.3,37 Surgeons are often unable to verify whether 
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bilateral damage has occurred, but it is not expected to occur frequently during a 
TME procedure.4 Damage to the sacral splanchnic nerves may lead to difficulty 
in bladder emptying and overflow incontinence.5 However, urinary incontinence 
was not significantly related to difficulty in bladder emptying in this study (data not 
shown). Therefore, we assume that the reported urinary incontinence was mainly 
stress incontinence. Stress incontinence may also result from impaired support to 
the urethra and bladder neck.38 As for faecal incontinence, a dysfunctional pelvic 
floor has been suggested as an important cause of urinary incontinence.15‑17 This is 
supported by our results, as faecal and urinary incontinence were occurring simulta‑
neously in a significant number of patients.
In conclusion, the results of our study lead us to state that, especially in patients 
with low rectal tumours, the risk of LAN disruption is substantial, which could 
contribute to an increased risk of urinary and faecal incontinence after TME, as 
indicated by our clinical data. Accidental disruption of the LAN during a surgically 
difficult procedure could be a factor that has been neglected thus far. The results 
of our surgical study imply that a correctly performed posterior dissection of the 
mesorectum would not disrupt the LAN, because the plane of posterior dissection 
in a TME procedure is between the pelvic parietal fascia and the mesorectal fascia. 
However, the surgical margin is so small that any deviation from this surgical plane 
easily results in disruption of the nerve. Adhering to the surgical plane, reducing the 
use of blunt dissection, and improving rectal retraction may lower the risk of LAN 
disruption during distal resection. Surgeons that perform TME should be aware of 
the anatomy of the LAN to avoid disrupting it. A nerve sparing TME should mean 
not only sparing the pelvic autonomic nerves, but sparing the LAN as well. The 
challenge is now to assess puborectalis function in patients suffering from faecal 
incontinence after TME, to actually see whether the puborectalis muscle is dener‑
vated. Further studies on faecal incontinence after TME should therefore include 
clinical assessment of pelvic floor denervation (ie, puborectalis muscle atrophy) in 
patients who suffer from faecal incontinence after TME.
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Leukocyte depletion of perioperative 
blood transfusion does not affect 
long-term survival and recurrence in 
gastrointestinal cancer patients
Lange MM, van Hilten JA, van de Watering LMG, Bijnen AB, Roumen RMH, 






Perioperative red blood cell (RBC) transfusions are reported to be associated with 
poor prognosis in cancer surgery. Allogeneic leukocytes are assumed to play a causal 
role. The present study evaluates the long‑term effect of leukocyte depletion of RBC 
transfusions in gastrointestinal (GI) cancer patients.
Methods
The Tactic‑study was a multicentre randomised controlled trial evaluating short‑
term benefits of leukocyte depleted (LD) versus non‑LD RBC transfusions. For the 
present study, five‑year survival and cancer recurrence of GI cancer patients included 
in the Tactic‑study were evaluated (n=512).
Results
Eighty‑nine percent of patients had a primary tumour and in 79.9 percent of patients 
surgery was with curative intent. Two hundred and forty‑three patients received peri‑
operative RBC transfusion, receiving a median of three units. The five‑year survival 
rate of patients with any type of GI cancer was 50.8 percent in the LD group and 45.8 
percent in the non‑LD group with a recurrence rate of 32.9 percent in the LD group 
and 34.3 percent in de non‑LD group (p=0.19 and p=0.86, respectively). Disease‑free 
survival was 60.0 percent in the LD group and 56.6 percent in the non‑LD group 
(p=0.48).
Conclusion
Leukocyte depletion is not associated with better long‑term survival and lower cancer 
recurrence in GI cancer patients.
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introduction
On the basis of the immunomodulatory effect of allogeneic blood transfusion im‑
proving renal allograft survival, in 1981 Gantt raised the question whether the effect 
of transfusion‑associated immunomodulation (TRIM) might also be associated 
with an increased risk of cancer recurrence in patients undergoing resection of a 
malignancy.1,2 This hypothesis was based on the premise that, if allogeneic blood 
transfusion down‑regulates the host’s immune surveillance that targets malignant 
cells, the receipt of allogeneic blood transfusion might enhance tumour growth.
Since 1981 more than 150 clinical studies have examined the association of peri‑
operative allogeneic blood transfusion with cancer recurrence.3 Most of these were 
observational studies comparing patients who did or did not receive transfusions and 
produced contradictive results.4‑7
Since allogeneic leukocytes may play a key role in the TRIM effect, leukocyte 
depletion could be effective in inhibiting TRIM.8 Many randomised controlled trials 
(RCTs) investigated a role of leukocytes in blood products on postoperative infec‑
tions.9‑12 However, only two RCTs have been conducted to evaluate a role of allogeneic 
leukocyte on cancer surveillance.9,13,14 In a third RCT, the Tactic‑study (Transfusion 
Associated Complications=Transfusion Induced Complications?) which included 
gastrointestinal (GI) cancer patients, leukocyte‑depleted (LD) red blood cell (RBC) 
transfusions resulted in a reduced in‑hospital mortality. Given the scarcity of data 
on the effect of leukocyte containing transfusions on cancer and the ongoing risk of 
recurrence up to five years after surgery, a follow‑up of this trial to five years was 
performed to evaluate the long‑term effects on cancer recurrence and survival.12
Methods
The Tactic‑study was conducted between June 2000 and December 2001 at 19 
Dutch hospitals. Twelve hundred patients were randomised to LD or non‑LD RBC 
transfusion. Details of the design of the study, patient intake and outcome have 
been described previously.12 In the original Tactic‑study 560 patients who were 
operated for a GI malignancy were included. However, in 48 of the patients benign 
instead of malignant disease was found during surgery. Because the present study 
concerns oncologic outcome, only those patients were selected with confirmed GI 
malignancy after surgery (n=512). Gastrointestinal procedures included resections of 
the stomach, oesophagus, liver, colon, rectum, pancreas or isolated liver perfusions 
(Table 1). Units of RBC concentrates with the buffy coat removed contained up to 
8x108 white blood cells/unit, whereas in RBC filtered before storage the maximum 
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count was <106 white blood cells/unit. Both RBC products were plasmareduced and 
reconstituted with SAG‑M.
Outcome measures
New outcome measures were formulated: overall survival (OS), disease‑free survival 
(DFS) and local or distant recurrence since the date of surgery. With respect to DFS, 
an event was defined as local or distant recurrence of disease or death due to any 
cause, whichever occurred first.
Data collection
Pre‑ and peroperative characteristics of the patients had been systematically record‑
ed.12 For the long‑term follow‑up clinical data were collected five years after surgery 
from medical records in each hospital. Subsequently, questionnaires were sent to 
the general practitioner for each patient to complete the data collection. In case of 
missing survival data, the regional Comprehensive Cancer Centre was addressed. 
All medical data were entered in a database by number. Neither the identity of the 
patient nor the randomisation group were stored in the main database. The actual 
randomisation was provided only at the final analysis.
statistical analysis
Univariate comparison of baseline qualitative variables was performed by χ2 test; 
for quantitative parameters t test or Mann‑Whitney U test were used. To analyse the 
influence of leukocyte depletion on the outcome measures Kaplan‑Meier curves were 
calculated and differences between survival curves were assessed with the log rank 
test. Patients with missing data were included until the time point at which data were 
missing. Patients who were lost to follow‑up before five years postoperatively were 
censored from five‑year survival and recurrence analyses. Patients treated without 
curative intent were excluded from DFS and recurrence analyses. Both intention‑
to‑treat analysis and analysis according to transfusion were performed, however, as 
these resulted in similar findings, only results of the intention‑to‑treat analysis are 
shown.
Combined analysis
In addition, a combined analysis was performed with a previous multicentre RCT, 
the CRAB‑study (Cancer Recurrence And Blood Transfusion). The CRAB‑study 
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had been conducted between 1987 and 1990 including patients with primary col‑
orectal cancer undergoing surgery with curative intent (n=698).9 In 2001 a five‑year 
follow‑up of these patients has been reported.14 This study had a comparable study 
design with the Tactic‑study and blood products used from 1986 throughout 2001 
were virtually similar. A subgroup of the Tactic‑study group, who met the criteria 
of the CRAB‑study (surgery with curative intent for primary colorectal cancer) was 
selected (n=277). To evaluate whether combined analysis was justified these CRAB‑ 
and Tactic‑ subgroups were analysed separately. Subsequently, analyses of OS, DFS 
and recurrence rates were repeated in the combined study‑group (n=975). Further‑
more, an observational analysis was done comparing the prognosis of transfused 
patients with that of non‑transfused patients. Variables with a p<0.10 were included 
in a Cox regression analysis, conducted to correct for confounding factors. p≤0.05 
was considered statistically significant.
resuLts
study population
The mean age at surgery was 65.3 years. Eighty‑nine percent of patients had a pri‑
mary tumour and in 79.9 percent of patients surgery was with curative intent. Two 
hundred and sixty‑nine patients did not receive any RBC transfusion, leaving 243 
patients for analysis according to transfusion. In patients who received RBC transfu‑
sion on average 4.9 units were transfused. Patient and treatment characteristics are 
listed in Table 1. The mean follow‑up was ±70 months.
Overall survival
In OS analysis 504 patients were included. No significant difference between both 
randomisation arms was found (p=0.19, hazard ratio=0.85; Figure 1). Five‑year OS 
was 50.8 percent in the LD group and 45.8 percent in the non‑LD group (11 patients, 
4 in LD and 7 in non‑LD group, lost to follow‑up within five years after surgery).
Disease-free survival and recurrence
In the analyses of DFS and recurrence rate 341 patients were included. No significant 
difference between both randomisation arms was found (p=0.48, hazard ratio=0.89 
and p=0.86, hazard ratio=0.97, respectively; Figure 2). Five‑year DFS was 60.0 per‑
cent in the LD group and 56.6 percent in the non‑LD group (5 patients, 2 in LD and 
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table 1. Clinical data of the 512 patients with gastrointestinal cancer in the Tactic‑study. The 
separate column at the right shows data of the 243 transfused patients only. (LD=leukocyte 
depleted ; continuous: median (interquartile range); categorical: n (%); *LD versus non‑LD)

































Indication primary tumour 
(n=473)
214 (90.3) 208 (88.1) 0.45 92 (87.6) 93 (86.1) 0.75
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(neo)adjuvant therapy (n=256) 71 (54.2) 59 (47.2) 0.26 38 (65.5) 27 (45.0) 0.025
Curative intention (n=439) 177 (79.7) 173 (79.7) 1.00 76 (79.2) 78 (80.4) 0.83
Tumour free resection margin 
(n=280)
129 (90.2) 128 (93.4) 0.33 55 (88.7) 63 (96.9) 0.071












Number of transfused units 
(n=512)
0 (0, 2) 0 (0, 3) 0.48 3 (2, 6) 3 (2, 5) 0.84
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Figure 1. Overall survival of 504 patients who were allocated to leukocyte depleted or to non‑
leukocyte depleted blood product in the Tactic‑study.
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Figure 2. Disease‑free survival (illustrated by the two upper curves) and recurrence (illustrated 
by the two lower curves) of 341 patients who were allocated to leukocyte depleted or non‑
leukocyte depleted blood product in the Tactic‑study.
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3 in non‑LD group, lost to follow‑up within five years after surgery). The mean time 
to recurrence was 22 months. In the LD‑group 32.9 percent of patients developed a 
recurrence compared to 34.3 percent in the non‑LD group (46 patients, 20 in LD and 
26 in non‑LD group, lost to follow‑up within five years after surgery).
Combined analysis for recurrence of colorectal cancer after curative surgery
The combined analysis consisted of 277 patients of the Tactic‑study and 698 patients 
of the CRAB‑study, who underwent curative surgery for primary colorectal cancer. 
Both subgroups were homogenous (Figure 3). Patient and treatment characteristics 
of the combined study‑group are listed in Table 2. The mean follow‑up of the patients 
in the combined study‑group was ±76 months. In OS analysis 975 patients were 
included and no significant difference between both randomisation groups was 















      Favors LD  ←  → Favors non-LD    
Figure 3. The Tactic‑subgroup study and the CRAB‑study showing homogenous results with 
respect to the association of leukocyte depletion with five‑year overall survival (OS), disease‑
free survival (DFS) and recurrence (REC) in patients who underwent surgery with curative 
intent for a primary colorectal malignancy. For each study the hazard ratio is given as calculated 
from intention‑to‑treat analysis. Each hazard ratio is surrounded by its 95% confidence interval.
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(37 patients, 17 in LD and 20 in non‑LD group, lost to follow‑up within five years 
after surgery). In analyses of DFS and recurrence rate 970 patients were included 
showing no significant difference between both randomisation arms (p=0.92, hazard 
ratio=0.99 and p=0.94, hazard ratio 0.99, respectively). Five‑year DFS was 58.9 
percent in the LD group and 59.3 percent in the non‑LD group (29 patients, 13 in 
LD and 16 in non‑LD group, lost to follow‑up within five years after surgery). In 
the LD group 32.2 percent of patients developed a recurrence versus 33.1 percent in 
the non‑LD group (151 patients, 74 in LD and 77 in non‑LD group, lost to follow‑up 
within five years after surgery).
red blood cell transfusion
Observational analysis of the combined study‑group showed worse OS, DFS and 
recurrence rates in patients who received RBC transfusions (59.5 percent, 54.2 
percent and 36.2 percent, respectively) compared to patients who did not receive 
any perioperative RBC transfusion (72.7 percent, 66.1 percent and 26.5 percent, 
respectively). Even after correcting for gender, tumour stage and age in multivariable 
analysis, RBC transfusion remained a significant risk factor (Table 3).
table 2. Clinical data of the combined group of 975 patients with primary colorectal cancer 
operated with curative intent in the Tactic‑study (n=277) and the CRAB‑study (n=698). The 
separate column at the right shows data of the 576 transfused patients only. (LD=leukocyte 
reduced; continuous: median (interquartile range); categorical: n (%); *LD versus non‑LD)













































(neo)adjuvant therapy (n=853) 58 (13.8) 48 (11.1) 0.23 30 (12.0) 23 (8.5) 0.18
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(n=734)




The presence of allogeneic leukocytes in transfusion products is presumed to impair 
response against cancer.8 However, only two RCTs addressed this presumption.13,14 
Patients operated for various types of GI cancer in the Tactic‑study, receiving LD 
RBC transfusions had shown a lower in‑hospital mortality (4 percent versus 8 per‑
cent).12 The follow‑up study however showed that there was no long‑term beneficial 
effect of leukocyte depletion of perioperative RBC transfusion on the prognosis of 
(GI) cancer patients.
The present analysis of the Tactic‑study, comprising all types of GI cancer, 
showed no significant differences in five‑year OS and DFS in patients receiving LD 
transfusions compared to patients receiving non‑LD transfusion. In the combined 
analyses with the CRAB study, addressing the question of recurrence in patients 
with colorectal cancer after intentionally curative surgery, the two trial arms showed 
similar results with respect to five‑year OS, DFS and recurrence rate.
The Tactic‑ and the CRAB‑study compared prestorage leukocyte depletion, by 
filtration of buffy‑coat depleted RBCs, eliminating release of breakdown products 
of leukocytes that could mediate TRIM.15,16 The absence of any effect of leukocyte 
depletion in our study may on one hand be explained by lack of antigenicity of 
table 3. Multivariable analysis of overall survival, disease‑free survival and recurrence in 
the combined analysis of patients who underwent surgery with curative intent for a primary 
colorectal malignancy. (HR=hazard ratio; CI=confidence interval; LD=leukocyte depletion; 
RBC=red blood cell; *age was not included in the analysis of recurrence rate, as it was not a 
significant factor in univariate analysis (p=0.80, hazard ratio=1.00); **number of patients is too 
small for analysis)
Overall survival Disease‑free survival Recurrence
p‑value HR 95% CI p‑value HR 95% CI p‑value HR 95% CI
LD 0.60 0.94 0.74 – 1.20 0.56 0.94 0.75 – 1.17 0.73 0.95 0.72 – 1.26
RBC 
transfusion
0.003 1.48 1.14 – 1.91 0.022 1.32 1.04 – 1.67 0.055 1.33 0.99 – 1.78
male gender 0.019 1.34 1.05 – 1.72 0.002 2.43 1.13 – 1.79 0.018 1.41 1.06 – 1.87
age <0.001 1.04 1.03 – 1.05 <0.001 1.03 1.02 – 1.04 *
stage <0.001 <0.001 <0.001
I
II 0.34 1.22 0.82 – 1.82 0.51 1.13 0.79 – 1.62 0.89 0.97 1.54
III <0.001 2.83 1.89 – 4.25 <0.001 2.72 1.89 – 3.90 <0.001 3.31 5.16
IV 0.019 2.88 1.19 – 7.00 0.78 1.18 0.36 – 3.84 **
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colorectal cancer, not capable to elicit host immunity.17 On the other hand, specific 
constituants of allogeneic blood, not related to residual contaminating leukocytes 
may mediate the TRIM effect. Next to allogeneic leukocytes, allogeneic platelets, 
plasma and substances that accumulate in erythrocyte components during storage 
have all been implicated in the pathogenesis of TRIM.3
The differences in outcome between transfused and non‑transfused patients have 
been reproduced in the present study. However, important other risk factors reflecting 
clinical status, such as invasion of tumour into lymph or blood vessels, were not as‑
sessed and could not be included in the analysis. The better clinical status of patients 
not requiring blood transfusions, make it unjust to ascribe differences solely to the 
transfusion status of the patients. An increased recurrence rate in transfused patients, 
either allogeneic or autologous, compared to patients who had not required a transfu‑
sion, has been discussed before, concluding that this was due to the (confounding) 
circumstances that necessitated transfusions.18 In 468 patients with rectal cancer, 
Bentzen et al. revealed that well‑established prognostic factors accounted for the 
worsened prognosis in transfused patients, not transfusion as such, and that patients 
receiving RBC transfusion performed as expected from their clinicopathological 
characteristics.19
Irrespective of a possible effect of RBC transfusion, the present study shows that, 
despite the short‑term benefits, leukocyte depletion does not improve long‑term 
outcome of GI cancer patients.
The United Kingdom, Ireland, Portugal, France, Canada, Scandinavia and The 
Netherlands have implemented universal leukocyte depletion of all transfused cel‑
lular blood components as precautionary action. Some countries based their decision 
on the hypothesis that this practice would prevent the theoretical risk of transmission 
by transfusion of the agent of variant Creutzfeldt‑Jakob disease, while others on the 
hypothesis that this practice would reduce the number of transfusion complications 
like fever, viral transmission, alloimmunisation, cancer recurrence and mortality.20 
There is no reason with respect to cancer recurrence or long‑term (disease‑free) 
survival to use LD RBC in GI cancer patients instead of simple buffy‑coat removal 
as program of transfusion. This may be important for those countries that have not 
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Curative rectal cancer treatment has been performed for more than 100 years. It was 
initiated by Miles, who established the focus of attention on the importance of local 
tumour spread and lymph node involvement. In 1908 he introduced radical tumour 
resection by abdominoperineal resection (APR). In the subsequent century rectal 
cancer treatment has tremendously progressed. Rectal cancer surgery turned from 
destructive amputative surgery to restorative surgery by changing surgical technique 
from conventional blunt dissection to total mesorectal excision (TME) with sharp 
dissection.1 Sharp dissection in the avascular plane between the mesorectum and 
surrounding tissues led to improved overall survival (from 48 percent to >60 per‑
cent), reduced local recurrence rates (from >20 percent to <10 percent), higher inci‑
dence of sphincter preservation and reduced peroperative blood loss and autonomic 
nerve damage.2‑5 The addition of radiotherapy further improved outcome of rectal 
cancer treatment. In the Dutch TME trial five‑year local recurrence risk of patients 
undergoing a macroscopically complete local resection was significantly reduced in 
case of short‑course preoperative radiotherapy (PRT; 5x5 Gy over 5 days) compared 
to patients undergoing surgery alone (5.6 versus 10.9 percent; p<0.001).6 However, 
PRT was shown to be ineffective in case of incomplete tumour resection.7 Involve‑
ment of the circumferential resection margin (CRM) remained the most important 
prognostic factor.8 Reducing the risk of CRM involvement was recognized to be a 
matter of team work. Standardised pathological examination of the surgical speci‑
men has become an important tool to evaluate surgical quality and provide feedback 
to the individual surgeon. Furthermore, the MERCURY‑study group demonstrated 
that high‑resolution magnetic resonance imaging (MRI) is accurate in predicting 
whether the CRM will be affected by tumour.9 In that case, radiation and medical 
oncologists decrease tumour burden by administering prolonged chemoradiotherapy 
(CRT), increasing the likelihood that the surgeon can perform a radical (R0) re‑
section. Burton et al. showed that multidisciplinary team discussion of MRI and 
implementation of a preoperative treatment strategy result in significantly reduced 
positive CRM rates in rectal cancer patients.10 In this manner rectal cancer treatment 
has evolved into a multidisciplinary treatment with standardised surgical, pathologi‑
cal and radiotherapeutical procedures.
Today rectal cancer treatment continues to develop explicitly. First of all, an increas‑
ing role of adjuvant chemotherapy is to be expected. In contrast to the amazing 
achievements with respect to locoregional control, the rates of distant metastasis 
have not changed since the early eighties.11 Distant metastases are accountable for 
mortality and frequently occur, regardless of radiotherapy (25.8 percent versus 28.3 
percent).4 Adjuvant chemotherapy might approach micrometastatic disease early, 
trying to control it and by this, curing more patients and prolonging survival over 
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locoregional therapies alone. The development of effective adjuvant chemotherapy 
for rectal cancer is a priority issue. In the past adding adjuvant chemotherapy to 
long‑course PRT (45‑55 Gy in 1.8 Gy fractions over 4‑6 weeks) has been proven to 
be ineffective for improving survival of rectal cancer patients, however this was in 
the era of conventional surgery.12 In the more recent EORTC 22921 and FFCD 9203 
trials, adjuvant chemotherapy did not improve survival either.13,14 Furthermore, in 
the Polish study survival of patients treated with long‑course CRT was similar to 
survival in patients treated with short‑course PRT only.15 However, in these stud‑
ies surgical quality control was not performed. Currently, the SCRIPT (Simply 
Capecitabine in Rectal Cancer after Irradiation Plus TME) trial randomises stage II/
III rectal cancer patients who have had 5x5 Gy plus TME between oral capecitabine 
and observation.
Another purpose of chemotherapy in the multimodality approach of rectal cancer 
is enhancing the efficacy of radiation. Due to the modulating effect of chemotherapy 
on tumour cells and therefore increased sensitivity for radiation damage, CRT was 
expected to be superior to radiotherapy alone with respect to local control. Buijko 
et al. reported similar local recurrence rates in patients treated with short‑course 
PRT compared to patients treated with long‑course CRT.15 However, the addition 
of chemotherapy to long‑course PRT in the EORTC 22921 and FFCD 9203 trials 
resulted in a significant reduction of local recurrence rates.13,14 Furthermore, higher 
rates of tumour eradication (pathologic complete response, pCR) were found. The 
sterilisation effect of CRT would significantly reduce the risk of lymph node metas‑
tases, which may reach rates over 13 percent even in T1 rectal cancer.16 Therefore, 
patients with early rectal cancer after neoadjuvant treatment (ypT1 and ypT2) might 
be considered candidates for local excision by means of transanal endoscopic mi‑
crosurgery (TEM), which has shown disappointing local recurrence rates of 15‑30 
percent in patients treated without neoadjuvant treatment.17 In case of pCR, which 
has been reported in 10–30 percent of patients treated with preoperative CRT, sur‑
gery might even be omitted.18,19 Rutten et al. recently stated that treatments that keep 
surgical trauma to a minimum and optimise the use of radiotherapy might be more 
suitable for elderly patients with diminished physiological reserves and comorbid 
conditions.20 The development of rectum saving treatment is further encouraged by 
our finding that surgery is the main cause of functional morbidity after rectal cancer 
treatment. However, discrepancy exists between clinical complete response (cCR) 
and pCR.21 In case of cCR cancer cells are found in 40‑75 percent of postoperative 
specimens.18,21‑24 Moreover, following preoperative CRT, the incidence of residual 
mesorectal lymph node involvement remains significant.25 Nevertheless, the study of 
Habr‑Gama et al. in which patients with sustained cCR were managed by observation 
alone has shown excellent results.26 However, results of patients with cCR who did 
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not receive surgical treatment and developed a recurrence within one year were not 
provided. Furthermore, as local recurrences after CRT tend to occur late, follow‑up 
was too short. Therefore, long‑term follow‑up of prospectively conceived multicentre 
data concerning safety and functional outcome are needed.
The overall aim of clinical research in rectal cancer should be to develop a range 
of multidisciplinary treatment strategies that can be tailored to the requirements of 
individual patients, taking into consideration disease factors and patient factors, such 
as the presence of comorbidities and risks of suffering treatment‑related complica‑
tions. Improved imaging techniques and translational research are required for the 
identification of patients groups which will gain the maximum benefit from each 
treatment option. Magnetic resonance imaging with lymph node specific contrast 
enhancement may be the most promising modality for distinguishing between the 
lower risk N0 rectal cancer patients, for whom TEM or TME might suffice and 
higher risk N1 and N2 rectal cancer patients, which should be treated with PRT 
followed by TME. New MRI contrast agents, like ultrasmall superparamagnetic iron 
oxide (USPIO) and MS 325 may help radiologists to solve the problem of lymph node 
identification in the near future.27 A cohort study in which 322 patients were stratified 
into different treatment groups after USPIO‑MRI has shown promising results (95 
percent complete resections). Furthermore, translational research will contribute to 
tailored treatment based on individual tumour profiles in the near future. Genomics 
and proteomics enable identification of biomarkers which may be used to predict 
prognosis and response to treatment. For example, local recurrence can be predicted 
by detection of tumour apoptosis‑levels through measurements of caspase‑3 activity.28 
Research on cancer biology and the discovery of a number of molecular pathways 
has also led to the development of molecular targeted treatments. Bevacizumab, the 
monoclonal antibody targeting the vascular endothelial growth factor, as well as 
cetuximab, which is a monoclonal antibody against epidermal growth factor recep‑
tor, have recently been approved to be used against advanced colorectal cancer. The 
optimal use of these agents, as well as their combined administration, are currently 
the focus of several ongoing studies.29
In the progress of rectal cancer treatment during the upcoming century, surgeons 
will remain the key characters. Several aspects of surgical performance are to be 
improved. Firstly, anastomotic leakage remains a frequently reported complication 
after low anterior resection (LAR) and is associated with postoperative mortality 
and increased recurrence rates.30 At present, temporary defunctioning stomas are 
often created as it has recently been shown to limit the consequences of anastomotic 
leakage.31 However, den Dulk et al. showed that a substantial proportion of these 
stomas are never reversed (19 percent).32 Therefore, the chance of stoma reversal 
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should be estimated preoperatively and an individualized decision should be made 
on resection type by counterbalancing the possible loss of quality of life (QoL) in 
case of a definitive colostoma created during APR, which depends on the patient’s 
preferences and socio‑demographical characteristics, with the patient’s comorbidity, 
which might limit successful reversal of a temporary stoma after LAR. Furthermore, 
vascular ligation technique might influence anastomotic healing. Although data are 
not conclusive, Chapter 2 suggests that high tie ligation, which is the most popular 
technique, might be less preferable than low tie ligation.33 However, a change of 
practice is unlikely to occur. As anastomotic leakage will probably remain a prob‑
lem in the upcoming decades, it is important to control the consequences in case 
anastomotic leakage occurs. Currently, a standardised postoperative surveillance is 
being introduced in The Netherlands to reduce delay in the diagnosis of anastomotic 
leakage and mortality.34
Secondly, APR resection technique needs to be improved. At present, APR is 
associated with worse local control and a 10 percent reduction in overall survival.35‑37 
Positive CRM rates are 26.5 percent after APR versus 12.6 percent after LAR 
(p<0.001), which indicates that the quality of the surgical procedure is a crucial 
factor contributing to the poor results after APR.36 In this respect preoperative CRT 
is suggested. Chemoradiotherapy and delayed surgery has been shown to downstage 
and downsize tumours.23,38 However, downstaging and downsizing are not the only 
contributors to free CRM. In the EORTC 22921 trial, it was shown that no signifi‑
cant difference in CRM involvement was obtained after preoperative CRT despite 
an impact on tumour stage and size.39 Therefore, improvement in surgical technique 
remains necessary to reduce CRM involvement. Wider perineal and pelvic floor 
resections for low rectal cancers will improve results after APR in the upcoming 
decade.35,36,40
Upgrading surgical performance also implies reducing variability among sur‑
geons. Total mesorectal excision is a difficult and technically demanding operation 
and the skills of the surgeon are of major importance in achieving good results.41 
Surgical trainee programmes can have a major impact. The national Scandinavian 
and Dutch surgical initiatives have shown lasting effects of training of surgeons in 
resection technique.34 Also case volume appears to be related to variability in patient 
outcome.41 In order to improve results in the future all patients should be offered cure 
by a well educated, multidisciplinary team in high‑volume centres. In addition, CRM 
involvement should be determined in daily practice as it is an important parameter of 
outcome and essential for feedback to the individual surgeon.41 A recent study evalu‑
ating the rate of reported CRM in the pathology report, found an increase from 37 to 
70 percent after feedback to the regional pathology working group.42 This illustrates 
the importance of registration to assess and improve quality of rectal cancer treat‑
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ment. From January 1st 2009 a Multidisciplinary Quality Assurance Program will 
be started under the initiative of the European Society of Surgical Oncology (ESSO) 
implicating outcomes registry which will enable assessment of structure and process 
of care, identification and implementation of best practices and subsequent confirma‑
tion of improvement of rectal cancer treatment. In this manner, reliable treatment 
evaluation becomes within reach for individual centres and individual surgeons. In 
case of suboptimal performance, treating teams can be encouraged either to improve 
their treatment results by seeking additional training or to stop treating rectal cancer 
patients. This will reduce variability and contribute to improved clinical outcome. 
When counterbalancing this against expensive chemotherapy regimens and universal 
leukocyte depletion of transfused blood products, both beneficial to only a minority 
of patients, one has to conclude that upgrading the surgical performance is cheap and 
definitely cost effective.43,44
Given the increasing number of treatment alternatives in rectal cancer treatment, 
it will become increasingly important to accurately capture the impact of different 
treatment regimens on QoL. This would help in making difficult decisions, in which 
modest changes in survival or local control must be balanced against effects on QoL, 
from chemotherapy and radiotherapy toxicities to permanent colostomies. Under‑
standing the impact of various treatment alternatives on postoperative QoL will help 
to choose a plan optimising both oncologic outcome and function. Therefore, QoL 
is now regarded as a key measurement in assessing outcomes of interventions.45,46 
However, as patients adjust to the functional changes after having survived cancer, 
their perception of QoL might shift and might not accurately reflect postoperative 
functional differences.46‑49 Interestingly, QoL of rectal cancer patients is comparable 
to that of the same aged general population, despite significant problems with respect 
to anorectal and urogenital functioning.46,50‑52 Therefore, QoL measurements, such 
as the EORTC C‑30 and CR‑38 are not suitable to detect functional differences 
and thus to determine the optimal treatment strategy.53,54 More data concerning 
specific organ dysfunction before and after rectal cancer treatment are required. 
This may help patients set realistic expectations for their postoperative life. More 
realistic expectations may, in turn, help patients to adapt to functional alterations 
postoperatively, resulting in a better QoL. Next to informing patients, it has been 
suggested that patients need to be involved in treatment decision making. Especially 
when a patient presents with a serious illness, different treatment options exist, the 
gains of treatment should be weighed against possible adverse effects, or outcomes 
are uncertain, patient involvement is required.55 This is supported by the fact that 
both individual patients and individual oncologists greatly vary in their perception 
of how tumour control, survival and functional outcome should be weighed in decid‑
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ing upon the most preferable treatment.56,57 At present, patients are often informed 
through internet and prefer a more active role in decision making. However, there is 
considerable evidence suggesting that patients do not wish to be involved in decisions 
regarding their own care and instead prefer a more paternalistic approach in which 
their physicians make the decisions for them.58 An ongoing project is investigating to 
what extent patients and oncologists believe that patients should also participate in 
decision making regarding therapy.
To adequately balance benefits and costs of each treatment alternative and to 
elucidate etiology for prevention and treatment of postoperative organ dysfunction, 
systematic registration of preoperative and long‑term postoperative pelvic organ 
dysfunction is needed. In this respect the Dutch TME trial has been exceptional. 
This study, which was a surgical initiative conducted by the Dutch Colorectal Can‑
cer Group (DCCG) organised rectal cancer treatment for the first time and realised 
specialisation of surgeons in TME surgery and nerve preservation and pathologists 
in assessment of the quality of resected specimens. High compliance of patients, 
radiotherapists, surgeons and pathologists has generated a unique set of long‑term 
data, among which different aspects of QoL. Through the current thesis the Dutch 
TME trial has provided insight in the incidence and etiology of long‑term pelvic 
organ dysfunction after rectal cancer treatment. Poor functional outcome appears to 
occur commonly: about one third of patients reported urinary dysfunction, half of 
patients suffered from faecal incontinence and more than half of patients experienced 
deterioration of sexual functioning. Significant adverse effects of short‑course PRT 
on long‑term anorectal and urogenital functioning were observed, which is supported 
by the Stockholm trials.52,65,68 This has resulted in criticism against short‑course PRT. 
However, reliable data concerning late side‑effects of other regimens are lacking. In 
a study of Buijko et al. short‑course PRT was compared with preoperative CRT and 
no increased toxicity was observed after short‑course PRT.15 Furthermore, the addi‑
tion of chemotherapy might result in even more dysfunction, as it has been shown to 
induce nerve damage.72 Long‑term functional outcome of long‑course CRT should 
be evaluated extensively.
In this thesis, it has been shown that despite the additional effect of PRT, anorectal 
dysfunction seems to be mainly caused by surgical damage, as even without PRT 
faecal incontinence occurs in 40 percent of patients.50,73 In addition, in Chapter 4 we 
found only a minor effect of PRT on sexual dysfunction . Moreover, no contribution of 
PRT in the development of urinary dysfunction was shown in Chapter 5.51 Therefore 
we conclude that pelvic organ dysfunction is mainly caused by surgical factors. First 
of all, surgical resection of rectal cancer inevitably results in a decrease in maximum 
tolerated volumes, as the neorectum has a relatively low capacity.71 Moreover, the 
rich network of nerve endings to the anal canal, sensitive to pain, temperature and 
155
Discussion and future perspectives
touch differentiating solid or liquid stool from flatus and allowing selective passage 
is removed. This also explains why patients with a small neorectum after resec‑
tion of a distal tumour are at increased risk of faecal incontinence. Other surgical 
factors influencing functional outcome, which were identified in our study, include 
anastomotic leakage and excessive peroperative blood loss. Inflammation and hae‑
mostasis by diathermic coagulation and numerous sutures may cause nerve damage. 
Surgical nerve disruption during dissection is also believed to be a cause of pelvic 
organ dysfunction.74‑76 Some authors support the idea that specific identification of 
the pelvic autonomic nerves is not essential during TME surgery.77 By following the 
concept of the TME procedure, the pelvic autonomic nerves would be automatically 
preserved. However, the data presented in this thesis do suggest that avoiding pelvic 
autonomic nerve damage during TME surgery might be more troublesome than it 
seems. In a quarter of the cases the surgeon stated that the pelvic autonomic nerves 
had or might have been disrupted. We found an association between damage to the 
parasympathetic nerves (pelvic splanchnic nerves and inferior hypogastric plexus) 
and difficulty in bladder emptying in addition to an association between damage 
to the sympathetic nerves (superior hypogastric plexus and hypogastric nerves) and 
ejaculatory dysfunction.51 The parasympathetic nerves may be disrupted during deep 
dissection of the lateral planes. The sympathetic nerves are at risk during presacral 
and ventrolateral dissection of the mesorectum. Regarding the dysfunction rates, 
it seems probable that the surgeons have underreported nerve damage. Moreover, 
damage to the levator ani nerve was not reported, as this nerve was not addressed at 
during the Dutch TME trial. However, the levator ani nerve is responsible for the in‑
nervation of the main body of the pelvic floor muscle, which is of major importance 
for the urinary and faecal continence system.78,79 The levator ani nerve has been 
neglected so far, but we have shown this nerve might be involved in the etiology of 
incontinence after rectal cancer treatment. It is interesting that such a new concept 
can be developed after rectal resection has been performed for more than 100 years. 
Although the levator ani nerve has been illustrated in detail as early as in the 19th 
century (Hirschfield), in current anatomy textbooks it is hardly ever mentioned. 
Anatomy, as well as surgery, is still developing, and cooperation of anatomists and 
surgeons may be an effective tool for further progress in the future. Besides the 
superior and inferior hypogastric plexuses, the hypogastric and pelvic splanchnic 
nerves, the levator ani nerve also would not be disrupted during a correctly performed 
TME. However the surgical ‘margin’ is so small that any deviation from the surgical 
plane easily results in nerve damage. Differences among individuals in the running 
patterns of the nerves and variations in the volumes of nerve fibres in each region 
of the pelvis make appropriate identification difficult. Especially when excessive 
peroperative blood loss hinders sight in the pelvis, in most cases due to disruption of 
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the presacral venous plexus, nerve sparing is virtually impossible.63,64,80 The use of a 
nerve stimulating device might facilitate preservation of the pelvic autonomic nerves 
during TME in the future.81 Data concerning nerve disruption during laparoscopic 
TME should be awaited. Theoretically, the magnified view of the pelvis afforded by 
the laparoscope might facilitate nerve identification and thus prevent nerve injury.
In conclusion, this thesis indicates that nerve preservation during rectal cancer 
surgery needs to be more emphasised in daily practice. In this respect systematic 
registration of identified crucial structures (superior and inferior hypogastric plex‑
uses, hypogastric and pelvic splanchnic nerves, levator ani nerve) during surgery 
is needed. Additionally, structured education in pelvic neuroanatomy and training 
as a prerequisite for certification as a rectal cancer surgeon, would be the key to 
improvement of functional outcome.
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In The Netherlands about 2 500 new cases of rectal cancer are diagnosed each year. 
Approximately 75 percent is considered surgical resectable and will be treated with 
total mesorectal excision (TME), which removes the complete mesorectum through 
sharp dissection of pre‑existing embryologically determined planes, allowing the 
preservation of the pelvic autonomic nerves. The Dutch TME trial showed the benefit 
of adding preoperative radiotherapy (PRT) to TME on local control, which is con‑
sidered standard treatment in Europe. Most patients undergo low anterior resection 
(LAR), which preserves the sphincter. However, anastomotic leakage is a frequent 
(5‑26 percent) and dangerous complication of LAR. Also, faecal incontinence may 
occur which can have a major impact on quality of life. In this respect, consensus 
does not exist concerning the benefit of sphincter preservation versus definitive 
colostomy after abdominoperineal resection (APR).
There is a general lack of large prospective studies concerning long‑term functional 
morbidity after rectal cancer treatment. Anorectal and urogenital dysfunction have 
been reported, but the etiology remains unclear. Surgical disruption of the pelvic 
nerve system and radiation damage might be involved. The aim of the current thesis 
was to evaluate long‑term results of rectal cancer treatment, specifically focusing on 
the etiology of long‑term morbidity.
chaPter 2
This chapter is a historical overview describing the impact of Miles on the develop‑
ment of rectal cancer treatment. One hundred years ago he introduced the basis of 
modern rectal cancer surgery by establishing the importance of lymphatic spread of 
cancer cells. He developed a radical APR, removing all primary lymph nodes en bloc. 
Miles’ concept has dominated the minds of surgeons throughout the 20th century 
and his surgical technique has been the gold standard for several decades. However, 
when a distal margin of two centimetres was proven to be safe and circular staplers 
were developed, a shift took place from radical APR to the use of sphincter saving 
surgery. Since the introduction of TME, APR has been performed in only a minority 
of patients. Further improvement in surgical technique consisted of autonomic nerve 
preservation, improving functional outcome. From a historical overview, it can be 
concluded that the management of rectal cancer has been progressed tremendously 
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over the past hundred years, mainly because of an increased understanding of the 
pathology and natural history of the disease, which has been initiated by Miles.
chaPter 3
Ever since Miles and Moynihan proposed low tie (ligation at the level of the superior 
rectal artery) and high tie technique (ligation at the level of the inferior mesenteric 
artery), respectively, in the beginning of the 20th century, the level of central arte‑
rial ligation has been under debate. The choice of central ligation can be based on 
three considerations: oncologic, anatomic and technical. This chapter systematically 
reviews the evidence of possible benefits of both ligation techniques regarding these 
three different considerations. From a literature review it is concluded that neither 
the high tie nor the low tie strategy is evidence based and that low tie is anatomically 
less invasive with respect to circulation and autonomous innervation of the proximal 
limb of anastomosis. As a consequence, in rectal cancer surgery low tie should be 
the preferred method.
chaPter 4
In order to gain insight in the etiology of sexual dysfunction of rectal cancer treat‑
ment, long‑term sexual dysfunction was evaluated in the Dutch TME trial, in which 
patients with resectable rectal cancer were randomised to TME with or without PRT. 
A questionnaire study allowed male and female patients to report general sexual 
dysfunction, erectile dysfunction (♂), ejaculatory problems (♂), dyspareunia (♀) and 
vaginal dryness (♀). Most patients were sexually active before rectal cancer treat‑
ment (526 of 757 patients). Of preoperative sexually active patients 15.2 percent of 
men and 13.7 percent of women never indicated to be sexually active after treatment, 
which was related to age>65 years and in male patients also to anastomotic leak‑
age. Of the patients who were sexually active preoperatively, the majority reported 
deterioration of sexual functioning after rectal cancer treatment. In male patients 
this was associated with autonomic nerve damage, excessive peroperative blood loss, 
anastomotic leakage, PRT and the presence of a temporary or definitive colostomy. 
The presence of a colostomy and PRT were risk factors in female patients. From 
these results it can be concluded that sexual dysfunction is a frequent and serious 
problem after treatment for rectal cancer, which can be mainly attributed to surgical 




Urinary dysfunction (UD) after rectal cancer treatment is a common problem, of 
which the contributing factors are unclear. To evaluate UD during five years after 
TME and to identify contributing factors, 785 patients of the Dutch TME trial 
were analysed. Long‑term incontinence was reported by 38.1 percent of patients 
of whom 72.0 percent had normal preoperative function. Preoperative incontinence 
and female gender were independent risk factors (p=0.001, RR=2.75 and p<0.001, 
RR=2.77, respectively). Long‑term difficulty in bladder emptying was reported by 
30.6 percent of patients of whom 65.0 percent had normal preoperative function. 
Preoperative difficulty in bladder emptying (p<0.001, RR=2.94), peroperative blood 
loss (p=0.028, RR=1.73) and autonomic nerve damage (p=0.024, RR=2.82) were in‑
dependent risk factors. Preoperative radiotherapy was not associated with UD. From 
this chapter it can be concluded that UD is a significant clinical problem after rectal 
cancer treatment and is not related to PRT but rather to surgical nerve damage.
chaPter 6
Low anterior resection results in faecal incontinence in a large number of patients. 
This chapter reports on risk factors associated with long‑term faecal incontinence in 
the Dutch TME trial.
Faecal incontinence was reported by 39 percent of patients without PRT and 62 
percent of patients with PRT at five years after TME. Preoperative radiotherapy was 
associated with increased incontinence in both a quantitative and qualitative way. Only 
in patients treated with TME and PRT excessive peroperative blood loss, tumour and 
anastomotic height were associated with long‑term faecal incontinence. If the perineum 
was included in the radiotherapy field and a low anastomosis was constructed, faecal 
incontinence occurred in 14 out of 15 patients. Therefore, patients with distal tumours 
should be warned that faecal incontinence is likely to occur after PRT, especially 
when the perineum is irradiated. In these patients APR might be preferable.
chaPter 7
This chapter presents a female patient suffering from combined faecal and urinary 
incontinence five years after rectal cancer treatment. Based on the literature, several 
aspects are discussed, such as incidence, etiology, progression over time, prevention 




major impact on quality of life.
•	 Patients	 should	 be	 informed	 about	 the	 surgical	 options,	 LAR	 and	 APR,	 and	
about their potential outcomes.
•	 Surgical	nerve	damage	may	play	a	major	role	in	the	development	of	faecal	and	
urinary incontinence, with an additional effect of radiotherapy.
•	 Faecal	incontinence	can	worsen	over	time	in	case	of	radiotherapy.
•	 Several	non-surgical	and	surgical	therapies	of	incontinence	problems	are	avail‑
able; conservative therapies should be the first line choice.
chaPter 8
In this chapter anatomical and clinical findings are reported concerning the pos‑
sible role of levator ani nerve disruption in the development of faecal and urinary 
incontinence after TME. Cadaver TME surgery demonstrated that, especially in low 
tumours, the pelvic floor innervation can be damaged. Furthermore, the origin of the 
levator ani nerve was located in close proximity of the origin of the pelvic splanchnic 
nerves. Analysis of the TME trial data showed that newly developed urinary and fae‑
cal incontinence was present in 33.7 percent and 38.8 percent of patients, respectively. 
Both types of incontinence were significantly associated with each other (p=0.027). 
Low anastomosis was significantly associated with urinary incontinence (p=0.049). 
One third of the patients with newly developed urinary and faecal incontinence also 
reported difficulty in bladder emptying, for which excessive peroperative blood loss 
was a significant risk factor. It is concluded that peroperative damage to the levator 
ani nerve, which is at risk in case of a low anastomosis or in case of damage to the 
pelvic splanchnic nerves, could be a factor that has been neglected so far.
Together with the results in Chapter 4, 5 and 6, these results indicate that patients 
should be informed preoperatively about functional outcome and that education 
of surgeons in pelvic neuroanatomy and crucial anatomical dissection planes may 
provide the key to improvement of functional outcome.
chaPter 9
Perioperative red blood cell (RBC) transfusions are reported to be associated with 
poor prognosis in cancer surgery and allogeneic leukocytes in RBC transfusions 
are assumed to play a causal role. This chapter reports the results of a randomised 
controlled trial comparing leukocyte depleted (LD) and non‑leukocyte depleted red 
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blood cell transfusion in gastrointestinal cancer patients (n=512). Also a combined 
analysis with a similar randomised controlled trial, in which only colorectal cancer 
patients treated with curative intent were included, was performed (n=975). The 
five‑year survival rate of patients with any type of gastrointestinal cancer was 50.8 
percent in the LD group and 45.8 percent in the non‑LD group with a recurrence rate 
of 32.9 percent in the LD group and 34.3 percent in de non‑LD group (p=0.19 and 
p=0.86, respectively). The combined analysis of colorectal cancer patients revealed 
no difference in long‑term survival (64.9 percent in both groups) and recurrence 
rates (32.2 percent versus 33.1 percent) between the two transfusion arms (p=0.94 
and p=0.94, respectively). From these results it can be concluded that in patients with 
gastrointestinal cancer, leukocyte depletion is not associated with better long‑term 
survival and lower cancer recurrence.
chaPter 10
Rectal cancer treatment has tremendously progressed in the past 100 years. Im‑
provement of surgical technique has been the key factor in this progression. Further 
improvement of local control has been established by the addition of radiotherapy. 
Nowadays, rectal cancer treatment is a multidisciplinary treatment with standardised 
surgical, pathological and radiotherapeutical procedures.
Rectal cancer treatment continues to develop explicitly. First of all, an increasing 
role of chemotherapy is to be expected. On one hand to approach micrometastatic 
disease early, trying to control it and by this, curing more patients and prolonging 
survival. This is currently under investigation (SCRIPT study). On the other hand 
chemotherapy is added to enhance the efficacy of radiation. The sterilisation effect 
of chemoradiotherapy has led to the development of rectum saving treatments. Local 
excision of early rectal cancer with transanal endoscopic microsurgery (TEM) and 
neoadjuvant chemoradiation therapy alone in case of complete clinical response have 
shown promising results. However, long‑term follow‑up of prospectively conceived 
multicentre data concerning safety and functional outcome are needed.
The overall aim of clinical research in rectal cancer should be to develop a range 
of multidisciplinary treatment strategies that can be tailored to the requirements 
of individual patients. Improved imaging techniques and translational research are 
required for the identification of patient groups which will gain the maximum benefit 
from each treatment option.
Especially surgical performance is to be improved in the upcoming century. The 
risk of anastomotic leakage, positive resection margins (especially during abdomi‑
noperineal resections) and surgical variability should be reduced. Currently, the 
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European CanCer Organisation (ECCO) is organising a Multidisciplinary Quality 
Assurance Program which enables assessment of structure and process of care, 
identification and implementation of best practices and subsequent confirmation of 
improvement of rectal cancer treatment. In addition, giving the increasing number of 
treatment alternatives in rectal cancer treatment, it will become increasingly impor‑
tant to accurately capture the impact of different treatment regimens on quality of life. 
Registration of specific organ dysfunction before and after rectal cancer treatment is 
required. In this respect the Dutch TME trial has been exceptional. Through the cur‑
rent thesis it has provided insight in the incidence and etiology of long‑term pelvic 
organ dysfunction after rectal cancer treatment. Poor functional outcome appears to 
occur commonly and to be mainly caused by surgical (nerve) damage. According to 
our results, the levator ani nerve, which has been neglected so far, might be involved. 
In this respect systematic registration of identified crucial structures (superior and 
inferior hypogastric plexuses, hypogastric and pelvic splanchnic nerves, levator ani 
nerve) during surgery is needed. Additionally, structured education in pelvic neuro‑
anatomy and training as a prerequisite for certification as a rectal cancer surgeon, 




Ieder jaar worden in Nederland ongeveer 2 500 nieuwe gevallen van rectumcarcinoom 
gediagnosticeerd. Vijfenzeventig procent van de rectumcarcinomen is resectabel en 
wordt verwijderd met behulp van totale mesorectale excisie (TME). Deze operatie 
is een en bloc resectie van de primaire tumor met het mesorectum door middel van 
scherpe dissectie in het circumferentiele, avasculaire vlak tussen de viscerale en 
parietale fascie van het rectum, waarbij de autonome pelviene zenuwen gespaard 
kunnen worden. De Nederlandse TME‑studie heeft uitgewezen dat preoperatieve 
radiotherapie (PRT) vast onderdeel van de behandeling van het rectumcarcinoom 
dient te zijn omdat het resulteert in een significant verbeterde lokale controle. De 
meerderheid van de patiënten met rectumcarcinoom wordt behandeld met een lage 
anterieure resectie (LAR), waarbij de sfincter wordt gespaard. Naadlekkage is een 
veelvoorkomende (5‑26 procent) en ernstige complicatie van LAR. Bovendien kan 
faecale incontinentie ontstaan, wat een aanzienlijke impact kan hebben op de kwali‑
teit van leven. In dit opzicht ontbreekt consensus met betrekking tot het voordeel van 
behoud van de sfincter versus een definitief colostoma zoals bij een abdominoperine‑
ale resectie (APR) wordt aangelegd. Het aantal grote prospectieve studies betreffende 
lange termijn‑functionele morbiditeit na behandeling van het rectumcarcinoom is 
beperkt. Anorectale en urogenitale disfuncties zijn veelvoorkomende problemen, 
maar de etiologie is vooralsnog onbekend. Chirurgische zenuwschade en schade 
door bestraling zouden een rol kunnen spelen. Dit proefschrift richt zich op de lange 
termijn‑resultaten van behandeling van het rectumcarcinoom en in het bijzonder op 
de etiologie van lange termijn‑morbiditeit.
hooFdstuK 2
Dit hoofdstuk bevat een historisch overzicht waarin de invloed van Miles op de 
ontwikkelingen in de behandeling van het rectumcarcinoom wordt beschreven. 
Honderd jaar geleden introduceerde Miles het concept van lymfogene metastasering 
en zijn daarop toegesneden operatie met en bloc resectie van het rectumcarcinoom 
en de primaire lymfeklierstations. Deze radicale APR werd vervolgens wereldwijd 
ingevoerd als gouden standaard voor een groot deel van de 20e eeuw. Maar de bevin‑
ding dat een distale marge van slechts twee centimeter adequaat was en de ontwik‑
keling van automatische circulaire staplers luidden de historische verschuiving van 
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APR naar sfinctersparende chirurgie in. Na de introductie van TME, waarbij het 
recidiefpercentage tot ongeveer vijf procent daalde, werd APR veel minder frequent 
(15 procent) uitgevoerd. Verdere verbeteringen betroffen onder andere de ontwikke‑
ling van zenuwsparende technieken. Uit dit historische overzicht kan geconcludeerd 
worden dat er in de afgelopen eeuw op het gebied van de behandeling van het 
rectumcarcinoom een enorme vooruitgang geboekt is. Dit is vooral te danken aan 
verbeterde chirurgie op basis van toegenomen pathologische en biologische kennis, 
geïnitieerd door Miles.
hooFdstuK 3
Sinds Miles en Moynihan respectievelijk low tie‑ (ligatie ter hoogte van de a. 
rectalis superior) en high tie‑techniek (ligatie ter hoogte van de a. mesenterica 
inferior) voorstelden, ontbreekt consensus met betrekking tot het niveau van de 
vasculaire ligatie bij rectumresectie. Bij de keuze tussen beide ligatietechnieken 
spelen oncologische, anatomische en technische aspecten een rol. Dit hoofdstuk 
is een systematische review van de literatuur betreffende eventuele voordelen van 
beide technieken met betrekking tot deze aspecten. Hoewel van beide ligatietech‑
nieken het oncologische, anatomische of technische voordeel nooit voldoende is 
aangetoond, verdient de low tie‑techniek de voorkeur omdat deze minder invasief 
is met betrekking tot de bloedvoorziening en innervatie van de aanvoerende 
colonlis.
hooFdstuK 4
Dit hoofdstuk rapporteert de resultaten van een studie naar seksuele disfunctie op 
de lange termijn na behandeling van rectumcarcinoom. Gegevens van patiënten 
uit de Nederlandse TME‑studie, waarbij werd gerandomiseerd voor TME met of 
zonder PRT werden geanalyseerd. Preoperatief en tot twee jaar postoperatief werden 
vragenlijsten ingevuld met onder andere vragen over seksuele activiteit, algemeen 
seksueel functioneren, erectiele disfunctie (♂), ejaculatiestoornissen (♂), dyspareunie 
(♀) en lubricatiestoornissen (♀). Voor behandeling van het rectumcarcinoom waren 
de meeste patiënten seksueel actief (526 van de 757 patiënten). Van de patiënten 
die voor TME seksueel actief waren, rapporteerde de meerderheid verslechtering 
van het seksueel functioneren sinds de behandeling van het rectumcarcinoom. Bij 
mannen was dit gerelateerd aan autonome zenuwschade, excessief peroperatief 
bloedverlies, naadlekkage, PRT en de aanwezigheid van een tijdelijk of definitief 
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stoma. De aanwezigheid van een stoma en PRT waren risicofactoren bij vrouwelijke 
patiënten. Uit deze resultaten blijkt dat seksuele dysfunctie na behandeling van het 
rectumcarcinoom een veelvoorkomend probleem is en voornamelijk te wijten is aan 
chirurgische (zenuw‑) schade, met een additioneel effect van PRT.
hooFdstuK 5
Ook mictieproblemen kunnen ontstaan na behandeling van het rectumcarcinoom. 
Om mictieproblemen tot vijf jaar na TME te evalueren en etiologische factoren te 
identificeren werden gegevens van 785 patiënten uit de Nederlandse TME‑studie 
geanalyseerd. Vijf jaar na TME gaf 38.1 procent van de patiënten aan incontinent 
te zijn voor urine, waarvan 72.0 procent preoperatief geen incontinentieklachten 
had. Preoperatieve incontinentie en vrouwelijk geslacht waren onafhankelijke risi‑
cofactoren (respectievelijk p=0.001, RR=2.75 en p<0.001, RR=2.77). Bemoeilijkte 
blaaslediging werd gerapporteerd door 30.5 procent van de patiënten, van wie 65.0 
procent een normale preoperatieve functie had. Preoperatieve bemoeilijkte blaasle‑
diging (p<0.001, RR=2.94), excessief peroperatief bloedverlies (p=0.028, RR=1.73) 
en autonome zenuwschade (p=0.024, RR=2.82) waren onafhankelijk risicofactoren. 
Mictieproblemen waren niet gerelateerd aan PRT. Hieruit kan geconcludeerd worden 
dat mictieproblematiek een significant klinisch probleem is na behandeling van het 
rectumcarcinoom en niet gerelateerd is aan PRT maar aan chirurgische zenuw‑
schade.
hooFdstuK 6
Na LAR is een groot deel van de patiënten incontinent voor faeces. Dit hoofdstuk 
rapporteert de resultaten van een studie waarbij risicofactoren voor faecale inconti‑
nentie werden geïdentificeerd in de Nederlandse TME‑studie. Vijf jaar na TME gaf 
39 procent van de onbestraalde en 62 procent van de bestraalde patiënten aan faecaal 
incontinent te zijn. Faecale incontinentie was zowel kwalitatief als kwantitatief gere‑
lateerd aan PRT. Alleen in bestraalde patiënten waren excessief peroperatief bloed‑
verlies, tumor‑ en naadhoogte significante risicofactoren voor faecale incontinentie. 
Veertien van de 15 patiënten van wie het perineum in het bestralingsveld had gelegen 
werden incontinent voor faeces. Patiënten met een distale tumor zouden daarom 
preoperatief geïnformeerd moeten worden over het risico op het ontwikkelen van 
faecale incontinentie na PRT. Als bestraling van het perineum onvermijdelijk is, 




In dit hoofdstuk wordt aan de hand van een casus het probleem van gecombineerde 
faecale en urine incontinentie op de lange termijn na behandeling van het rectum‑
carcinoom besproken. Op basis van de literatuur wordt op verschillende aspecten 
ingegaan, waaronder incidentie, etiologie, verloop, preventie en behandeling van 
incontinentie.
De belangrijkste leerpunten van dit hoofdstuk:
•	 Incontinentie	problemen	na	behandeling	van	het	rectumcarcinoom	komen	veel	
voor en kunnen een grote impact hebben op de kwaliteit van leven.
•	 Patiënten	zouden	preoperatief	geïnformeerd	moeten	worden	over	de	chirurgische	
opties, LAR en APR, en over de mogelijke uitkomsten.
•	 Chirurgische	 zenuwschade	 speelt	 mogelijk	 een	 grote	 rol	 bij	 het	 ontstaan	 van	




tie zijn beschikbaar; in de eerste lijn zijn conservatieve therapieën het meest 
geschikt
hooFdstuK 8
Dit hoofdstuk evalueert aan de hand van een anatomische en klinische studie de 
mogelijke rol van chirurgische beschadiging van de n. levator ani bij het ontstaan 
van faecale en urine incontinentie na TME. Uit gesimuleerde TME‑operaties op 
bekkenpreparaten bleek dat deze zenuw beschadigd kan worden, vooral bij het 
aanleggen van een lage naad. Bovendien bleek de origo van de n. levator ani ter 
hoogte van S3‑4 samen met de origo van de nn. splanchnici pelvici te verlopen. 
Analyse van de TME database toonde aan dat faecale en urine‑incontinentie in res‑
pectievelijk 33.7 procent en 38.8 procent van patiënten zonder preoperatieve klachten 
ontstond. Beide vormen van incontinentie waren significant aan elkaar gerelateerd 
(p=0.027). Een lage naad was een significante risicofactor voor urine incontinentie 
(p=0.049). Een derde van de patiënten met het incontinentiesyndroom rapporteerde 
tevens bemoeilijkte blaaslediging, waarvoor excessief peroperatief bloedverlies een 
significante risicofactor was. Geconcludeerd kan worden dat vooral in patiënten met 
een laag rectumcarcinoom het risico op beschadiging van de n. levator ani aanzien‑
lijk is, hetgeen zou kunnen bijdragen aan een verhoogd risico op faecale en urine 
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incontinentie na TME. Ook gecombineerde schade van de n. levator ani en de nn. 
splanchnici pelvici lijkt reëel.
Samen met hoofdstuk 4,5 en 6 geven deze resultaten aan dat patiënten preope‑
ratief geïnformeerd moeten worden over functionele morbiditeit en dat chirurgisch 
onderwijs in de neuroanatomie van het kleine bekken en in de cruciale anatomische 
snijvlakken de functionele uitkomsten zouden kunnen verbeteren.
hooFdstuK 9
Verschillende studies hebben aangetoond dat perioperatieve bloedtransfusie een 
belangrijke risicofactor is met betrekking tot recidief en overleving bij oncologische 
patiënten. Allogene leukocyten in getransfundeerde erytrocytenconcentraten (RBC) 
worden hiervoor verantwoordelijk gehouden. Dit hoofdstuk beschrijft de resultaten 
van een gerandomiseerde studie naar de lange termijn‑effecten van RBC‑transfusie 
met of zonder leukocytenfiltratie op het optreden van recidief en op de overleving 
bij patiënten met een gastro‑intestinale maligniteit (n=512). Daarnaast is een 
gecombineerde analyse uitgevoerd met een vergelijkbare gerandomiseerde studie, 
waarin uitsluitend patiënten met een resectabele primaire colorectale maligniteit 
waren geïncludeerd (n=975). De vijfjaars‑overleving van patiënten met een gastro‑
intestinaal carcinoom was 50.8 procent in de gefiltreerde groep en 45.8 procent in de 
ongefiltreerde groep, met een recidiefpercentage van 32.9 procent in de gefiltreerde 
en 34.3 procent in de ongefiltreerde groep (respectievelijk p=0.19 en p=0.86). Ook in 
de gecombineerde analyse werd geen verschil gevonden in vijfjaars‑overleving (64.9 
procent in beide groepen) en recidiefpercentage (32.2 procent versus 33.1 procent) 
tussen beide transfusiearmen. Geconcludeerd kan worden dat leukocytenfiltratie niet 
resulteert in een betere lange termijn‑overleving en lagere recidiefkans in patiënten 
met een gastro‑intestinale maligniteit.
hooFdstuK 10
De behandeling voor rectumcarcinoom is sterk verbeterd in de afgelopen 100 jaar. 
Dit is vooral te danken aan vooruitgang van de chirurgische techniek. Ook de toe‑
voeging van radiotherapie heeft de lokale controle positief beïnvloed. De behande‑
ling voor rectumcarcinoom is ontwikkeld tot een multidisciplinaire behandeling met 
gestandaardiseerde chirurgische, pathologische en radiotherapeutische procedures.
Ook nu nog is de behandeling voor rectumcarcinoom nadrukkelijk in beweging. 
Ten eerste zal chemotherapie steeds belangrijker worden. Aan de ene kant zou 
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chemotherapie micrometastases in een vroeg stadium kunnen behandelen en daarmee 
meer patiënten genezen en de overleving verlengen. Dit wordt momenteel onderzocht 
in de SCRIPT (Simply Capecitabine in Rectal Cancer after Irradiation Plus TME) 
–studie. Aan de andere kant, wordt chemotherapie toegevoegd aan radiotherapie om 
het effect te versterken. Het steriliserende effect van chemoradiotherapie heeft geleid 
tot de ontwikkeling van rectumsparende behandelingen. Locale excisie van vroeg‑
stadium tumoren met transanale endoscopische microchirurgie en neoadjuvante 
chemoradiatie zónder chirurgische resectie in geval van complete klinische remissie 
heeft geleid tot veelbelovende resultaten. Deze behandelingen zijn vooralsnog erg 
omstreden en de veiligheid en functionele uitkomsten zullen bevestigd moeten wor‑
den aan de hand van prospectief verkregen multicenter lange‑termijn gegevens.
Het uiteindelijke doel van klinisch onderzoek naar de behandeling van het 
rectumcarcinoom is het ontwikkelen van een spectrum van multidisciplinaire 
behandelingsstrategieën voor een “therapie op maat”. Beeldvormingstechnieken 
worden verbeterd en biomarkers worden geïdentificeerd om prognose en respons op 
behandeling te kunnen voorspellen.
Maar vooral op het gebied van chirurgie zijn verbeteringen te verwachten. Het 
risico op naadlekkage, positieve resectiemarges en de chirurgische variabiliteit 
moeten verminderd worden. Op dit moment organiseert de European CanCer Or‑
ganisation (ECCO) een multidisciplinair “quality assurance programme” waardoor 
het mogelijk wordt de structuur en processen in de zorg vast te stellen, best practices 
te bepalen en te implementeren en vervolgens verbetering van behandeling voor 
rectumcarcinoom te bevestigen. Verder zal, gezien het groeiende aantal behande‑
lingsstrategieën, het steeds belangrijker worden de impact van de behandelingen op 
de kwaliteit van leven te bepalen. Registratie van specifieke functionele stoornissen 
voor en na behandeling van het rectumcarcinoom is noodzakelijk. In dit opzicht is 
de Nederlandse TME‑studie uniek geweest. Middels dit proefschrift heeft het inzicht 
gebracht in de incidentie en etiologie van lange‑termijn anorectale en urogenitale 
stoornissen na behandeling van het rectumcarcinoom. Functionele problemen blij‑
ken vaak voor te komen en voornamelijk veroorzaakt te worden door chirurgische 
(zenuw‑)schade. Onze resultaten hebben laten zien dat de n. levator ani, een zenuw 
die tot nu toe weinig aandacht heeft gekregen, mogelijk een rol speelt. Systematische 
registratie van de identificatie van cruciale structuren (plexus hypogastricus superior 
en inferior, nn. hypogastrici en pelvici splanchnici, n. levator ani) zou deel uit moeten 
maken van het operatieplan. Verder zou gestructureerde educatie en training in de 
neuroanatomie van het bekken als een vereiste voor certificering als rectumchirurg 
de sleutel zijn voor een verbetering van de functionele resultaten.
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